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ABSTRACT 
 
Cerebral small vessel disease (SVD) is a distinct microvascular disorder that can lead to 
lacunar stroke, an important stroke subtype that accounts for a quarter of all ischaemic 
strokes.  SVD is associated with imaging biomarkers such as white matter hyperintensities 
(WMH).  The cause of SVD is largely unknown, although inflammation and blood-brain 
barrier failure via endothelial dysfunction have been implicated.  Elevated plasma 
biomarkers of inflammation are associated with coronary heart disease and large vessel 
stroke but the role of inflammation in SVD is less well understood. Our hypothesis is that 
inflammation plays a role in SVD and we sought to examine this by reviewing the 
literature for evidence of this, and by conducting a brain imaging study of patients with a 
known inflammatory disease and reviewing the images for evidence of inflammation and 
SVD, and comparing findings with controls groups. 
Section A: This thesis begins with a systematic review and meta-analysis of 13 plasma 
biomarkers of four physiological processes (coagulation, fibrinolysis, endothelial 
dysfunction and inflammation) in lacunar stroke versus non-lacunar stroke (to control for 
having any stroke) and non-stroke (to compare to the general population).  We sought to 
know if there were differences in these biomarkers between lacunar stroke and other 
stroke subtypes and non-stroke controls as a way of generating hypotheses for the disease 
mechanisms that might lead to lacunar stroke. Findings revealed differences in several 
biomarkers between lacunar stroke and healthy controls but only fibrinogen, D-dimer, 
von Willebrand factor and interleukin-6 were different (all significantly lower in lacunar 
stroke) between lacunar stroke and other stroke subtypes. There was heterogeneity 
between studies, including variations in the definition of lacunar stroke and most studies 
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measured the biomarkers in the acute phase post stroke, which is potentially confounding.  
To further examine plasma biomarkers of inflammation and endothelial dysfunction in 
SVD, we used data from a prior study of mild stroke conducted at the Brain Research 
Imaging Centre, University of Edinburgh, UK.  Lacunar stroke patients were compared 
to cortical stroke patients. The lacunar group had lower levels of tissue plasminogen 
activator independent of age, sex and vascular risk factors but we found no difference in 
the other plasma biomarkers. 
Section B: Non-resolving systemic inflammation is a feature of inflammatory 
autoimmune rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE).  These patients are at increased risk of stroke but much knowledge 
relates to stroke in general; less is known about associations with stroke subtypes 
including SVD, or when in life stroke risk is greatest.   Consequently, we sought to better 
understand the influence of inflammatory rheumatic diseases on stroke and SVD. The 
review and meta-analysis of cerebrovascular disease in rheumatic diseases showed an 
excess risk of stroke in RA, SLE, ankylosing spondylitis, gout and psoriasis over the 
general population.  Meta-analyses of stroke subtypes (ischaemic and haemorrhagic) in 
RA and SLE showed an excess risk of stroke over the general population.  Stroke risk 
across rheumatic diseases was highest in those aged <50 years and reduced with ageing.  
We then requested data from NHS Lothian covering 15 years so that we could assess 
stroke, including stroke subtypes, among patients diagnosed with various arthropathies.  
We linked 6,613 rheumatology patients’ records with stroke admission records, grouped 
the various rheumatic diseases into the two main types of arthritis, inflammatory and non-
inflammatory, and also compared the strokes in these rheumatology patients to general 
population data.  There was no difference in stroke prevalence between inflammatory and 
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degenerative (non-inflammatory) arthropathies, although the strokes occurred up to two 
decades earlier than in the general population.      
Section C: Lastly, we conducted MRI neuroimaging in patients with SLE and reviewed 
and meta-analysed diffusion tensor imaging (DTI) (an imaging technique used to assess 
sub-visible white matter microstructure damage) in SLE to place our findings into 
context.  The research question here was to ascertain if patients with a known 
inflammatory disease had brain imaging evidence of SVD, and to compare findings to 
controls. We compared imaging markers of SVD and DTI between SLE patients and age-
matched healthy controls and sought associations between the imaging biomarkers and 
plasma biomarkers of inflammation and endothelial dysfunction, measures of fatigue and 
cognition, and scores of rheumatic disease activity.  Fifty-one patients were recruited.  
There was higher mean diffusivity in all white matter tracts versus controls indicating a 
diffuse increase in brain water mobility in SLE.  Meta-analysis confirmed higher mean 
diffusivity in SLE patients versus controls.  Fatigue in SLE was significantly higher than 
a normal reference range and was associated with depression, anxiety, higher body mass 
index, lower mean diffusivity and some blood markers of inflammation and endothelial 
dysfunction.  The most fatigued were youngest which explained the association with 
lower mean diffusivity.  Damage to the brain’s white matter microstructure may be 
accelerated in SLE as the age-related declines in the general population are normally seen 
much later in life.  The aging pattern is consistent with inflammation-related 
microvascular-mediated brain damage where the inflammation is systemic in origin. 
Summary: This thesis has demonstrated an increase in SVD burden in the inflammatory 
rheumatic disease SLE and increased stroke risk at younger ages in other inflammatory 
rheumatic diseases.  Thus, systemic inflammation as seen in inflammatory rheumatic 
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diseases could have effects on the brain directly, including influencing stroke risk which 
is clinically noteworthy and would benefit from further testing in appropriately designed 
studies such as an inception cohort that follows inflammatory rheumatic patients from 
diagnosis, with regular brain imaging to track brain changes and correlates with 
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LAY SUMMARY 
 
Cerebral small vessel disease (SVD) is a disease of the blood vessels in the brain that can 
lead to stroke. The cause of SVD is largely unknown, although inflammation has been 
implicated.  Elevated blood markers of inflammation play a role in heart disease but the 
role of inflammation in SVD is less well understood. 
 
Section A: This thesis begins with a review of the scientific literature of molecules found 
in blood tests between lacunar stroke (an important type of stroke) and other types of 
stroke, and with healthy people that have not had a stroke.  It revealed differences in 
several of these molecules which helps scientists understand why and how different types 
of strokes might happen.  However, there were differences in the quality of the studies 
and the methods they used which limits how much we can infer from them.  Most of the 
studies drew blood too soon after stroke when many biological processes are likely to be 
highly active because of the stroke and this limits what scientists can infer.  To further 
examine inflammation in SVD we used data from a prior study of stroke conducted at our 
Centre.  Lacunar stroke patients were compared to another type of stroke. The lacunar 
group had lower levels of one type of blood biomarker (tissue plasminogen activator) 
independent of age, sex and risk factors for stroke such as high blood pressure but we 
found no difference in the other biomarkers. 
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Section B: Patients with inflammatory arthritis (e.g. rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE)) are at increased risk of having a stroke.  However, 
much knowledge relates to stroke in general and less is known about lacunar stroke or 
when during the course of a person’s life stroke is most likely to happen. Our review of 
the scientific literature of stroke and SVD in arthritis showed that people diagnosed with 
RA and SLE as well as other types of arthritis such as ankylosing spondylitis, gout and 
psoriasis were more likely to suffer a stroke.  Stroke risk across different types of arthritis 
was highest in those aged <50 years.  We then requested data from NHS Lothian covering 
15 years so that we could look at stroke among a local group of patients diagnosed with 
various types of arthritis.  We linked 6,613 rheumatology patients’ records with stroke 
admission records, grouped the various types of arthritis into ‘inflammatory’ and ‘non-
inflammatory’ and also compared the strokes to the general population (i.e., people with 
no arthritis).  There was no difference in the number of strokes occurring between 
inflammatory (e.g., RA) and degenerative arthritis (e.g., osteoarthritis) although the 
strokes in the arthritis patients occurred up to two decades earlier than in the general 
population meaning patients with arthritis are at risk of stroke earlier in life which was a 
similar conclusion with our other study. 
 
Section C: Lastly, we undertook a brain imaging study (using MRI) with patients 
diagnosed with SLE.  We reviewed the scientific literature for one type of advanced 
neuroimaging technique used to see the tiny white matter fibres in the brain.  We looked 
at a range of measurements taken from the brain scans between the patients with SLE and 
other groups of people.  We also looked at fatigue and cognitive abilities in these patients 
in relation to the brain scans.  Fifty-one patients were recruited.  The ‘wiring’ (the brain’s 
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white matter) of the brain in the SLE patients was more disorganised compared to the 
people who did not have SLE. Our review of the literature confirmed this finding.  Fatigue 
in SLE was significantly higher than would have been expected if you test a group of 
people at random and was related with depression, anxiety, higher body mass index and 
inflammation.  We concluded that damage to the brain’s white matter may be accelerated 
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Chapter 1: General introduction and aims of thesis 
 
Stroke – a global health problem 
Stroke is a key global health issue of growing importance in ageing populations and 
with increasing socioeconomic affluence among the developing economies1,2.  In high-
income countries, stroke has overtaken all cancers combined to become the second 
commonest cause of death behind heart disease, while in low-income countries stroke 
is in the top four killers3,4.  The risk of stroke deaths in adults aged 20–64 years is 
lower than that in older adults, but there was a 37% increase in the number of total 
stroke deaths among younger adults in developing countries between 1990 and 20135.  
In 2010, the absolute number of people with first stroke (16.9 million), stroke survivors 
(33 million) and stroke-related deaths (5.9 million) were high and had significantly 
increased since 1990 (68%, 84% and 26% increase, respectively)2,4.  In the US, the 
direct healthcare costs and lost productivity costs of stroke are estimated at $34 billion 
each year6.  Stroke is the leading cause of worldwide adult disability and so primary 
prevention is a public health priority in most countries, particularly as many strokes 
are likely to be avoided via lifestyle choices that reduce risk factors7,8. 
Stroke and stroke subtypes 
A stroke is a sudden brain injury caused by an interruption to cerebral blood flow with 
symptoms lasting more than 24 hours9,10.  The resultant focal neurological deficit can 
present symptomatically as loss of speech, loss of limb function, etc, depending on the 
region and amount of brain affected.  A transient ischaemic attack, or ‘mini stroke’, 
exhibits the same signs and symptoms as stroke, but these resolve within 24 hours.   
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There are two main stroke subtypes: ischaemic stroke and haemorrhagic stroke.  
Ischaemic strokes are commonest, accounting for about 80% of new strokes.  Such 
strokes result from ischaemia, i.e., a restriction of cerebral blood flow caused by 
stenosis (narrowing) due to plaque build-up within vessels supplying blood to the 
brain, or occlusion (partial or full blockage) due to emboli from the heart, aorta or 
common carotid arteries, or arising locally within the cerebral circulation (thrombi).  
Emboli and thrombi are also known as clots.  The loss of blood supply to brain tissue 
results in an infarct.  The extent of brain damage will depend on the location of the 
blockage and extent of the ischaemia.  Ischaemia is seldom complete and collateral 
perfusion can keep cells viable11,12.  Reperfusion can occur spontaneously as clots 
naturally break up.  This process can be accelerated by thrombolysis therapy, now used 
routinely to treat acute ischaemic stroke, or by mechanical clot retrieval.  Some infarcts 
can be silent13.  Ischaemic strokes can be further subtyped: half are caused by large 
artery atheroma, 20% by cardioembolism, 25% are classified as lacunar (see below) 
and the remainder result from rare causes14.  Haemorrhagic stroke, also known as 
intracerebral haemorrhage (ICH), results from a tear or dissection in the wall of a blood 
vessel and accounts for 10-15% of strokes.  The remaining strokes are subarachnoid 
haemorrhage in type (about 3-5% of all strokes). 
Lacunar stroke, an important clinical manifestation of cerebral small vessel 
disease (SVD) 
Lacunar stroke is a distinct stroke subtype, presenting with distinct clinical features, 
and is classified according to how the symptoms manifest as per the classical clinical 
lacunar syndromes, being: pure motor weakness (in two areas, e.g., face and arm); 
sensory loss; combined motor-sensory loss; ataxic hemiparesis or clumsy hand 
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dysarthria syndrome15.  It can be caused by ischaemia or haemorrhage, and when 
ischaemic the size of the infarcts are usually < 20 mm in axial diameter and located in 
the subcortical parts of the brain supplied by the perforating cerebral arterioles16–19.  
About 10% of lacunar ischaemic strokes are cardioembolic or atherothromboembolic 
– the rest are presumed due to cerebral small vessel disease (SVD).   
Risk factors for lacunar stroke include age, hypertension, diabetes, hyperlipidemia and 
smoking, although non-lacunar strokes are equally associated with many of these 
risks20.   
Clinical lacunar ischaemic stroke is associated with imaging features of SVD (see 
Table 1.1 and Figure 1.1 overleaf) being any of: recent small subcortical infarcts 
(RSSI), white mater hyperintensities (WMH), lacunes, enlarged perivascular spaces 
(PVS) and cerebral microbleeds, more than are other stroke subtypes.  Imaging 
features of SVD were recently formalised in an international consensus paper19.   
Cerebral SVD is a spectrum disorder, and is used to refer to the clinical, cognitive, 
neuroimaging and pathological findings thought to arise from diseased perforating 
cerebral arterioles18.  SVD doubles the risk of future stroke21.  However, SVD is also 
partly responsible for non-stroke brain diseases, such as contributing substantially to 
up to 45% of dementias22, and can affect mood, gait and cause urinary problems16,23–
29.  Additionally, much of SVD is clinically silent and probably accumulates across the 
lifecourse before symptoms occur18.  Observed pathological changes of SVD include 
vessel wall thickening that narrows the lumen (lipohyalinosis), hardening and loss of 
essential vessel wall elasticity (arteriosclerosis), inflammation or endothelial 
dysfunction and blood-brain barrier (BBB) dysfunction.    
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“neuroimaging evidence of recent infarction in the territory of one 
perforating arteriole, with imaging features or clinical symptoms 
consistent with a lesion occurring in the previous few weeks”19  
white matter 
hyperintensity 
(WMH) of presumed 
vascular origin 
“WHM are hyperintense on T2-weighted sequences and can appear as 
isointense or hypointense (although not as hypointense as CSF) on T1-
weighted sequences, depending on the sequence parameters and severity 
of the pathological change”19  
lacune “a round or ovoid, subcortical, fluid-filled (similar signal as CSF) cavity 
of between 3 mm and about 15 mm in diameter, consistent with a previous 
acute small deep brain infarct or haemorrhage in the territory of one 
perforating arteriole”19  
perivascular space 
(PVS) 
“fluid-filled spaces that follow the typical course of a vessel as it goes 
through grey or white mater.  The spaces have signal intensity similar to 
that of CSF on all sequences.  They appear linear when imaged parallel to 
the course of the vessel, and round or ovoid, with a diameter generally 
smaller than 3mm, when imaged perpendicular to the vessel”19  
cerebral microbleed “small (generally 2–5 mm in diameter, but up to 10 mm) areas of signal 
void with associated blooming seen on T2*-weighted MRI or other 
sequences that are sensitive to susceptibility effects.  When imaged with 
T2*- weighted GRE sequences, cerebral microbleeds are well defined, of 
homogeneous low signal, and are either round or oval in shape”19  
 
 
Figure 1.1 MRI findings for lesions related to SVD.  Shows examples (upper row) and 
schemaic representation (middle row) of MRI features related to SVD, with a summary of 
imaging characteristics (lower row) for individidual lesions.  DWI = diffusion-weighted 
imaging, FLAIR = fluid-attenuated inversion recovery, GRE = gradient-recalled echo, SWI = 
susceptability-weighted imaging.  Reproduced from Wardlaw et al. Lancet Neurol 
2013;12:822–38 with permission from the publishers Elsevier Ltd (license number 
3832420235618 dated 19 March 2016).  
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What is the blood-brain barrier and why is it important? 
The endothelium is a single cell lining of endothelial cells that covers the internal 
surface of the vascular system, including cerebral blood vessels where it is the BBB.  
The BBB forms a mechanical and functional barrier between the systemic circulation 
and brain tissue30.  Junctional proteins link endothelial cells tightly to each other which 
forms a selectively permeable membrane which interfaces between circulating blood 
in the lumen and the vessel wall and interstitial spaces.  The BBB has many 
physiological roles, including: selectively mediating the passage of molecules between 
blood and brain tissue; regulating inflammatory activity into and out of the brain; 
maintaining haemostasis; clotting; new blood vessel formation; and, via its production 
of nitric oxide, it has a critical role in the constriction and dilation of blood vessels.  
The BBB is an important function of the cerebrovascular endothelium and therefore 
endothelial dysfunction of various sorts may affect the BBB. 
When the BBB becomes impaired (sometimes called BBB failure), blood-borne 
molecules may pass through the BBB, into the vessel wall and beyond, probably 
triggering an immune-mediated (inflammatory) reaction that damages neurons and 
glial cells (astrocytes, microglia and oligodendrocytes)31.  Intravenous gadolinium 
given during MRI examinations has been shown to pass through the BBB more in 
lacunar versus non-lacunar stroke patients, and in older versus younger subjects, 
suggesting increased BBB permeability in these patients32.  Leakage of plasma 
proteins through the BBB and into the vessel wall and surrounding brain tissue could 
be the first step in perivascular lesions and subsequent axonal damage33. 
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Additionally, microbleeds (haemorrhagic leaks from small vessels) increase the risk 
of recurrent stroke (any stroke subtype) following ischaemic stroke34, and this is 
consistent with BBB dysfunction and subsequent increased small vessel permeability.  
The permeability of the BBB increases with normal ageing but is accelerated in 
vascular or Alzheimer’s dementia and with worsening SVD35. 
Cytokines – also known as signalling molecules – are small proteins released by cells 
to facilitate cell to cell communication during an immune response, and stimulate the 
movement of cells towards sites of inflammation, infection and trauma36.  Recently, a 
novel technique to observe BBB dysfunction in response to the peripheral 
administration of lipopolysaccharide (i.e., a systemic inflammatory challenge) resulted 
in a rapid increase in the pro-inflammatory cytokine tumour necrosis factor alpha 
(TNF-α) in the serum and brain tissue of rats37.  In mice there is worse ischaemic brain 
damage and more severe neurological deficits38 when given a systemic inflammatory 
challenge versus controls, and the mechanism could be initiated by the expression of 
the cytokine interleukin-1 because the effect was exacerbated when interleukin-1 was 
administered, and attenuated with interleukin-1 receptor antagonist38. 
Cerebral inflammation after stroke may contribute to ischaemic damage.  After stroke, 
endothelial cells express more intercellular adhesion molecule-1 (ICAM) to facilitate 
the transmigration of immune cells into the damaged brain tissue, and anti-ICAM 
antibodies have been shown to reduce brain injury in animal models39 but these 
findings have not been translated for human use as a randomised, double-blinded, 
placebo-controlled trial (n=625 stroke patients) failed to show efficacy40. 
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Under pathologic conditions a number of chemical mediators are released that increase 
BBB permeability and various mechanisms are implicated including hypoxia, 
infection, oxidative damage, activation of matrix metalloproteinases, inflammation 
and autoimmunity30,41 but the precise steps are not yet fully understood.  Increased 
cytokines result in greater endothelial adhesion and transmigration of immune cells 
across the BBB.  
There are at least four different pathways by which peripheral inflammation 
communicates with the brain, including: by-pass of the BBB at the circumventricular 
organs (where there is a lack of a BBB); circulating cytokines may activate cerebral 
endothelial cells, which in turn activate perivascular macrophages that signal to the 
microglia within the parenchyma; cytokines may activate the vagus nerve, which 
communicates with the brainstem; and lastly cytokines may be actively transported by 
endothelial cells across the BBB42. 
The human immune system and inflammation 
The human immune system is staggeringly complex.  Maintenance of health and 
modulation of disease requires a swathe of interrelated mediating and signalling tasks, 
from pattern recognition of exogenous foreign material (bacteria, virus, unrecognised 
proteins, etc) or endogenous dangers such as dying cells, to tagging molecules for 
destruction, to destroying and clearing the offending material.  There are two broad 
immune responses: innate (non-specific) and adaptive (specific).  The innate response 
is the rapid, first-line defence but its lack of specificity means that it will attack and 
attempt to clear anything it does not recognise.  In contrast, the adaptive immune 
response will selectively target pathogens which the immune system has been ‘trained’ 
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to recognise through prior exposure (e.g., CD8+ cells target virus infected cells, 
neutrophils target bacteria, etc). 
The inflammatory hypothesis 
Activation of the human immune system is sometimes generically described as 
“inflammation”.  A hallmark of inflammation is increased vascular permeability to 
facilitate the movement of immune response cells out of the blood and into the site of 
injury in order to deal with the injury.  When the immune response continues in the 
absence of specific pathogenic material, the body can start to destroy its own tissues 
(autoimmunity) and then the protective immune response becomes self-harming, as in 
diseases like rheumatoid arthritis (RA), Crohn’s and psoriasis.  These diseases are 
characterised by non-resolving, systemic inflammation, and in the brain could 
influence the BBB.  There is a broader literature on neuropsychiatric and neurological 
disorders with a primary inflammatory aetiology.  Evidence is emerging that 
inflammation may play a role in the pathogenesis of Alzheimer’s. 
Inflammation plausibly explains some of the excess stroke risk due to atheromatous 
large vessel stroke as inflammation is involved in all stages of atherosclerosis from 
fatty streak formation to plaque disruption43–45.  In sporadic SVD, inflammation and 
cell infiltrates are seen in the perforating arteriolar walls and microglial activation is 
seen in the perivascular tissue on pathology46,47.  The source of the inflammation is not 
known, whether intrinsic or systemic, but is associated with raised plasma markers of 
inflammation in healthy older subjects48.  C-reactive protein (CRP), one of the main 
clinical measures of inflammation, was associated with lacunar infarcts in a recent 
large (n=519) study, independent of age and traditional vascular risk factors49.  Factors 
  9 
that contribute to endothelial damage such as immune complex formation and 
complement activation/deposition might trigger vascular inflammation and disrupt 
small vessel integrity.  In animal models (including animal models of arthritis) 
systemic inflammation induces brain inflammation50,51 while inflammation is 
implicated as a pathological mechanism in dementia52.  Systemic inflammation is 
associated with an increase in cognitive decline in Alzheimer’s disease53.  One group 
of patients that are known to have systemic inflammation are patients diagnosed with 
inflammatory rheumatic arthropathies, and we study such diseases in this thesis as an 
in vivo model of inflammation.  
Inflammatory rheumatic diseases and increased stroke risk 
Inflammatory rheumatic diseases are characterised by inflammation (signs include 
redness or heat, swelling and pain) and loss of function of one or more connecting or 
supporting structures (such as joints)54.  Patients diagnosed with inflammatory 
rheumatic diseases such as rheumatoid arthritis (RA) and systemic lupus 
erythematosus (SLE) are at increased risk of cardiovascular disease including stroke 
in general (reviewed in Chapter 4)55,56 but little is known about lacunar stroke or SVD 
in these patients.  Many of the symptoms seen in SVD (failing cognition, changes in 
mood, gait disturbances) are also seen in patients with rheumatic diseases57–60, and 
brain imaging biomarkers of SVD such as WMH are more common in these patients 
versus the general population in some61 but not all62 studies.  Consequently, it is 
reasonable to hypothesise that the mechanisms that cause rheumatic symptoms could 
also trigger pre-clinical brain damage and increase lacunar stroke risk in these patients. 
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Biomarkers aid our understanding of disease mechanisms 
Biomarkers provide insights into normal biological processes, pathogenic processes, 
or pharmacologic response to a therapeutic intervention63.  Biomarkers are measured 
in blood (plasma or serum), cerebrospinal fluid and brain tissue and can be hypothesis-
generating by providing mechanistic insights into underlying disease processes and 
pathways.  Although observational studies are unable to determine causation, with 
accumulating evidence biomarkers become established and provide vital information 
on disease risk and prognosis (there were no randomised interventions testing the 
effects of smoking on lung cancer risk but evidence from observational studies became 
overwhelming).  Other examples include: 
 high serum cholesterol leads to the development of atherosclerosis64 which is 
a major cause of large vessel stroke; 
 
 elevated homocysteine (a breakdown product of methionine (found mostly in 
animal protein)) is an independent risk factor for Alzheimer’s Disease65,66. 
 
Plasma biomarkers of inflammation, endothelial dysfunction and haemostasis may 
provide mechanistic insights to the cause of lacunar stroke and SVD via implicated 
processes such as systemic inflammation, BBB failure or occlusive 
microthrombus18,67–71.   
The common clinical marker of inflammation, CRP, was significantly raised in lacunar 
stroke (n=124) versus non-stroke controls (n=600), within 10 days of the stroke 
(p<0.001) and at three months follow-up (p<0.001)72 but another study73 did not find 
a difference in levels of CRP between lacunar stroke (n=128) and atherothrombotic 
stroke (n=151) or cardioembolic stroke (n=259) possibly indicating that inflammation 
is raised in all strokes. 
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A previous review68 of symptomatic lacunar stroke versus non-stroke controls 
suggests a pathogenic role for endothelial dysfunction but this could simply reflect 
having an ischaemic stroke in general70.  Another review74 found CRP and 
homocysteine to differ significantly between ischaemic stroke and non-stroke controls, 
but did not assess levels of blood markers between ischaemic stroke subtypes.   
Prior stroke studies often take the plasma samples too early making it difficult to 
isolate underlying immune system pathway activity independent from an acute phase 
response.  Few studies have assessed a range of biomarkers simultaneously in one 
population.  Studying biomarkers in SVD is one strategy for increasing our knowledge 
of SVD mechanisms, which is a necessary precursor to developing therapies to reduce 
the burden of SVD.    
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Summary and thesis aims 
Stroke is a global health problem.  Inflammation is implicated in large vessel stroke 
but the role of inflammation in SVD and lacunar stroke is less well understood.  
Inflammation in SVD is seen pathologically, but the source of the inflammation is not 
known.  Therefore we undertook work to better understand inflammation in SVD, in 
particular the role of systemic inflammation, and our aims are split into three sections: 
 Section A. To see if differences exist in plasma biomarkers of coagulation, 
fibrinolysis, endothelial dysfunction, and inflammation between lacunar stroke, 
other ischaemic stroke subtypes and non-stroke controls (by literature review 
(Chapter 2) and experiment (Chapter 3)) and to see if there are relationships 
between plasma biomarkers and common SVD features such as WMH (Chapter 3); 
 Section B. To review associations between stroke, including stroke subtypes, and 
rheumatic diseases, and to determine if rheumatic diseases increase the risk of 
specific stroke subtypes or ‘silent’ vascular disease on neuroimaging (by literature 
review (Chapter 4) and via a large national data linkage study of a regional 
rheumatology service (Chapter 5)); 
 Section C.  To conduct a pilot magnetic resonance (MR) neuroimaging study to 
assess the burden of SVD among patients with the inflammatory disease SLE versus 
a cohort of stroke patients (i.e., clinically overt SVD) and non-stroke controls, and 
to assess relationships between total SVD burden and biomarkers of inflammation 
and endothelial dysfunction (Chapter 7); and also investigate evidence of SVD 
mechanisms in the brain including microstructural damage (including a review of 
the literature) in SLE including relationships with cognition, fatigue, SLE disease 
activity and inflammatory markers (Chapter 8).  
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Chapter 2: Blood markers of coagulation, fibrinolysis, endothelial 
dysfunction, and inflammation in lacunar stroke versus non-lacunar 
stroke and non-stroke: Systematic review and meta-analysis 




One-quarter of ischaemic strokes are lacunar in type making lacunar stroke an 
important stroke subtype.  The aetiology of lacunar stroke is different from other stroke 
subtypes, usually being the symptomatic manifestation of SVD rather than large vessel 
atheroma or cardioembolism.   
Plasma biomarkers could provide mechanistic insights.  A previous review68 of 
symptomatic lacunar stroke versus non-stroke controls suggests a pathogenic role for 
endothelial dysfunction but this could simply reflect having an ischaemic stroke in 
general70.  Another review74 found C-reactive protein (CRP), P-selectin and 
homocysteine to differ significantly between ischaemic stroke and non-stroke controls, 
but did not assess levels of blood markers between ischaemic stroke subtypes.  
Our aims were to see if differences exist in blood markers between lacunar stroke and 
other ischaemic stroke subtypes by reviewing the literature for studies measuring 
coagulation, fibrinolysis, endothelial dysfunction and inflammation.  To disentangle 
the acute phase response, the analysis was split on timing of the blood draw in relation 
to the stroke. 
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Methods 
This review has been prepared in accordance with the Preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) statement75.  We extracted data and 
conducted the meta-analysis in accordance with Meta-analysis of observational 
studies (MOOSE) guidelines76, modified using three reporting standards77–79. 
Search strategy 
We used OVID to search MEDLINE (from 1966) and EMBASE (from 1980) on 15th 
July 2012 using a search strategy (Table 2.1) developed with advice from the Cochrane 
Stroke Group (http://stroke.cochrane.org/). 
Table 2.1 Search strategy 
1. brain ischemia/ or brain infarction/ or brain stem infarctions/ or cerebral infarction/ or hypoxia-
ischemia, brain/ or stroke/ 
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw. 
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or 
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
4. 1 or 2 or 3 
5. (lacun$ or small vessel$ or small infarct$ or microinfarct$ or subcortical lesion$ or subcortical 
infarct$ or microvascular$ or microcirculation$).tw. 
6. 4 and 5 
7. blood-brain barrier/ or endothel$, vascular/ or tunica intima/ or microcirculation/ 
8. (endotheli$ adj5 (function$ or dysfunction$ or impairment$)).tw. 





14. (ICAM or Intra cellular adhesion molecule).tw 
15. (VCAM or Vascular Cell Adhesion Molecule).tw 
16. (IL6 or Interleukin 6).tw 
17. (CRP or C reactive protein).tw 
18. von Willebrand factor.tw 
19. plasminogen activator inhibitor.tw 
20. selectin$.tw 
21. D-dimer.tw 
22. (TNF or TNF-a or TNF-alpha or TNF-α or tumo?r necrosis factor alpha).tw 
23.  or/7-22 
24.  6 and 23 
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Inclusion and exclusion 
We included English language studies published in full measuring blood markers in 
plasma or serum as follows: tissue plasminogen activator (t-PA) as an indicator of 
fibrinolytic and thrombotic state; plasminogen activator inhibitor (PAI) as an inhibitor 
of t-PA; fibrinogen as a measure of coagulation; D-dimer as a measure of fibrinolysis; 
homocysteine as a marker of endothelial toxicity; von Willebrand factor (vWF) as a 
marker of endothelial damage; E-selectin, P-selectin, intercellular adhesion molecule-
1 (ICAM) and vascular cellular adhesion molecule-1 (VCAM) as markers of 
endothelial activation and CRP, interleukin-6 (IL-6) and tumour necrosis factor alpha 
(TNF-α) as markers of inflammation.  We excluded studies that did not provide 
information on blood markers in lacunar stroke and a control group.    
Data extracted 
Data was extracted on study population (sample size, age, sex, co-morbidities, current 
medications); study design; control group (including details on matching for age, sex 
and covariates); blinding of stroke assessor to blood markers and assay investigator to 
stroke diagnosis; blood markers assessed; time to all blood draws; whether the authors 
gave details on how samples were obtained, stored and processed and results of blood 
marker levels (both measures of average and spread where given).  We recorded 
method of stroke diagnosis, criteria/system used for stroke subtyping, details of 
imaging, definition of lacunar stroke and the grade of clinician making the stroke 
diagnosis.  We contacted one author80 to clarify time of blood draw. Some studies drew 
blood at multiple time points.  We recorded data at multiple time points where a 
relevant comparator was also available.  We avoided duplicate publications. 
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Definition of lacunar stroke 
Our gold standard definition of lacunar stroke was all of: reference to one of the 
classical clinical lacunar syndromes; no evidence of cortical dysfunction; imaging, 
including noting that a normal scan does not exclude a lacunar diagnosis; and mention 
of expertise of the person who subtyped the stroke. We relied on the clinical stroke 
definitions used in the primary papers but tried to harmonise these to a clinical stroke 
syndrome with support from imaging where available19. 
Meta-analysis 
We used the Review Manager 5 software to calculate standardized mean differences 
(where data were in a suitable format) using the inverse variance method and a fixed 
effects model with 95% confidence interval (CI).  Our forest plots compare lacunar 
stroke to non-lacunar stroke (atherothrombotic stroke and/or cardioembolic stroke) or 
to non-stroke.  Studies81–83 reporting a geometric mean with 95% CI were converted 
to standard deviations using methods described in the Cochrane Handbook84.   
Not all studies could be meta-analyzed due to heterogeneity of reporting.  The 
following markers were reviewed solely by summary of individual study data: t-PA, 
PAI, E-selectin, P-selectin, ICAM, VCAM, CRP and TNF-α.   
Where studies provided data at more than one acute time point, we meta-analysed only 
the first time point as this most often corresponded with data for non-stroke 
comparators. In order to see if an acute phase response affected the results we split our 
analysis into ‘acute’ and ‘chronic’ (bloods drawn up to and after 21 days of stroke 
respectively).  
  17 
Results 
We identified 1,468 full papers.  In all, 1,389 titles were excluded following a survey 
of titles and abstracts leaving 79 for reading.  Of these 10 were excluded (unable to 
translate) and 32 did not meet inclusion criteria (duplicates; asymptomatic subjects; 
non-relevant blood markers; no control group).  A hand-search found five papers so 
42 papers were eligible for inclusion (Figure 2.1), including 4,816 ischaemic strokes, 
of which 2,196 were lacunar, and 2,500 non-stroke controls.   
 
 
Figure 2.1 Summary of search and selection 
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Critical appraisal of included studies 
Over 50% of studies (22/42) used Trial of Org 10172 in Acute Stroke Treatment 
(TOAST)85 to subtype ischaemic stroke.  Just four studies81,86–88 (under 10%) met our 
gold standard definition of lacunar stroke.  More than half of the studies (57%) 
reported a ‘minimal’ definition of lacunar stroke.  One study89 failed to define lacunar 
stroke.  Most studies (31/42) recruited patients consecutively.  One study recruited 
non-consecutively86 and 10/42 did not report on recruitment. Two-thirds of studies 
reported excluding cases based on co-existing disease such as infection, cancer, 
inflammatory disease and renal failure.  One-third of studies did not report on 
exclusion criteria.  Most studies (24/42) reported matching controls by age and sex.  
Three studies did not report on matching.  Matching for co-morbidities varied from 
study to study. Under 20% of studies (8/42) reported blinding of stroke assessor to 
blood marker values.  Fewer still reported blinding of laboratory staff to stroke data.  
Characteristics of included studies and quality of assessment thereon is given in Tables 
2.2 and 2.3, respectively. 
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Table 2.2 Characteristics of included studies  
Study Markers Imaging Stroke subtyping Number of 




(SD or range) 
Takano, 1992 D-dimer CT and angio Clinical + imaging 73 / 23 65 
Kilpatrick, 1993 Fibrinogen CT in all, Doppler / angio in some Clinical + imaging 19 / 9 69.7 (12.8) 
Beamer, 1995 IL-6 CT or MR NSt 50 / 23 66 (9) 
Lindgren, 1996 t-PA, PAI CT OCSP 135 / 33 75.2 (38-98) 
Bath, 1998 vWF, P-selectin, fibrinogen CT OCSP 163 / 56 74 (7) 
Eikelboom, 2000 Homocysteine CT in all, Doppler in some OCSP 219 / 68 66.1 (12.4) 
Kataoka, 2000 Fibrinogen, D-dimer CT or MR, angio NINDS III 137 / 58 67.6 (12.6) 
Vila, 2000 IL-6 CT TOAST 231 / 33 NSt 
Ageno, 2002 D-dimer CT and Doppler OCSP 126 / 31 74.7 
Castellanos, 2002 ICAM-1, IL-6, TNF-α CT or MR and Doppler OCSP 113 / 113 69.7 (9.3) 
Kozuka, 2002 vWF, E-selectin, P-selectin,  CT or MR NINDS III 52 / 27 68 (63-72) 
Salobir, 2002 t-PA, PAI, fibrinogen, D-dimer CT OCSP 192 / 16 42 (36-48) 
Hassan, 2003 ICAM Neuroimaging and Doppler or MRA OCSP 110 / 110 67.1 (10.3) 
Hassan, 2004 Homocysteine Neuroimaging and Doppler or MRA OCSP 172 / 172 67.1 (10.3) 
Parnetti, 2004 Homocysteine NSt TOAST 161 / 50 72 (13) 
Salobir, 2004 IL-6 CT OCSP 192 / 16 42 (36-48) 
Jood, 2005 t-PA, PAI CT or MR, Doppler / angio in some TOAST 600 / 124 58 (7) 
Licata, 2006 TNF-α CT or MR or ce-CT TOAST 60 / 29 72 (64-82) 
Ladenvall, 2006 CRP CT or MR, Doppler / angio in some TOAST 600 / 124 58 (7) 
Domac, 2007 IL-6, TNF-α CT or MR and Doppler OCSP 70 / 19 68.5 (12.4) 
Khan, 2007 Homocysteine CT or MR and Doppler TOAST 47 / 47 65.3 (10.4) 
Guldiken, 2008 IL-6 CT TOAST 28 / 16 66.9 (9.8) 
Jood, 2008 Fibrinogen CT or MR, Doppler / angio in some TOAST 599 / 123 58 (7) 
Khan, 2008 Homocysteine CT or MR, Doppler / angio in most Mod TOAST 457 / 152 65.4 (12.2) 
Montaner, 2008 CRP, D-dimer Neuroimaging and carotid 
ultrasound 
TOAST 
707 / 128 
72 (12) 
Nakase, 2008 CRP, IL-6, TNF-α NSt TOAST 105 / 42 71.4 (13.8) 
Yokokawa, 2008 PAI, CRP, homocysteine MR Clinical + imaging 222 / 55 71 (41-88) 
Bronus, 2009 D-dimer CT or MR, Doppler / angio TOAST 128 / 23 72.2 (11.7) 
Licata, 2009 vWF, CRP, IL-6, TNF-α CT or MR or ce-CT TOAST 120 / 46 72 (64-82) 
Tsai, 2009 P-selectin MR and MRA TOAST 54 / 32 68.1 (10.2) 
Tuttolomondo, 2009a t-PA, vWF, ICAM, VCAM, PAI, E-
selectin, P-selectin, IL-6, TNF-α 
CT or MR TOAST 
107 / 32 
71 (63-80.5) 
Tuttolomondo, 2009b t-PA, ICAM, VCAM, PAI, E-selectin, P-
selectin 
CT or MR or ce-CT TOAST 
120 / 46 
72 (64-82) 
Ilhan, 2010 PAI, P-selectin, D-dimer CT or MR, Doppler / angio TOAST 30 / 30 65.4 (10.8) 
Isenegger, 2010 D-dimer CT or MR, Doppler / angio TOAST 98 / 5 67 (19) 
Alvarez-Perez, 2011 Fibrinogen, CRP, D-dimer Doppler TOAST 200 / 50 72 (11.5) 
Beer, 2011 vWF, E-selectin, Fibrinogen, CRP, 
homocysteine 
NSt TOAST 
129 / 25 
66.1 (12.7) 
Hanson, 2011 vWF CT or MR, Doppler / angio TOAST 599 / 123 58 (7) 
Jeong, 2011 Homocysteine MR and Doppler TOAST 83 / 83 62.1 (11.9) 
Pavlovic, 2011 Homocysteine MR and Doppler NSt 95 / 95 59.8 (10.9) 
Supanc, 2011 ICAM, VCAM CT and Doppler Neurologist 110 / 43 70.2 (9.6) 
Turgut, 2011 P-selectin, CRP CT or MR, Doppler / angio TOAST 72 / 20 65.2 (1.4) 
Zhang, 2011 Fibrinogen CT or MR Clinical + imaging 626 / 262 40.9 (5.4) 
CRP = C-reactive protein.  CT = computed tomography.  ICAM = intercellular adhesion molecule-1.  IL-6 = interleukin-6.  MR = magnetic resonance.  NSt = not stated.  
OCSP = Oxfordshire Community Stroke Project.  TNF-α = tumour necrosis factor alpha.  TOAST = Trial of Org 10172 in Acute Stroke Treatment.  t-PA = tissue 
plasminogen activator.  VACM = vascular cellular adhesion molecule-1.  vWF = von Willebrand factor. 
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Takano, 1992 1 Yes Yes Yes Age only NSt NSt NSt 
Kilpatrick, 1993 4 No Yes Yes e e Yes f 
Beamer, 1995 0 NSt Yes Yes a Age only NSt NSt Yes 
Lindgren, 1996 2 Yes Yes NSt Sex only Partly q NSt Yes 
Bath, 1998 1 Yes NSt NSt Yes NSt NSt Yes 
Eikelboom, 2000 4 Yes Yes NSt Yes Yes Yes NSt 
Kataoka, 2000 2 NSt NSt Yes Yes Partly p NSt Yes 
Vila, 2000 1 Yes NSt Yes NSt NSt NSt NSt 
Ageno, 2002 1 NSt NSt Yes Age only NSt NSt Yes 
Castellanos, 2002 4 Yes Yes Yes NSt NSt Yes NSt 
Kozuka, 2002 1 Yes Yes Yes Age only NSt NSt Yes 
Salobir, 2002 1 NSt NSt NSt Yes Yes NSt NSt 
Hassan, 2003 3 Yes Yes Yes Yes Yes Yes Yes 
Hassan, 2004 3 Yes Yes NSt Yes Partly o Yes Yes 
Parnetti, 2004 1 Yes Yes Yes  Yes Partly n NSt Yes 
Salobir, 2004 1 Yes Yes NSt Yes Partly m NSt NSt 
Jood, 2005 1 Yes Yes NSt Yes Yes NSt Yes 
Licata, 2006 1 Yes Yes Yes Yes Partly b NSt NSt 
Ladenvall, 2006 1 Yes Yes NSt Yes Yes NSt Yes 
Domac, 2007 4 Yes NSt Yes Age only NSt Yes NSt 
Khan, 2007 1 NSt Yes NSt Yes Yes NSt NSt 
Guldiken, 2008 3 NSt Yes Yes Yes Partly l NSt Yes 
Jood, 2008 1 Yes Yes NSt Yes Yes NSt Yes 
Khan, 2008 3 Yes Yes Yes j Yes Partly k NSt NSt 
Montaner, 2008 3 Yes Yes Yes e e Yes NSt i 
Nakase, 2008 1 Yes Yes Yes e e NSt NSt 
Yokokawa, 2008 1 NSt Yes NSt e e NSt NSt 
Bronus, 2009 2 Yes Yes Yes e e NSt f 
Licata, 2009 1 Yes Yes Yes Yes Yes NSt Yes  
Tsai, 2009 2 Yes Yes Yes Yes Yes NSt NSt 
Tuttolomondo, 2009a 3 NSt Yes Yes Yes Yes NSt Yes 
Tuttolomondo, 2009b 1 Yes Yes Yes Yes Yes NSt Yes 
Ilhan, 2010 3 NSt NSt Yes h NSt NSt NSt NSt 
Isenegger, 2010 1 Yes Yes Yes e e Yes NSt 
Alvarez-Perez, 2011 1 Yes Yes Yes Yes Partly g NSt f 
Beer, 2011 1 NSt NSt Yes d e e NSt NSt 
Hanson, 2011 1 Yes Yes NSt Yes Yes NSt Yes  
Jeong, 2011 2 Yes Yes NSt Yes Partly r NSt Yes 
Pavlovic, 2011 1 Yes Yes Yes c Yes NSt NSt NSt 
Supanc, 2011 1 Yes NSt Yes Yes NSt NSt NSt 
Turgut, 2011 1 Yes Yes Yes Age only Yes NSt NSt 
Zhang, 2011 3 Yes Yes NSt e e NSt NSt 
No = used when authors specifically report in the negative, otherwise NSt = not stated.  a. Although infection not an exclusion criteria.  b. Not matched for 
blood pressure or cholesterol.  c. Excluded if renal insufficiency, B12 and folate deficiency and alcohol abuse.  d. Excluded if high glucose or co-morbid acute 
illness.  e. No non-stroke control group, study investigates differences in biomarkers between subtypes of ischaemic stroke only.  f. Laboratory normal ranges 
reported.  g. Not matched for hypertension.  h. Excluded if ICH, cardiac sources of emboli or concomitant severe systemic disease.  i. Authors report testing 
samples twice but do not report intra-assay variability statistic.  j. Excluded if on folic acid or Vit B12 due to the influence on homocysteine.  k. Not matched 
for hypertension and diabetes. l. Not matched for systolic blood pressure and cholesterol.  m. Not matched for hyperlipidemia.  n. Not matched for 
hyperlipidemia.  o. Not matched for hypertension, smoking and diabetes.  p. Hypertension in atherothrombotic and lacunar subtypes not matched to controls.  
q. Not matched for diabetes and ischaemic heart disease.  r. Not matched for hypertension.  * We assessed the quality of the definition of lacunar stroke as 
follows: 0 = no definition, 1 = minimal (such as imaging + reference to recognized ischaemic stroke subtyping system), 2 = acceptable (such as imaging + 
reference to a recognized lacunar syndrome clinically), 3 = full (such as imaging including noting that a normal scan does not exclude a lacunar diagnosis + 
reference to one of the classical lacunar syndromes + mention of no evidence of cortical dysfunction, and 4 = gold standard as 3 but also reported on who 
subtyped the stroke.  
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Plasma biomarkers 
Plasma biomarker data of included studies is reported here (see also Table 2.4). 
Coagulation / fibrinolysis 
t-PA: Five studies90–94 (251 lacunar strokes) of which one study92 contributes 50% of 
the data.  There were insufficient data in an appropriate format for meta-analysis. 
Individual studies suggest t-PA was significantly higher in lacunar stroke versus non-
stroke controls, both acutely and chronically.  Meanwhile, t-PA does not differ 
between lacunar stroke and other stroke subtypes, either acutely or chronically. 
PAI: Seven studies90–96 (336 lacunar strokes) but available data did not permit meta-
analysis.  Jood et al.92 report levels of PAI significantly higher in lacunar stroke versus 
non-stroke controls acutely and chronically. They also report lower PAI in lacunar 
stroke versus atherothrombotic and cardioembolic stroke acutely but not chronically92.  
Four other studies report no difference between lacunar and non-lacunar stroke90,93–95. 
Fibrinogen: Nine studies86,89,91,97–102 (622 lacunar strokes), of which six permitted 
meta-analysis (Figure 2.2). Fibrinogen showed no difference in lacunar stroke versus 
non-stroke controls acutely but was significantly higher in lacunar stroke chronically. 
Fibrinogen was significantly lower in lacunar stroke versus other ischaemic stroke 
subtypes, both acutely (atherothrombotic SMD -0.37 (95% CI -0.51 to -0.22); 
cardioembolic SMD -0.83 (-1.15 to -0.51)) and chronically (Figure 2.2), although the 
chronic data comprised only one study98.  Two97,100 of three97,99,100 studies that could 
not be meta-analyzed report no difference in levels of fibrinogen between lacunar 
stroke and non-lacunar stroke in the acute phase.    
  22 
 
Figure 2.2 Forest plot – fibrinogen.  Standardized mean difference of blood markers 
in lacunar stoke versus non-stroke controls and versus non-lacunar stroke at different 
times after stroke.  AT = atherothrombotic, CE = cardioembolic 
 
D-dimer: Nine studies73,91,96,98,100,103–106 (364 lacunar strokes) of which four could be 
meta-analyzed (Figure 2.3).  D-dimer was significantly higher in lacunar stroke versus 
non-stroke controls, both acutely (SMD 1.42 (1.14 to 1.69)) and chronically (SMD 
3.22 (2.65 to 3.78)).  D-dimer was significantly lower in lacunar versus non-lacunar 
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stroke, both atherothrombotic (e.g. acute SMD -3.59 (-4.06 to -3.12)) and 
cardioembolic (e.g. acute SMD -5.73 (-6.38 to -5.09)), acutely and chronically.  The 
largest (n=128 lacunar strokes) of five studies73 that could not be meta-analyzed found 
no difference in D-dimer between lacunar and atherothrombotic stroke acutely (which 
disagrees with the meta-analysis) and found D-dimer significantly lower in lacunar 
versus cardioembolic stroke acutely (in agreement with the meta-analysis). 
 
Figure 2.3 Forest plot – D-dimer. Standardized mean difference of blood markers in 
lacunar stroke versus non-stroke controls and versus non-lacunar stroke at different 
times after stroke. AT = atherothrombotic, CE = cardioembolic 
Study or Subgroup
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Endothelial activation / dysfunction 
Homocysteine: Nine studies80–82,95,101,107–110 (747 lacunar strokes) of which eight could 
be meta-analyzed (Figure 2.4).  Homocysteine was significantly higher in lacunar 
stroke versus non-stroke controls, both acutely (e.g. SMD 0.55 (0.42 to 0.69)) and 
chronically. Studies comparing lacunar to non-lacunar stroke drew blood acutely only 
and found no difference (atherothrombotic SMD -0.02 (-0.22 to 0.18); cardioembolic 
SMD 0.16 (-0.02 to 0.35)).  One study95 not included in the meta-analysis found no 
difference in homocysteine between lacunar and non-lacunar stroke acutely.  
 
Figure 2.4 Forest plot – homocysteine.  Standardized mean difference of blood 
markers in lacunar stoke versus non-stroke controls and versus non-lacunar stroke at 
different times after stroke.  AT = atherothrombotic, CE = cardioembolic 
Study or Subgroup
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vWF: Six studies83,93,97,101,111,112 (293 lacunar strokes) of which two83,101 were meta-
analyzable (Figure 2.5). vWF was significantly higher in lacunar stroke versus non-
stroke controls acutely.   vWF was significantly lower in lacunar versus non-lacunar 
stroke (both atherothrombotic (SMD -0.34 (-0.61 to -0.08)) and cardioembolic (SMD 
-0.38 (-0.62 to -0.14)) acutely.  The four non meta-analyzable93,97,111,112 studies show 
conflicting results.  
 
Figure 2.5 Forest plot – von Willebrand factor. Standardized mean difference of blood 
markers in lacunar stoke versus non-stroke controls and versus non-lacunar stroke at 
different times after stroke.  AT = atherothrombotic, CE = cardioembolic 
 
E-selectin: Four studies93,94,101,111 (130 lacunar strokes) but available data did not 
permit meta-analysis.  One study111 found E-selectin significantly higher in lacunar 
stroke versus non-stroke controls acutely but not at one month.  Individual studies’ 
reports suggest no difference between lacunar and non-lacunar stroke.   
P-selectin: Seven studies93,94,96,97,111,113,114 (227 lacunar strokes) but available data did 
not permit meta-analysis. P-selectin was significantly higher in lacunar versus non-
stroke acutely in two studies111,114 but another96 found no difference.  One study113 
found P-selectin significantly lower in lacunar versus atherothrombotic stroke acutely 
Study or Subgroup
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but all other studies found no difference.  Tsai and colleagues113 continued to show 
levels to be significantly lower at one month but this difference disappeared at three 
months.  Only one study97 found P-selectin significantly lower in lacunar versus 
cardioembolic stroke acutely; all other studies found no difference or did not report 
significance levels. 
ICAM: Five studies87,93,94,115,116 (344 lacunar strokes) but available data did not permit 
meta-analysis.  One study87 found significantly higher ICAM in lacunar stroke versus 
non-stroke controls acutely; another study115 found ICAM significantly higher in 
lacunar versus non-stroke controls chronically.  There was no difference between 
lacunar and other stroke subtypes acutely and no data for lacunar versus non-lacunar 
stroke chronically.    
VCAM: Three studies93,94,116 (121 lacunar strokes) but available data did not permit 
meta-analysis. Results suggested no difference between lacunar stroke and non-stroke 
acutely and no difference between lacunar and non-lacunar stroke acutely.  No studies 
measured VCAM chronically. 
Inflammation 
CRP: Eight studies72,73,95,100,101,112,114,117 (490 lacunar strokes) but available data did 
not permit meta-analysis.  Two studies72,73 provide just over 50% of the data.  CRP 
was higher in lacunar stroke versus non-stroke acutely in three studies72,100,114, 
significantly so in two and a third100 that did not report if the higher value was 
significant.  CRP was significantly lower in lacunar versus atherothrombotic stroke in 
one study100 acutely; all other studies report no difference (or did not state significance) 
between lacunar and non-lacunar stroke, acutely and chronically. 
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TNF-α: Five studies87,88,93,112,117 (252 lacunar strokes) but available data did not permit 
meta-analysis.  One study87 provides 45% of the data.  Two studies87,88 found levels of 
TNF-α significantly higher in lacunar stroke versus non-stroke controls acutely.  TNF-
α was significantly lower in two93,112 and no different in two88,117 studies reporting on 
lacunar versus non-lacunar stroke acutely.  No studies measured TNF-α chronically. 
IL-6: Nine studies87–89,93,112,117–120 (340 lacunar strokes) of which five could be meta-
analyzed (Figure 2.6).  IL-6 was significantly higher in lacunar stroke versus non-
stroke acutely (SMD 1.3 (0.9, 1.7)).  IL-6 was significantly lower in lacunar versus 
non-lacunar stroke: both atherothrombotic (SMD -0.37 (-0.63 to -0.10)) and 
cardioembolic (SMD -0.52 (-0.82 to -0.22)) acutely. One non-metaanalyzable study87 
found IL-6 significantly higher in lacunar stroke versus non-stroke acutely while two 
non-metaanalyzable studies93,112 found IL-6 significantly lower in lacunar versus non-
lacunar stroke acutely, all in agreement with the meta-analyzed studies.   
 
Figure 2.6 Forest plot – Il-6. Standardized mean difference of blood markers in 
lacunar stoke versus non-stroke controls and versus non-lacunar stroke at different 
times after stroke.  AT = atherothrombotic, CE = cardioembolic  
Study or Subgroup
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Table 2.4 Results from included studies  
 
Lacunar versus: 
 Units Time n Lacunar n Non stroke  p1 n AT  p2 n CE  p3 
t-PA 
Lindgren, 1996 ug/l 2d 33 11 77 6 Sig1 34 9.5 ♣ ≠1 38 9 ♥ ≠1 
Salobir, 2002 ng/ml chron 16 6.9 (5.8-8.5) 47 5.3 (4.1-7.1) p<0.05 -- -- -- -- -- -- 
Jood, 2005 ug/l <10d 124 11.8 (8.4-14.7) 600 9.8 p<0.001 73 12.6 (9.7-17.5) NSt 98 14.1 (10.2-18.7) NSt 
  3m 124 11.2 (8.9-13.2) -- Used <10d data p<0.001 73 12.5 (9.7-16.3) NSt 98 13.2 (9.5-16.3) NSt 
Tuttolomondo, 2009a pg/ml <12h 32 27 (20-39) 102 55 (29-88) § 41 34 (14-43) p=0.85^ 29 21 (17-23) p=0.85^ 
Tuttolomondo, 2009b pg/ml <72h 46 28 (20-38) 123 74 (59-98) § 50 24 (14-36) p=0.85^ 20 22 (17-23) p=0.85^ 
PAI 
Lindgren, 1996 ug/l 2d 33 22 77 8 Sig2 34 15 ♣ ≠1 39 12 ♥ ≠1 
Salobir, 2002 ng/ml chron 16 10.6 (5.9-16.4) 47 8.8 (6.0-16.1) ≠ -- -- -- -- -- -- 
Jood, 2005 ug/l <10d 124 51.2 (38.7-71.8) 600 39.1 (23.6-60.0) p<0.001 73 56.7 (38.8-74.2) NSt 98 52.7 (35-68.8) NSt 
  3m 124 53.8 (34.4-77.1) -- Used <10d data p<0.001 73 61.9 (44.1-78.8) ≠ 98 52.9 (34.2-75.7) ≠ 
Yokokawa, 2008 ng/ml On 55 19 (10-94) -- -- -- 87 19 (10-200) ≠ 19 25 (10-62) ≠ 
Tuttolomondo, 2009a pg/ml <12h 32 145 (118-192) 102 23 (11-24) § 41 124 (89-159) p=0.41^ 29 152 (103-197) p=0.41^ 
Tuttolomondo, 2009b pg/ml <72h 46 155 (108-172) 123 21 (12-26) § 50 134 (98-168) p=0.61^ 20 162 (123-187) p=0.61^ 
Ilhan, 2010 ng/ml 0-5d 30 50.74 ±10.49 30 57.14 ±9.72 p=0.034 -- -- -- -- -- -- 
  15d 30 48.90 ±8.95 -- -- -- -- -- -- -- -- -- 
  30d 30 51.75 ±12.39 -- -- -- -- -- -- -- -- -- 
D-dimer 
Takano, 1992 ng/ml 1d 23 115.3 ±15.5 20 82.1 ±9.1 ≠ 10 171.3 ±29.4 NSt 21 607 ±167.6 NSt 
  7d 23 125 ±20 ♠ -- -- ≠2 10 280 ±35 ♠ NSt 21 400 ±80 ♠ NSt 
  30d 23 110 ±18 ♠ -- -- ≠2 10 125 ±20 ♠ NSt 21 255 ±40 ♠ NSt 
Kataoka, 2000 ng/ml <48h 58 0.7 ±0.1 ♠ 32 0.6 ±0.1 ≠ 41 1.7 ±0.4 ♠ NSt 38 3.0 ±0.5 ♠ p<0.001 
  1w 58 1.4 ±0.2 ♠ -- -- ≠ 41 2.2 ±0.4 ♠ NSt 38 5.2 ±0.8 ♠ p<0.0001 
  3w 58 1.5 ±0.2 ♠ -- -- NSt 41 2.3 ±0.4 ♠ NSt 38 3.2 ±0.5 ♠ p<0.0001 
Ageno, 2002 ug/ml 1d 31 0.67 ±0.08 63 0.53 ±0.14 ≠ 34 1.34 ±0.21 p=0.01 34 2.96 ±0.51 p=0.009 
  6d 31 0.72 ±0.06 -- -- -- 34 1.53 ±0.26 P=0.002 34 2.58 ±0.4 p=0.009 
  12d 31 0.64 ±0.1 -- -- -- 34 2.91 ±0.59 p=0.03 34 3.79 ±0.53 p=0.009 
Salobir, 2002 ng/ml chron 16 57 (54-83) 47 59 (50-73) ≠ -- -- -- -- -- -- 
Montaner, 2008 ug/ml 8h 128 0.6 (0.3-1.3) -- -- -- 151 0.5 (0.2-1.7) ≠ 259 1.1 (0.5-2.3) p<0.001 
Brouns, 2009 ng/ml <9h 23 362 -- -- -- 105 1500 ‡ p<0.001 -- -- -- 
Ilhan, 2010 ug/dl 0-5d 30 1.36 ±0.62 30 0.35 ±0.21 p<0.001 -- -- -- -- -- -- 
  15d 30 0.77 ±0.24 -- -- -- -- -- -- -- -- -- 
  30d 30 0.64 ±0.17 -- -- -- -- -- -- -- -- -- 
Isenegger, 2010 ug/l 4h 5 290 (217) -- -- -- 11 465 (835) NSt 53 615 (405) p<0.001 & 
Alvarez-Perez, 2011 ng/ml <48h 50 224.5 (162-281) 50 190.5 (140-240.5) p=0.042 50 218 (156.8-406) NSt 50 500 (235.5-675) p<0.0001 
Homocysteine 
Eikelboom, 2000 umol/l <7d 68 12.7 (11.4-14.1) ♂ 205 10.5 (10-11) ♂ p=0.004 63 14.1 (12.5-15.9) ♂ NSt 45 11.6 (10.2-13.1) NSt 
Hassan, 2004 umol/l >2m 172 14.5 (13.78-15.35) ♂ 172 12.0 (11.42-12.64) ♂ p<0.0005 -- -- -- -- -- -- 
Parnetti, 2004 umol/l NSt 50 13.9 ±5.4 152 8.1 ±2.5 p<0.0001 43 17.8 ±13.5 p=0.046 31 13.0 ±2.5 ≠ 
Khan, 2007 umol/l >3m 47 15.14 ±5.59 38 12.49 ±4.15 p=0.029 -- -- -- -- -- -- 
Khan, 2008 umol/l On 152 16.2 ±11.6 179 11.8 ±5.7 p<0.001 40 11.6 ±4.8 p<0.005 72 14.3 ±6.3 ≠ 
Yokokawa, 2008 nmol/ml On 55 10.6 {6.0-50.0} -- -- -- 87 11.2 {5.0-26.3} ≠ 19 9.4 {5.7-26.4} ≠ 
Beer, 2011 umol/l ~63h 25 10.1 ±3.6 -- -- -- 19 9.9 ±4.9 ≠ 43 10.2 ±3.9 ≠ 
Jeong, 2011 umol/l 3d 83 11.3 ±3.8 135 11.2 ±3.4 p=0.871 -- -- -- -- -- -- 
Pavlovic, 2011 umol/l 1-6m 95 14.4 ±5.0 41 8.9 ±3.9 p<0.0001 -- -- -- -- -- -- 
von Willebrand factor 
Bath, 1998 IU/dl <48h 40 144 [19] 25 114 [16] NSt 28 140 [15] ♣ ≠1 39 158 [25] ♥ ≠1 
Kozuka, 2002 % <48h 27 165 (123-206) 86 132.5 (102-166) p=0.011 16 176.5 (145-195.5) NSt 9 223 (166-253) NSt 
  1m 27 176 (143.5-202.3) -- Used <48h data p<0.001 16 190.5 (167.5-251.5) NSt 5 182.5 (172-228) NSt 
Licata, 2009 ng/ml 36h 46 6 (3-8) 123 4 (3-8) § 50 8 (6-10) p=0.005^ 20 10 (5-12) p=0.005^ 
Tuttolomondo, 2009a ng/ml <12h 32 5 (2-9) 102 4 (3-9) § 41 7 (4-11) p=0.005^ 29 12 (6-13) p=0.005^ 
Beer, 2011 % ~63h 25 164 ±56.7 -- -- -- 19 163.0 ±67.3 ≠ 43 158.8 ±61.0 ≠ 
Hanson, 2011 IU/dl <10d 123 213 (197-229) ♂ 599 180 (145-245) ♠ p<0.01 69 253 (230-279) ♂ Sig0 94 263 (242-286) ♂ Sig0 
  3m 123 201 (189-215) ♂ -- Used <10d data ≠ 69 NSt NSt 94 240 (224-256) ♂ Sig0 
Fibrinogen 
Kilpatrick, 1993 g/l <48h 9 3.9 ±1.1 ♦ 2.0-5.0  ≠ 10 4.1 ±1.2 NSt -- -- -- 
Beamer, 1995 mg/dl 4d 23 377 ±133 20 334 ±39 § 12 452 ±91 ≠ 6 493 ±184 ≠ 
Bath, 1998 g/l <48h 56 4.65 [0.7] 33 3.7 [0.7] NSt 38 4.6 [0.75] ♣ ≠1 53 4.8 [0.9] ♥ ≠1 
Kataoka, 2000 mg/ml <48h 58 316 ♠ 32 315 ±16.2 NSt 41 415 ♠ p<0.0001 38 340 ♠ NSt 
  1w 58 400 ♠ -- -- -- 41 520 ♠ p<0.0001 38 490 ♠ p<0.001 
  3w 58 350 ♠ -- -- -- 41 480 ♠ p<0.0001 38 450 ♠ NSt 
Salobir, 2002 g/l chron 16 2.6 ±0.4 47 2.3 ±0.4 p<0.05 -- -- -- -- -- -- 
Jood, 2008 g/l <10d 123 3.55 (2.91-4.18) 599 2.91 (2.61-3.30) p<0.001 69 4.14 (3.31-5.10) NSt 94 3.86 (3.35-4.61) NSt 
  3m 123 3.27 (2.89-3.69) -- Used <10d data p<0.001 69 3.64 (3.06-4.65) NSt 94 3.43 (2.92-4.09) NSt 
Alvarez-Perez, 2011 mg/dl <48h 50 322.5 (270-390) 50 281 (255-319.5) NSt 50 325 (287-374) ≠ 50 340 (293-408.5) ≠ 
Beer, 2011 g/l ~63h 25 4.1 ±0.8 -- -- -- 19 4.3 ±1.1 ≠ 43 4.2 ±0.9 ≠ 
Zhang, 2011 g/l On 262 2.96 ±1.04 -- -- -- 364* 3.23 ±1.37 p=0.02 -- -- -- 
CRP 
Ladenvall, 2006 mg/l <10d 124 3.08 (1.52-5.79) 600 1.61 (0.85-3.38) p<0.001 73 4.66 (1.79-13.9) NSt 98 7.07 (2.39-17.8) NSt 
  3m 124 2.65 (1.26-4.82) -- Used <10d data p<0.001 73 3.48 (1.42-9.99) NSt 98 2.66 (1.07-5.46) NSt 
Montaner, 2008 ug/ml 8h 128 9.8 (4.6-23.7) -- -- -- 151 8.7 (4.1-21.7) ≠ 259 11.7 (4.6-28.6) ≠ 
Nakase, 2008 ng/dl On 42 103.4 ±138.4 -- -- -- 20 140.6 ±133.3 NSt 30 174.2 ±262.9 NSt 
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Yokokawa, 2008 mg/l On 55 0.095 {0.029-0.95} -- -- -- 87 0.092 {0.029-8.97} ≠ 19 0.115 {0.029-1.43} ≠ 
Licata, 2009 mg/dl 36h 46 3.1 (1.4-4.1) 123 1.3 (0.8-1.5) § 50 3.2 (1.3-4.0) p=0.35^ 20 3.4 (1.5-4.3) p=0.35^ 
Alvarez-Perez, 2011 mg/dl <48h 50 0.32 (0.16-0.68) 50 0.18 (0.08-0.30) NSt 50 0.58 (0.24-1.09) p=0.01 50 0.36 (0.24-0.97) NSt 
Beer, 2011 mg/l ~63h 25 4.6 ±4.7 -- -- -- 19 11.4 ±25.4 ≠ 43 14.1 ±19.7 ≠ 
Turgut, 2011 mg/l 1w 20 1.59 ±1.63 37 0.19 ±0.24 p<0.0001 31 3.34 ±4.58 ≠ 21 2.93 ±4.56 ≠ 
ICAM 
Castellanos, 2002 pg/ml ~10h 113 187 (172-223) 43 167 (140-207) p=0.015 -- -- -- -- -- -- 
Hassan, 2003 ng/ml 210d 110 425.3 (395-457) ♂ 50 341.9 (320-364) ♂ p<0.0005 -- -- -- -- -- -- 
Tuttolomondo, 2009a ng/ml <12h 32 20.51 (15-23) 102 10.9 (12-16.1) § 41 23.8 (15.9-24) p=0.57^ 29 22.52 (18.55-23) p<0.57^ 
Tuttolomondo, 2009b ng/ml <72h 46 19.91 (15-23) 123 15.9 (12-18.1) § 50 20.8 (15.9-24) p=0.56^ 20 19.52 (18.55-23) p=0.56^ 
Supanc, 2011 ng/ml <24h 43 358 {14.8-673} 93 385.7 {213.7-464} NSt 67 376.5 {40-745} NSt -- -- -- 
VCAM 
Tuttolomondo, 2009a ng/ml <12h 32 16 (15-20) 102 10 (7-15) § 41 21 (13-22) p=0.52^ 29 20 (14.7-24) p<0.52^ 
Tuttolomondo, 2009b ng/ml <72h 46 17 (15-20) 123 14 (13-17) § 50 20 (15-24) p=0.53^ 20 20 (15.7-26) p=0.53^ 
Supanc, 2011 ng/ml <24h 43 675 (445-1210) 93 688 (555-850) NSt 67 730 (90-1810) NSt -- -- -- 
E-selectin 
Kozuka, 2002 ng/ml <48h 27 53.9 (34.8-65.5) 86 38.4 (28.6-46) p=0.001 16 44.3 (30.3-69) NSt 9 39.7 (31.8-54.6) NSt 
  1m 27 44.2 (34.9-55.8) -- Used <48h data p=0.09 16 55.5 (30-68.7) NSt 5 41.7 (29.2-57.2) NSt 
Tuttolomondo, 2009a ng/ml <12h 32 3 (2-5) 102 2 (1-2) § 41 4 (2-6) p<0.68^ 29 2.25 (1-4.5) p<0.68^ 
Tuttolomondo, 2009b ng/ml <72h 46 2 (2-4) 123 2 (1-2) § 50 3 (2-4) p=0.80^ 20 2.75 (2-3.5) p=0.80^ 
Beer, 2011 ng/ml ~63h 25 31.5 ±19.7 -- -- -- 19 22.4 ±17.0 ≠ 43 25.4 ±17.6 ≠ 
P-selectin 
Bath, 1998 ng/ml <48h 40 300 [108] 26 324 [121] NSt 28 265 [101] ♣ ≠1 39 408 [101] ♥ p<0.05 
Kozuka, 2002 ng/ml <48h 27 41.2 (33.9-62.5) 86 24.6 (20.8-30.5) p<0.001 16 48.9 (39.5-62.8) NSt 9 70.2 (35.7-83.0) NSt 
  1m 27 39.7 (29.3-60.0) -- Used <48h data p<0.001 16 65.1 (40.2-76.8) NSt 5 64.1 (45.9-87.8) NSt 
Tsai, 2009 % <48h 32 4.9 (1.7-8.2) -- -- -- 22 9.9 (4.3-12.7) p<0.001 -- -- -- 
  7d 32 4.4 (1.7-5.5) -- -- -- 22 8.6 (3.0-11.5) p<0.05 -- -- -- 
  30d 32 3.8 (1.1-6.0) -- -- -- 22 7.7 (4.0-11.3) p<0.05 -- -- -- 
  90d 32 2.3 (0.9-3.4) -- -- -- 22 5.1 (1.9-7.1) ≠ -- -- -- 
Tuttolomondo, 2009a ng/ml <12h 32 4 (2.2-7) 102 3.1 (2.1-4) § 41 4.05 (2-6) p<0.34^ 29 3.1 (1.3-6.3) p<0.68^ 
Tuttolomondo, 2009b ng/ml <72h 46 4 (2.4-6) 123 3.1 (2.1-4) § 50 4.95 (2-6.5) p=0.49^ 20 3.4 (1.46-6.43) p=0.49^ 
Ilhan, 2010 ng/ml 0-5d 30 44.03 ±18.7 30 48.06 ±9.19 p=0.243 -- -- -- -- -- -- 
  15d 30 42.70 ±23.80 -- -- -- -- -- -- -- -- -- 
  30d 30 42.86 ±16.05 -- -- -- -- -- -- -- -- -- 
Turgut, 2011 % 1w 20 7.26 ±2.49 37 3.89 ±4.16 p=0.02 31 7.49 ±5.06 ≠ 21 7.16 ±3.56 ≠ 
TNF-α 
Castellanos, 2002 pg/ml ~10h 113 8.2 (6.4-15.3) 43 7.0 (5.7-8.4) p=0.001 -- -- -- -- -- -- 
Domac, 2007 pg/ml 12h 19 41.7±26.3$ 22 16.7 ±5.5 p<0.0001 16 39.2 ±25.3$$ ≠ -- -- -- 
Licata, 2009 pg/ml 36h 46 19.4 (9-23) 123 3.7 (1.1-4.3) § 50 27.5 (13-40.5) p<0.0001 20 38.5 (22.2-46) p<0.0001 
Tuttolomondo, 2009a pg/ml <12h 32 18.4 (11-23) 102 5.1 (1.1-4.3) § 41 29.5 (15-44.5) p<0.0001 29 37.2 (21.2-48) p<0.0001 
Nakase, 2008 pg/ml On 42 1.9 ±1.7 -- -- -- 20 1.5 ±0.6 ≠ 30 1.7 ±1.5 ≠ 
IL-6 
Beamer, 1995 pg/ml 4d 23 2.8 ±2.8 20 1.0 ±0.9 § 12 5.4 ±2.7 ≠ 6 9.9 ±6.6 p<0.01 
Vila, 2000 pg/ml <24h 33 9.6 ±9.3 -- -- -- 84 24.5 ±14.2 p<0.01 76 18.0 ±16.4 p<0.01 
Castellanos, 2002 pg/ml ~10h 113 13.9 (9.2-23.8) 43 3.1 (1.3-4.1) p<0.001 -- -- -- -- -- -- 
Salobir, 2004 pg/ml 3.5y 16 1.6 (0-2.6) 47 1.4 (0-2.0) ≠ -- -- -- -- -- -- 
Guldiken, 2008 pg/ml <72h 16 8.79 ±3.73 23 4.68 ±3.0 p<0.01 12 4.28 ±3.97 p<0.01 -- -- -- 
Domac, 2007 pg/ml 12h 19 43.8±18.5$ 22 15.1 ±4.9 p<0.0001 16 34.1 ±17.05$$ ≠ -- -- -- 
Nakase, 2008 pg/ml On 42 3.0 ±3.7 -- -- -- 20 3.3 ±3.1 ≠ 30 3.6 ±2.6 ≠ 
Licata, 2009 pg/ml 36h 46 4.0 (2.0-9.0) 123 9 (2.90-18) § 50 8 (4-12) p=0.003^ 20 11 (5.5-19) p=0.003^ 
Tuttolomondo, 2009a pg/ml <12h 32 5 (2-8) 102 8 (3.1-12) § 41 7 (4-11) p=0.003^ 29 12 (6.5-18) p=0.003^ 
Values in units given, either as means alone or means ±SD or medians (IQR) or medians (Q1-Q3) or medians [semi-quartiles] or medians {min-max} or ♂ geometric mean with 95% CI. 
-- = not investigated / measured.   NSt = not stated 
AT = atherothrombotic stroke, CE = cardioembolic stroke 
p1 = lacunar versus non-stroke controls, p2 = lacunar versus atherothrombotic stroke, p3 = lacunar versus cardioembolic stroke 
≠ no p value given but authors stated “not statistically significant” (typically against p<0.05) 
≠1 not significant across multiple stroke subtypes but no specific pairwise analysis to lacunar stroke, assumed not sig.   ≠2 not significant versus the non-stroke control 1d value 
Time is average time to blood draw following initial stroke event, either mean or median.  On = blood markers measured on admission to hospital. Chron = authors state “a chronic, stable phase after LACI”. 
* Non-lacunar strokes (ie, includes some cardioembolic strokes) 
♦ Used a laboratory normal range to compare lacunar to. 
♠ Authors only present results graphically; this systematic review has read data off the graph. 
♣ PACI (not AT)  ♥ TACI (not CE) 
$ small sub-cortical infarct, $$ small cortical infarct 
Sig0 Stated as significant but no p value given 
Sig1 Lacunar to non-stroke control not stated although all patients (TACI, PACI, LACI) differed from non-stroke controls, p=0.0001 
Sig2 Lacunar to non-stroke control not stated although all patients (TACI, PACI, LACI) differed from non-stroke controls, p<0.01 
& p value compares non-CE strokes (lacunar and AT) to CE 
§ All strokes (lacunar and non-lacunar) are compared to non-stroke controls, and so cannot isolate a p value comparison for lacunar to healthy control 
‡ Lacunar versus non-lacunar (AT+CE+UDE) 
^ Analysis of variance across multiple stroke groups (LAC, AT, CE) rather than solely lacunar to other individual subtype. 
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Discussion 
This review assessed blood markers of coagulation, fibrinolysis, endothelial 
dysfunction and inflammation in lacunar stroke versus non-stroke controls and other 
ischaemic stroke subtypes. While many markers were higher in lacunar stroke than in 
non-stroke controls, they were mostly lower in lacunar versus non-lacunar stroke. A 
brief summary follows.   
 
Coagulation/fibrinolysis 
t-PA/PAI were significantly higher in lacunar stroke versus non-stroke, acutely and 
chronically and did not differ between lacunar and non-lacunar stroke, acutely or 
chronically. 
Fibrinogen did not differ between lacunar stroke and non-stroke acutely although we 
only used a single time point from Kataoka et al.98 (bloods drawn at <24).  If we 
consider their second sample (at 7 days) as a further acute measurement, lacunar stroke 
tends towards being significantly higher than non-stroke.  Fibrinogen was significantly 
higher in lacunar stroke versus non-stroke chronically.  Fibrinogen was significantly 
lower in lacunar versus non-lacunar stroke, acutely and chronically.  However, studies 
excluded from the meta-analysis tended to show no overall difference between lacunar 
and non-lacunar stroke and chronic data came from a single study.   
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D-dimer was significantly higher in lacunar stroke versus non-stroke, acutely and 
chronically, and significantly lower in lacunar versus non-lacunar stroke, acutely and 
chronically. 
Endothelial dysfunction 
Homocysteine was significantly higher in lacunar stroke versus non-stroke, acutely 
and chronically, did not differ between lacunar and non-lacunar stroke acutely (but no 
chronic phase studies). 
vWF was significantly higher in lacunar stroke versus non-stroke, acutely, with 
conflicting evidence chronically.  vWF was significantly lower in lacunar than non-
lacunar stroke acutely (2 studies) with conflicting but non-meta-analyzable evidence 
in other studies both acutely and chronically.   
E-selectin was significantly higher in lacunar stroke versus non-stroke acutely (only 
one study) but not chronically and did not differ between lacunar and non-lacunar 
stroke, either acutely or chronically (only one study). 
P-selectin was significantly higher in lacunar stroke versus non-stroke acutely in some 
but not all studies, and in the only study that reported a chronic measurement.  P-
selectin did not differ between lacunar and non-lacunar stroke, either acutely or 
chronically (only one study). 
ICAM was significantly higher in lacunar stroke versus non-stroke, acutely and 
chronically (only one study), did not differ between lacunar and non-lacunar stroke 
acutely, with no studies chronically. 
  32 
VCAM did not differ between lacunar stroke and non-stroke, nor between lacunar and 
non-lacunar stroke acutely.  There were no studies chronically. 
Inflammation 
CRP was significantly higher in lacunar stroke versus non-stroke, acutely and 
chronically (only one study) and did not differ between lacunar and non-lacunar stroke 
acutely or chronically (only one study). 
TNF-α was significantly higher in lacunar stroke versus non-stroke acutely with no 
studies chronically.  There was conflicting evidence on levels of TNF-α in lacunar 
versus non-lacunar stroke acutely with no studies chronically. 
IL-6 was significantly higher in lacunar stroke versus non-stroke acutely but did not 
differ chronically. IL-6 was significantly lower in lacunar versus non-lacunar stroke 
acutely, but there were no chronic phase studies. 
 
This suggests that plasma marker elevation in lacunar stroke is likely to reflect the 
process of having a stroke rather than that systemic inflammation or endothelial 
dysfunction is specific to lacunar stroke.  The available data were limited and do not 
exclude the possibility that peripheral inflammatory or endothelial dysfunction 
processes are associated with lacunar stroke specifically.   
There were limitations in the studies.  Most were small, with varying methods and an 
inconsistent definition of ‘lacunar stroke’, as highlighted previously121.  Papers 
reviewed used the term lacunar stroke to reflect a clinical entity, ie clinical presentation 
with a stroke, but definitions varied.  We were not able to differentiate different 
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mechanisms of lacunar stroke.  Most lacunar strokes are due to recent small subcortical 
infarcts (RSSI), and most RSSI relate to intrinsic small vessel disease.  However, RSSI 
also arise from atherothromboembolism (large artery) or cardioembolism in a small 
proportion of patients and it was not possible to differentiate these cases. 
There was heterogeneity across several aspects of the methods. Many used TOAST85 
but as this uses risk-factors to categorize patients it potentially introduces classification 
bias.  A patient with an unclear diagnosis of lacunar stroke but concurrent hypertension 
or diabetes might (rightly or wrongly) be classified as ‘lacunar’ using this system 
although hypertension and diabetes were equally prevalent risk factors between 
ischaemic stroke subtypes in 21,980 stroke patients when subtypes were classified 
without risk factors20.  Several did not report on whether their findings achieved 
statistical significance; in the absence of an explicit statement, we report this as not 
stated.  Some studies drew blood after overnight fasting, others collected non-fasting 
blood.  Studies used different units of measurement and assay methods.  Timing of 
blood draw in relation to stroke varied but is important to account for each marker’s 
individual ‘response curve’ which changes over time.  Fassbender and colleagues122 
found levels of IL-6 to rise rapidly following onset of ischaemic stroke, reaching a 
plateau at 10 hours until 3 days before returning to normal by day 7.  Between-study 
heterogeneity on time to blood draw complicates subsequent analysis although meta-
analyses use within-study data thus minimising any effect of between-study variation.   
Our review had limitations. We did not study markers in cerebrospinal fluid.  We did 
not review the association of marker levels with lesion size or clinical outcome as data 
were sparse.  Ahmad et al.123 found markers of neuronal damage correlated with infarct 
size which might explain why marker levels in non-lacunar stroke were frequently 
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higher than in lacunar stroke in the acute phase.  We were not able to analyse 
differences between groups reported as top versus bottom quantiles.  There are also 
potential sources of bias in our review: we did not review non-English language 
studies, the studies meta-analysed were observational and also we did not use funnel 
plots to assess for publication bias.  We did not formally test the methodological 
quality of studies reviewed by sensitivity analysis to investigate impact on effect size. 
Our review had strengths including assessment of differences between stroke subtypes, 
quality assessment of included studies (but no formal testing for impact on effect size), 
meticulous extraction of data and meta-analysis thereon, wherever suitable data were 
available.  Previous reviews compared lacunar stroke to non-stroke controls only and 
therefore did not distinguish lacunar stroke specifically from stroke in general.   
To determine if there is a difference in coagulation, fibrinolysis, endothelial 
dysfunction and inflammation in lacunar versus other stroke subtypes requires a large 
prospective study of blood markers in accurately phenotyped patients with lacunar 
versus non-lacunar stroke classified using non-risk factor based definitions. Future 
studies should clearly define and diagnose lacunar stroke, avoid subtyping stroke using 
risk factor based classifications, and obtain blood several weeks post stroke to avoid 
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Chapter 3: Plasma biomarkers of inflammation, endothelial function and 
haemostasis in cerebral small vessel disease: the Mild Stroke Study  
[now published: Wiseman et al. Cerebrovasc Dis. 2015;40:157–64] 
 
Introduction 
Plasma biomarkers of inflammation, endothelial dysfunction and haemostasis may 
provide mechanistic insights to the cause of lacunar ischaemic stroke via implicated 
processes such as systemic inflammation, blood-brain barrier failure or occlusive 
microthrombus18,67–70.  Plasma biomarkers may predict outcome after stroke124 and 
could have a role in management of stroke patients125. 
In chapter 2, a systematic review and meta-analysis showed most plasma biomarkers 
were raised in lacunar stroke versus non-stroke controls, probably reflecting the acute 
response to having a stroke.  However, when lacunar stroke was compared to other 
ischaemic stroke subtypes to control for having a stroke, some biomarkers had lower 
values (D-dimer, vWF, fibrinogen and IL-6) but many other biomarkers either showed 
no difference to the other stroke subtypes, or data were limited or inconclusive.  
Magnetic resonance (MR) imaging features of SVD include white matter 
hyperintensities (WMH) and are associated with ischaemic and haemorrhagic stroke 
and dementia21.  WMH predict an increased risk of stroke21 and are associated with 
poor functional outcomes following stroke126.   
The relationship between plasma biomarkers and imaging biomarkers of SVD is not 
fully understood.  Systematic reviews68,74,127 are impeded by between-study 
heterogeneity in the source studies, and differ in their findings.  Generally, plasma 
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biomarkers are raised in lacunar stroke versus non-stroke healthy controls (used in 
most studies) but differences here are unsurprising, especially in the acute phase of 
stroke.  The situation is less clear when lacunar stroke is compared to other ischaemic 
stroke subtypes.   
In two large population studies of subjects without stroke, higher inflammatory 
biomarkers were independently associated with higher WMH volumes67,128  but not in 
three other studies129–131.  Biomarkers of endothelial activation were associated with 
WMH in cross sectional analysis132 and with WMH progression69.  Flow-mediated 
dilatation studies have shown endothelial dysfunction in lacunar stroke versus non-
stroke controls133.  
Prior stroke studies often take the plasma samples too early making it difficult to 
isolate underlying trends independent from an acute phase response.  Few studies 
assessed a range of biomarkers simultaneously in one population. 
The purpose of this study was (1) to determine if there were differences in levels of 
plasma biomarkers of a) inflammation, b) endothelial dysfunction or c) haemostasis 
between lacunar and cortical stroke subtypes, well after the acute event, as 
representative of three potential SVD mechanisms, adjusted for age and major vascular 
risk factors; (2) to update our meta-analysis and place current findings into context; 
and (3) to assess the association between the three plasma biomarker groups and 
WMH, irrespective of stroke subtype.  
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Methods 
Our definition of SVD is in accordance with Standards for reporting vascular changes 
on neuroimaging (STRIVE) neuroimaging reporting guidelines19.  
Patients 
We prospectively recruited patients as consecutively as possible who presented with 
ischaemic stroke of lacunar or mild (ie, non-disabling) cortical subtype seen at a 
regional stroke service, as detailed previously134.  Patients with cortical stroke acted as 
controls because they have many similar risk factors, medications and extent of 
damage due to the stroke to patients with lacunar stroke, thus controlling for potential 
confounders and allowing us to differentiate findings specific to SVD.    We excluded 
patients with contraindications to MR, haemorrhagic stroke or severe stroke, ie, 
disabling total anterior circulation stroke. The study was approved by the local 
research ethics committee (2002/8/64) and all patients gave written informed consent. 
Patient investigations 
Patients were clinically assessed at presentation and underwent MR brain imaging at 
1.5T, carotid Doppler ultrasound and electrocardiogram.  We recorded past medical 
histories including hypertension, diabetes, hypercholesterolemia and smoking, and 
measured blood pressure and blood lipids as per the usual stroke patient assessment. 
Stroke subtype 
We assessed stroke severity with the National Institute for Health Stroke Scale 
(NIHSS)135 (but did not use NIHSS as selection criteria) and classified the stroke 
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clinical syndrome (lacunar or cortical) according to the Oxfordshire Community 
Stroke Project (OCSP)15.  We defined “lacunar stroke” as per the classical clinical 
lacunar syndromes (pure motor weakness or sensory loss or both in face and arm, arm 
and leg or all three, ataxic hemiparesis or clumsy hand dysarthria syndrome).  We 
defined “mild cortical stroke” as a maximum clinical deficit of either: weakness or 
sensory loss in the face, arm or leg, or loss of higher cerebral function (dysphasia or 
neglect), or weakness in more than one limb in the presence of loss of higher cerebral 
function (all in keeping with a partial anterior circulation stroke), or a homonymous 
hemianopia suggestive of occipital cortical infarct (in keeping with a cortical posterior 
circulation stroke).   
We then assessed whether a recent infarct on MR was firstly present and secondly 
whether it was cortical or lacunar.  We based the final stroke subtype classification on 
both the clinical and radiological classification.  Where the clinical classification 
differed from the radiological classification, the radiological classification was used – 
using clinical criteria alone can result in misclassification of infarcts in up to 20% of 
cases136.  Where an infarct on imaging was absent, an expert panel with all available 
information assigned the final stroke subtype.  
Plasma biomarkers 
All patients had blood sampled after a minimum of one and maximum of three months 
following stroke to avoid the acute phase.  Samples were spun and frozen for batch 
analysis, blind to clinical data.  We measured markers of inflammation (C-reactive 
protein (CRP), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)), 
endothelial activation (von Willebrand factor (vWF) and intracellular adhesion 
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molecule-1 (ICAM)) and thrombotic/fibrinolytic activity (fibrinogen, tissue 
plasminogen activator antigen (t-PA) and D-dimer).  Intra- and inter-assay variation 
on biomarker testing was between 3.3% and 12.5% (Table 3.1). 
 
Table 3.1 Intra- and inter-assay variation on biomarker testing 







CRP Immunonephelometry (Prospec, Dade Behring 
Milton Keynes, UK) 
mg/l 4.7% 8.3% 
TNF-α ELISA (R&D Systems, Abingdon, UK) pg/ml 8.4% 12.5% 
IL-6 ELISA (R&D Systems, Abingdon, UK) pg/ml 7.5% 8.9% 
Endothelial dysfunction 
ICAM ELISA (R&D Systems, Abingdon, UK) ng/ml 3.6% 7.4% 
vWF ELISA (DAKO, High Wycombe, UK) IU/dl 3.3% 4.2% 
Thrombosis/fibrinolysis 
Fibrinogen Immunonephelometry (Prospec, Dade Behring 
Milton Keynes, UK) 
g/l 7.5% 8.9% 
t-PA ELISA (Biopool AB, Umea Sweden) ng/ml 6.6% 6.5% 
D-dimer ELISA (Biopool AB, Umea Sweden) ng/ml 4.7% 5.2% 
CRP = C-reactive protein, CV = coefficients of variation, ELISA = enzyme-linked immunosorbent 
assay, ICAM = intracellular adhesion molecule-1, IL-6 = interleukin-6, TNF-α = tumour necrosis 
factor alpha, t-PA = tissue plasminogen activator, vWF = von Willebrand factor. 
 
Image analysis 
All scans were reviewed by a neuroradiologist for the index infarct and rated for SVD 
features using standardized scales137–139 including the Fazekas scale for WMH.  A 
quantitative, volumetric measure of WMH (in mm3) was also calculated, as described 
previously140.  We corrected for head size by dividing the quantitative WMH load by 
the intracranial volume.  Visually rated WMH correlated strongly with quantitative 
WMH (r=0.84, 95% CI 0.77 to 0.89).  
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Statistical analysis 
We assessed differences in patient demographics and plasma biomarkers between 
stroke subtypes using Student’s t test, Mann-Whitney U test and Chi-squared test (χ2), 
as appropriate.  Quantitative WMH and some plasma biomarkers (CRP, TNF-α, IL-6, 
D-dimer) were not normally distributed so we log transformed these data. 
We explored the association between stroke subtypes and plasma biomarkers with 
multiple linear regression to control for age, sex and vascular risk factors.   
We used multiple linear regression to assess the contribution of plasma biomarkers in 
explaining variance in quantitative WMH volume (n=98; 27 scans were unavailable 
for WMH quantification), irrespective of stroke subtype.  We repeated the modelling 
with visually rated WMH, for which the full dataset was available (n=125). 
We used standardized units (mean=0, sd=1) for all plasma biomarkers in the regression 
models.  The standardized data have no units and are on the same scale, so different 
biomarkers can be added together into summed variables which reduces the number 
of predictor variables to help avoid model over-fitting.  We verified the correlation 
between the components of the summed variables.  The summed variables were: 
Inflammation (INF) (CRP + TNF-α + IL-6), Endothelial dysfunction (END) (vWF + 
ICAM) and Thrombosis (THR) (t-PA + D-dimer + fibrinogen).  
We fitted a baseline model with quantitative WMH volume as the outcome measure 
and age, sex, hypertension and smoking status as the predictor variables.  Patients with 
a past history of tobacco use were classified as non-smokers if they were non-smokers 
at time of stroke.   
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We fitted four further models: 
(Model 1) baseline + inflammation (INF) 
(Model 2) baseline + endothelial dysfunction (END) 
(Model 3) baseline + thrombosis/fibrinolysis (THR) 
(Model 4) baseline + INF + END + THR 
We compared each model for improvement over baseline.  Model improvement was 
defined as a reduction in residual standard error (RSE) and increase in adjusted r-
squared (R2). 
We checked for multicolinearity between predictor variables using variance inflation 
factor.  We checked model assumptions as follows: independence, linearity, constancy 
of variance and normality in the residuals.  A p value of <0.05 was considered 
significant.  All analyses were performed with the statistical programming language R 
version 3.0.1 (http://www.r-project.org/)141.  
Meta-analysis 
We used the Review Manager 5 software (The Cochrane Collaboration) to update our 
prior meta-analysis (Chapter 2)127, calculating the standardized mean difference using 
the inverse variance method and a fixed effects model with 95% CI.   
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Results 
We recruited 125 patients, 65 with lacunar stroke and 60 with cortical stroke.  The 
mean age of the total cohort was 66.4 ± 11.4 years and the median NIHSS was one 
(Q1-Q3 1-2).  The median time from stroke onset to blood sampling was 54.4 (Q1-Q3 
36-74) days.  Patient characteristics and plasma biomarkers by stroke subtype are listed 
in Table 3.2.  The lacunar group had fewer men (39 v 51, p=0.004), were younger (64 
v 69 years, p=0.015) and suffered less atrial fibrillation (2 v 9, p=0.042) compared with 
the cortical group (Table 3.2). 
 
Table 3.2 Comparing patient characteristics and plasma biomarkers between lacunar 
and cortical stroke 
 Lacunar stroke (n=65) Cortical stroke (n=60) p value 
Male, n (%) 39 (60%) 51 (85%) 0.004 * 
Age, mean (SD) years 64.1 (11.4) 69.0 (10.9) 0.015 * 
Hypertension, n (%) 37 (57%) 39 (65%) 0.458 
Diabetes, n (%) 14 (21.5%) 5 (8.3%) 0.071 
Current smoker, n (%) 24/64 (37.5%) 13/59 (22.0%) 0.095 
NIHSS, median (Q1 – Q3) 2 (1 – 3) 1 (0.75 – 2) 0.404 
Time to sample, median (Q1 – Q3) days 56 (38 – 74) 52 (36 – 77) 0.894 
Ischaemic heart disease, n (%) 8 (12.3%) 16 (26.6%) 0.070 
Atrial fibrillation, n (%) 2 (3.1%) 9 (15%) 0.042 * 
Hyperlipidemia, n (%) 26/64 (40.6%) 23 (38.3%) 0.939 
Total cholesterol, mean (sd) mmol/l 5.07 (1.10) (n=57) 5.06 (1.13) (n=53) 0.949 
Positive family history of stroke, n (%) 10/64 (15.6%) 4/58 (6.9%) 0.220 
Inflammation  
CRP, median (Q1 – Q3) mg/L 1.37 (0.84 – 3.44) 1.73 (0.97 – 3.54) 0.748 
TNF-α, median (Q1 – Q3) pg/mL 0.92 (0.72 – 1.33) 0.88 (0.76 – 1.23) 0.972 
IL-6, median (Q1 – Q3) pg/mL 2.57 (1.91 – 4.12) (n=64) 2.58 (1.90 – 3.77) 0.994 
Endothelial dysfunction  
ICAM, mean (SD) ng/mL 162.78 (57.97) 159.27 (46.1) (n=56) 0.711 
vWF, mean (SD) iu/dL 129.31 (41.49) 131.7 (39.2) 0.741 
Thrombosis/fibrinolysis 
Fibrinogen, mean (SD) g/L 3.84 (0.61) (n=64) 3.93 (0.67) (n=59) 0.452 
t-PA, mean (SD) ng/mL 7.39 (3.13) 8.59 (2.92) 0.029 * 
D-dimer, median (Q1 – Q3) ng/mL 100 (73 – 157) 128.5 (73.25 – 182.5) 0.498 
* p<0.05.   
CRP = C-reactive protein, ICAM = intracellular adhesion molecule-1, IL-6 = interleukin-6, NIHSS = National 
Institute Health Stroke Scale, TNF-α = tumour necrosis factor alpha, t-PA = tissue plasminogen activator, vWF = 
von Willebrand factor. 
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Plasma biomarker association with lacunar stroke 
The lacunar group had lower t-PA levels compared with the cortical group (7.39 v 8.59 
ng/mL, p=0.029) in unadjusted analyses (Table 3.2) and after adjustment for age, sex, 
hypertension, smoking, diabetes and atrial fibrillation (p=0.035, Table 3.3).   There 
were no differences in the other plasma biomarkers between lacunar stroke and cortical 
stroke whether adjusted or not (Tables 3.4–3.6).   
Table 3.3 Association of tissue plasminogen activator (t-PA) with lacunar stroke 
subtype (n=125) 
 Regression coefficient (95% CI) p value 
Lacunar stroke subtype -1.312  (-2.531 to -0.093) 0.035 * 
Age -0.017  (-0.073 to 0.038) 0.530 
Male sex 0.542  (-0.740 to 1.824) 0.404 
Hypertension 0.393  (-0.806 to 1.593) 0.517 
Smoking 1.027 (-0.277 to 2.333) 0.121 
Diabetes 0.266  (-1.324 to 1.855) 0.741 
Atrial fibrillation 0.240 (-1.854 to 2.334) 0.820 
* p<0.05. 
 
Table 3.4 Association of plasma biomarkers of inflammation (CRP, TNF-α and IL-
6) with lacunar stroke subtype (n=125) 
 Regression coefficient (95% CI) p value 
CRP 
Lacunar stroke subtype -1.441 (-4.711 to 1.830) 0.385 
Age -0.024 (-0.173 to 0.126) 0.753 
Male sex  1.000 (-2.533 to 4.533) 0.576 
Hypertension  1.004 (-2.390 to 4.399) 0.559 
Smoking -0.182 (-3.760 to 3.396) 0.920 
TNF-α 
Lacunar stroke subtype  0.288 (-0.203 to 0.779) 0.247 
Age -0.008 (-0.030 to 0.014) 0.473 
Male sex  0.004 (-0.526 to 0.534) 0.988 
Hypertension -0.162 (-0.671 to 0.347) 0.530 
Smoking -0.445 (-0.982 to 0.092) 0.103 
IL-6 
Lacunar stroke subtype  0.366 (-0.423 to 1.155) 0.360 
Age   0.029 (-0.007 to 0.065) 0.114 
Male sex  0.365 (-0.486 to 1.217) 0.397 
Hypertension -0.068 (-0.891 to 0.754) 0.869 
Smoking  0.425 (-0.439 to 1.290) 0.332 
CRP = C-reactive protein, IL-6 = interleukin-6, TNF-α = tumour necrosis factor 
alpha. 
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Table 3.5 Association of plasma biomarkers of endothelial dysfunction (ICAM and 
vWF) with lacunar stroke subtype (n=125) 
 Regression coefficient (95% CI) p value 
ICAM 
Lacunar stroke subtype   2.552 (-18.420 to 23.524) 0.810 
Age  -0.193 (-1.144  to 0.757) 0.688 
Male sex   7.954 (-14.608 to 30.517) 0.486 
Hypertension  -3.688 (-25.350 to 17.974) 0.737 
Smoking 11.386 (-11.437 to 34.210) 0.325 
vWF 
Lacunar stroke subtype  5.935 (-9.076 to 20.946) 0.435 
Age  1.225 (0.537 to 1.912) 0.000 *** 
Male sex  5.275 (-10.937 to 21.488) 0.520 
Hypertension -3.808 (-19.386 to 11.770) 0.629 
Smoking  1.331 (-15.089 to 17.752) 0.873 
*** p<0.001. 
ICAM = intracellular adhesion molecule-1, vWF = von Willebrand factor. 
 
Table 3.6 Association of plasma biomarkers of thrombosis (fibrinogen and D-dimer) 
with lacunar stroke subtype (n=125) 
 Regression coefficient (95% CI) p value 
Fibrinogen 
Lacunar stroke subtype -0.108 (-0.351 to 0.135) 0.382 
Age  0.006 (-0.004 to 0.017) 0.238 
Male sex -0.000 (-0.262 to 0.262) 0.998 
Hypertension  0.063 (-0.189 to 0.317) 0.620 
Smoking  0.440 (0.174 to 0.706) 0.001 *** 
D-dimer 
Lacunar stroke subtype -22.986 (-90.559 to 44.587) 0.502 
Age    2.094 (-1.000 to 5.188) 0.183 
Male sex  12.475 (-60.505 to 85.456) 0.736 
Hypertension    5.056 (-65.070 to 75.182) 0.887 
Smoking  56.899 (-17.019 to 130.817) 0.130 
*** p<0.001.   
 
To determine if the reduced t-PA was related to smoking, we repeated the analysis in 
non-smokers only (lacunar stroke, n=40 versus cortical stroke, n=46).  t-PA levels 
remained lower in lacunar stroke (Table 3.7). The difference became nonsignificant 
when adjusted for age, sex, hypertension and diabetes, but the change was slight, the 
regression coefficients and 95% confidence intervals were similar142 being -1.31 (95% 
CI -2.53 to -0.09) versus -1.37 (-2.84 to 0.09) and may reflect the reduced sample size.   
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Table 3.7 Comparing patient characteristics and plasma biomarkers between lacunar 
and cortical stroke in non-smokers 
 Lacunar stroke (n=40) Cortical stroke (n=46) p value 
Male sex, n (%) 21 (52.5%) 39 (84.7%) 0.002 ** 
Age, mean (SD) years 66.5 (11.3) 71.1 (10.9) 0.055 
Hypertension, n (%) 25 (63%) 29 (63%) 1.000 
Diabetes, n (%)  9 (22.5%)  5 (10.8%) 0.244 
IHD, n (%)  7 (17.5%) 12 (26.0%) 0.486 
Atrial fibrillation, n (%)  2 (5%)  8 (17.4%) 0.147 
Hyperlipidemia, n (%) 15 (37.5%) 17 (36.9%) 1.000 
Total cholesterol, mean (sd) mmol/l  5.26 (1.23) (n=35)  5.02 (1.14) (n=41) 0.382 
Positive family history of stroke, n (%)  5 (12.5%)  3 (6.5%) (n=45) 0.584 
Inflammation  
CRP, median (Q1 – Q3) mg/L 1.36 (0.74 – 3.10) 1.68 (0.84 – 3.25) 0.703 
TNF-α, median (Q1 – Q3) pg/mL 0.92 (0.72 – 1.37) 0.85 (0.76 – 1.37) 0.849 
IL-6, median (Q1 – Q3) pg/mL 2.57 (1.77 – 4.26) 2.54 (1.81 – 3.57) 0.962 
Endothelial dysfunction  
ICAM, mean (SD) ng/mL 155.03 (55.66) 158.93 (45.39) (n=44) 0.727 
vWF, mean (SD) iu/dL 131.8 (43.72) 133.9 (42.1) 0.822 
Thrombosis 
Fibrinogen, mean (SD) g/L 3.70 (0.59) 3.84 (0.61) (n=45) 0.478 
t-PA, mean (SD) ng/mL 6.94 (3.15) 8.29 (2.87) 0.042 * 
D-dimer, median (Q1 – Q3) ng/mL 91.5 (69 - 152) 119.5 (71 – 165) 0.828 
* p<0.05. **p<0.01.    CRP = C-reactive protein, ICAM = intracellular adhesion molecule-1, IL-6 = interleukin-6, 
NIHSS = National Institute Health Stroke Scale, TNF-α = tumour necrosis factor alpha, t-PA = tissue 
plasminogen activator, vWF = von Willebrand factor. 
 
Meta-analysis 
On addition of our study to the four prior studies (new total 300 lacunar strokes), we 
show lower t-PA in lacunar versus non-lacunar stroke although the difference was not 
significant (Figure 3.1).  Addition of this study’s data moves the standardised mean 
difference from 0.02 to (95% CI -0.18 to 0.21) to -0.08 (-0.25 to 0.09).   
 
Figure 3.1 Forest plot comparing t-PA levels between lacunar stroke and non-
lacunar stroke.  Values in bracket after Study refers to time to blood draw.   
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Biomarkers and WMH (all patients, lacunar and cortical) 
Quantitative WMH and plasma biomarkers were available for 98 patients.  The 
baseline model (age, sex, hypertension and smoking status) explained 29% of the 
variance in quantitative WMH (RSE 1.081, R2 0.289) with age, hypertension and 
smoking as significant predictors (Table 3.8). 
Model 1 (baseline + INF) showed minor improvement over baseline (RSE 1.066, R2 
0.291).  Models 2 (END), 3 (THR) and 4 (INF+END+THR) did not improve the 
baseline model.  All models met model assumptions.  There were no negative 
correlations between the components of the summed variables meaning a rise in one 
plasma marker was not offset by a fall in another.  
 
Table 3.8 Explaining variance in quantitative WMH with different predictor 
variables (n=98) 
Model Predictor variables RSE R2 
Baseline 
 
Age***,  male sex, hypertension*, smoking** 1.081 0.289 
Model 1 
 















Age***, male sex, hypertension*, smoking** + 
Inflammation + Endothelial activation + Thrombosis 
1.094 0.285 
* p<0.05, ** p<0.01, *** p<0.001.  
Inflammation = logCRP, logTNF-α, logIL-6 
Endothelial activation = vWF, ICAM  
Thrombosis = t-PA, logD-dimer, fibrinogen 
RSE = residual standard error (bold = improvement over baseline, ie, reduction in RSE) 
R2 = adjusted R-squared (bold = improvement over baseline, ie, increase in R2) 
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Discussion 
We show a difference in t-PA levels between lacunar stroke and mild cortical stroke 
from plasma sampled well after the acute phase, independent of age, sex and risk 
factors.  We did not find differences between stroke subtypes for biomarkers of 
inflammation (CRP, TNF-α or IL-6), endothelial dysfunction (vWF or ICAM) or other 
markers of haemostasis (fibrinogen or D-dimer).  Except for a minor additional 
predictive effect of summed inflammatory markers, plasma biomarkers did not 
considerably improve the baseline model in explaining WMH.  
t-PA 
t-PA is a glycoprotein released mainly by endothelial cells143,144 to mediate the 
breakdown of thrombus.  Its use as a thrombolytic agent might lead one to assume 
endogenous t-PA is protective against thrombosis144.  However, higher t-PA antigen 
levels are associated with risk of coronary heart disease in generally healthy 
populations143.  This may reflect increased endothelial disturbance resulting in 
increased t-PA secretion; or else increased levels of its inhibitor, tissue plasminogen 
activator inhibitor (PAI), resulting in increased levels of circulating complexes with t-
PA143–145.  The effect of recombinant t-PA subdivided by smoking status at baseline 
was not investigated in the IST-3146 trial although some147,148 but not all149 
observational studies suggest that smokers respond better to recombinant t-PA than 
non-smokers when treated with intravenous recombinant t-PA for acute ischaemic 
stroke.   
We found lower t-PA in lacunar versus cortical stroke.  Reduced t-PA could mean 
lacunar stroke patients have reduced vascular damage – vWF levels were also lower 
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in lacunar stroke but ICAM levels were higher (neither statistically significant).  
Alternatively lacunar stroke patients might have increased endogenous fibrinolytic 
activity, if lower t-PA levels reflect lower levels of its inhibitor, PAI. 
Knottnerus et al.150 found significantly lower t-PA levels (and significantly higher PAI 
levels) in 43 lacunar stroke patients with an isolated infarct versus 53 lacunar stroke 
patients with concurrent extensive WMH, hypothesizing that patients with extensive 
WMH lack the protective effect of PAI for t-PA induced tissue damage. 
In our recent meta-analysis (Chapter 2)127, t-PA was significantly higher in lacunar 
stroke versus non-stroke controls but did not differ significantly between lacunar 
stroke and other stroke subtypes, although data were limited and the timing of sample 
collection could be confounding.  The samples in the current study were collected well 
after the acute phase and are more likely to reflect underlying pathway activity.  The 
updated meta-analysis including the current data, moves the evidence in favour of 
lower t-PA in lacunar versus non-lacunar stroke (Figure 3.1).  The largest study to date 
to find lower levels of t-PA in small vessel stroke is the Sahlgrenska cohort, Sweden92:  
among 600 patients with ischaemic stroke, including 124 with small vessel stroke, 
small vessel stroke patients had higher t-PA levels compared to non-stroke controls in 
the acute phase and at three months but lower t-PA levels compared to other stroke 
subtypes.  
The lacunar group were significantly younger with fewer cases of atrial fibrillation and 
more smokers (nonsignificant) than the cortical group, although the association of 
lacunar stroke with lower t-PA was independent of these and the pattern persisted in 
analysis restricted to non-smokers.   
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WMH and biomarkers 
Age, hypertension and smoking were significant predictors of WMH.  The 
inflammatory biomarker summed variable appeared to improve the model (slight 
reduction in the residual standard error) but the additional explanatory power was 
small and could be interpreted as no model improvement.  On the other hand, a similar 
effect size confirmed in a larger study would indicate a modest but important effect of 
plasma markers of inflammation on WMH prediction. The other plasma markers did 
not have any additional explanatory power.    Studies that have measured WMH in 
non-stroke populations typically involve older people.  We have clearly shown age to 
be the most important predictor variable in the assessment of WMH and thus 
correcting for age is crucial. 
Two large studies67,128 showed independent associations between higher plasma 
inflammatory biomarkers and more WMH but had wide age ranges.  However, Rouhl 
et al.71 found no difference in CRP levels between 81 patients with and 265 patients 
without extensive WMH,  Wersching et al.129 found no association between CRP and 
WMH among 321 older stroke-free participants, Baune et al.151 found no association 
between TNF-α and WMH among 268 community-dwelling participants and Aribisala 
et al.48 found no association between inflammation (a latent factor comprising CRP, 
fibrinogen and IL-6) and WMH among 634 community-dwelling older people of near-
identical age. Thus it is possible that wide age ranges in some studies inflated 
associations between inflammatory markers and WMH.  Shoamanesh et al.131 found 
no association between some inflammatory biomarkers (including CRP, IL-6 and 
TNF-α) and SVD (defined as presence of silent infarcts and/or extensive WMH) in a 
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large cohort of younger stroke-free Framingham participants (n=522; mean age 60 
years) but did associate ICAM with SVD.  We found no association between ICAM 
and WMH in the present study but have much less power than the Framingham study.  
Our systematic review and meta-analysis (Chapter 2)127 found no difference in ICAM 
levels between lacunar stroke and other stroke subtypes although only a few studies 
contributed data.  ICAM was non-significantly higher in lacunar stroke versus cortical 
stroke patients in the present study.   
Conclusion 
Our findings show a difference in t-PA levels between lacunar and cortical stroke 
which should be verified in other datasets.  Future studies should obtain plasma 
samples in the chronic phase after stroke and concentrate on longitudinal associations, 
especially the role of t-PA in stroke subtypes as it could help explain mechanisms. A 
large prospective study of accurately phenotyped stroke patients would be helpful.  It 
is important to control for age specifically, but also hypertension and smoking when 
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Chapter 4: Cerebrovascular disease in rheumatic diseases: A 
systematic review and meta-analysis 




Stroke is a major health problem.  Overall incidence rates are falling152,153 but better 
access to medical care and improvements in secondary prevention increase survival so 
stroke prevalence, and thus healthcare costs, remain high.  An ageing population will 
increase this trend. 
Rheumatic diseases such as RA are an independent risk factor for stroke154,155.  People 
with these diseases die prematurely from cardiovascular disease including stroke,156,157 
so a deeper understanding of stroke risk among these patients is needed to reduce 
mortality.  However, data linking rheumatic diseases with higher stroke risk are based 
mostly on stroke reported from large population studies, ie, a composite outcome of 
any stroke.  Less is known about associations between rheumatic diseases 
(inflammatory or non-inflammatory) and major stroke subtypes whose mechanisms 
differ, e.g. ischaemic versus haemorrhagic stroke, or large artery atheromatous versus 
intrinsic small vessel ischaemic stroke, or with conditions associated with cerebral 
small vessel disease (SVD) such as cognitive decline, mood change and gait 
disturbances16,18.   
Population stroke incidence rises with age.  Stroke early in life is rare among the 
general population, yet most of the stroke associated with rheumatic diseases appears 
to be at younger ages,158–164 and may level off, as some studies161,162,165,166 report no 
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risk difference in those over 65 years.  However, there is currently no meta-analysis 
on the overall association of rheumatic diseases with stroke by age.  Clarifying timing 
of greatest stroke risk has important clinical implications. 
Studies to date do not fully explain the increased stroke risk among rheumatic 
populations by vascular risk factors167,168.  Some stroke risk in rheumatic diseases 
could relate to the higher inflammatory activity seen in many arthropathies which is 
systemic, non-resolving and often only controlled with aggressive anti-rheumatic 
drugs.  Inflammation therefore plausibly explains some of the excess risk due to 
atheromatous stroke as inflammation is involved in all stages of atherosclerosis from 
fatty streak formation to plaque disruption43–45.  The role of inflammation in SVD is 
less certain but inflammation is seen pathologically in the perforating arteriolar walls 
and perivascular tissue46,47.  Endothelial damage is a primary step in atherosclerosis 
and SVD and factors that contribute to endothelial damage (eg, immune complex 
formation and complement activation/deposition) are also seen in rheumatic diseases.   
The aims are to review associations between stroke and rheumatic disease; to 
summarise incidence rates and calculate pooled rate ratios for stroke subtypes versus 
the general population; to see if risk is greatest at specific ages; and to determine if 
rheumatic diseases increase the risk of ‘silent’ vascular disease on neuroimaging. 
 
  
  53 
Methods 
Study design 
We used a systematic approach to assess stroke and stroke subtypes as the outcome 
measure and various rheumatic diseases as the exposure. Research ethics committee 
approval was not required.  The study was not registered in any database. 
Data sources 
The review was prepared in accordance with the Preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) statement75.  Structured search terms 
(Table 4.1) were used to query EMBASE (from 1980) and MEDLINE (from inception) 
to 2014 on 14 December 2014.  Data were extracted in accordance with Meta-analysis 
of observational studies (MOOSE) guidelines76.  We categorized magnetic resonance 
imaging (MRI) findings according to STRIVE guidelines19.   
 
Table 4.1 Search strategy 
1. brain ischemia/ or brain infarction/ or brain stem infarctions/ or cerebral infarction/ or hypoxia-
ischemia, brain/ or stroke/ 
2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw. 
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or 
infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or 
infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw. 
4. 1 or 2 or 3 
5. Arthritis/ or Arthritis, Rheumatoid/ or Autoimmune Diseases/ or Musculoskeletal Diseases/ or 
Rheumatic Diseases/ 
6. 4 and 5 
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Study selection 
English language studies reporting on stroke in rheumatic disease and studies that 
assessed brain imaging features of SVD on MRI were included.  Studies using 
functional MRI, positron emission tomography, single photon emission computed 
tomography and Doppler ultrasound were excluded.  
Data extraction 
Data on study population demographics, control groups, stroke type (ischaemic / 
haemorrhagic), ischaemic stroke subtypes (large artery / lacunar), findings on stroke 
risk relative to a comparator group and MRI findings were extracted.  Stroke incidence 
rises with age, and we noted if studies controlled for age and vascular risk factors. 
Quality assessment 
A quality checklist adapted from the Strengthening the reporting of observational 
studies in epidemiology (STROBE) statement79 was used to assess the quality of 
included studies (Table 4.2).  
Table 4.2 Quality checklist for included studies 
Prospective or retrospective?  
Was stroke subtyped: ischaemic / haemorrhagic / large artery / lacunar?  
Was criteria/system used to subtype stroke well explained? 
Was neuroimaging used to confirm stroke diagnosis? Was diffusion-weighted imaging used? 
Did authors adequately describe and/or rule out stroke mimics? 
Did authors provide number of stroke events and number of person-years observation? 
Was the comparison group well described (including number of stroke events and number of 
person-years observation)? 
Did the study match comparators on age, sex and traditional vascular risk factors (hypertension, 
diabetes, hyperlipidaemia) or control for these at the analysis stage? 
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Data synthesis and analysis 
We defined SVD from MRI features as per STRIVE neuroimaging standards19, being 
any of: recent small sub-cortical infarcts, white matter hyperintensities (WMH), 
lacunes, microbleeds, prominent peri-vascular spaces (PVS) or atrophy.  Clinically, 
patients might show no symptoms, or they might suffer cognitive impairment or other 
neurological involvement in addition to stroke (lacunar stroke accounts for around 
25% of all ischaemic strokes169).    
We defined stroke incidence rates as number of strokes as a function of a follow-up 
period and stroke rate ratios as the ratio of stroke incidence rate in the observed group 
(eg, rheumatoid arthritis) over incidence rates in the general population.  We used 
unadjusted (crude) rates throughout as different studies controlled for different 
variables making comparison of uniform adjustments impossible. 
Stroke incidence rates were recorded when reported and calculated when not reported 
but where data (ie, number of stroke events and a follow-up period) were available.  
All incidence rates were converted to “per 100,000 person-years” for comparability.  
If follow-up duration (in patient-years) was not specifically reported, we estimated this 
by multiplying number of patients by the average years of follow-up.  
Where a rheumatic disease had contributing data from more than one study, we pooled 
incidence rates by taking the range of available values, which did not allow us to assess 
heterogeneity.  Next, we calculated a point estimate for incidence rate per 100,000 
person-years for individual rheumatic diseases based on the weighted mean, using 
study size as the weighting factor and then estimated a 95% CI based on the Poisson 
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distribution as implemented in the epitools package for the statistical programming 
language R version 3.0.1 (http://www.r-project.org/)141. 
Rate ratios were calculated using the Cochrane Collaboration’s Review Manager 5 
software when not reported but where required data were available.   
Some studies did not provided number of strokes and number of patient-years observed 
for the control group but instead only provided the rate ratio together with a CI.  As 
per Cochrane Handbook84, CIs can be converted to standard errors and the natural 
logarithms of rate ratios may be combined across studies using the generic inverse-
variance method.  We used this approach to pool stroke risk for ischaemic stroke and 
haemorrhagic stroke, and for the age category pooled analysis. 
Between-study heterogeneity was assessed using the I2 statistic.  We used random 
effects models in all meta-analyses. 
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Results 
The search returned 443 titles and abstracts; 69 papers were reviewed in full and 23 
studies contributed data to new meta-analyses. We excluded studies that did not 
measure stroke with appropriate imaging (n=12), pathology studies (n=5), guidelines 
and review papers (n=4) and small studies (<50 patients) that only described imaging 
features of SVD (n=25) (Figure 4.1). 
 
Figure 4.1 Summary of search and selection 
 
Any stroke 
Prior meta-analyses and large registry studies of any stroke are reported in Table 4.3.  
Briefly: RA (prototypical inflammatory rheumatic disease) showed significant risk of 
stroke over the general population (n=26,143 patients; incidence rate ratio (RR) 1.91, 
1.73 to 2.12)170 while osteoarthritis (degenerative) did not (n=40,817 patients; odds 
ratio (OR) 1.11, 0.95 to 1.29)171.  In direct comparison, patients with osteoarthritis 
alone (no comorbid RA) had lower stroke risk (11,633 RA versus 163,274 OA 
patients; OR 1.3, 1.2 to 1.3, i.e., higher stroke risk in RA)172.  Ankylosing spondylitis 
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(OR 1.51, 1.39 to 1.62) and gout (RR 1.71, 1.68 to 1.75) also showed higher risk of 
stroke than the general population.   




Stroke in general 
RA Meune et al.170 meta-analysed stroke death among nine studies involving 88,500 
rheumatoid arthritis (RA) patients and stroke incidence among three studies 
involving 26,143 RA patients: risk of death (standardised mortality ratio 1.46, 95% 
CI 1.31–1.63) and stroke incidence (incidence rate ratio 1.91, 95% CI 1.73–2.12) 
were higher than the general population, respectively.   
Lindhardsen et al.158 linked Danish national registers to follow 18,247 RA patients 
over 13 years.  Stroke incidence in RA was significantly higher than in the general 
population (rate ratio 1.33, 95% CI 1.23–1.43).   
SLE New meta-analysis (See text and Figure 4.2).  Included studies162,166,173–175. 
AS Meta-analysis176 of three studies of 9,791 ankylosing spondylitis (AS) patients 
found an increased risk of stroke versus the general population (odds ratio (OR) 
1.51, 95% CI 1.39–1.62).  Two subsequent studies (n=5,000 AS patients)177,178 not 
included in the meta-analysis show similar risk of stroke (hazards ratio 1.2 (1.0–
1.5) and 2.3 (1.9–2.8)) over the general population, while a third study179 reported 
an increased risk of vascular death (a composite end point of heart attack and 
stroke) among n=21,473 patients of 1.36 (1.13–1.65) versus healthy controls. 
Gout Gout patients have (rate ratio 1.71 (95% CI 1.68–1.75)) times the risk of stroke 
over the general population from a study of 767,725 person-years follow-up164. 
Psoriasis and 
PsA 
New meta-analysis (See text and Figure 4.3).  Included studies180–191.   
Additionally, Chin et al.192 compared psoriasis patients (n=383 strokes; n=7,397 
patients) to PsA patients (n=23 strokes; n=225 patients) in a population-based 
retrospective cohort study and found a non-significant increase in stroke risk in 
PsA patients (hazard ratio 1.5, 95% CI 0.98–2.29) which became significant on 
multivariate modelling controlling for age, hypertension diabetes, dyslipidaemia 
and phototherapy (HR 1.82, 95% CI 1.17–2.82). 
OA Compared to RA, patients with osteoarthritis (OA) alone (eg, no comorbid RA) are 
at lower risk of stroke (11,633 RA patients versus 163,274 OA patients; rate ratio 
1.3, 95% CI 1.2–1.3), ie, RA has higher risk172.  A more recent study171 of 40,817 
patients with OA concluded there was no additional stroke risk in OA versus the 
general population, although the strokes were self-reported. 
AS = ankylosing spondylitis, OA = osteoarthritis, PsA = psoriatic arthritis, RA = rheumatoid 
arthritis, SLE = systemic lupus erythematosus 
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We add new meta-analyses on any stroke in SLE, psoriasis and psoriatic arthritis. The 
pooled odds of any stroke in SLE from five studies162,166,173–175 (772 strokes, 40,652 
SLE patients) was 2.13 (1.53 to 2.98) (Figure 4.2).  
 
Figure 4.2 Any stroke in systemic lupus erythematosus 
 
We updated two psoriasis meta-analyses193,194 and added a new meta-analysis for 
psoriatic arthritis.  The pooled odds of any stroke in psoriasis (nine studies,180–186,190,191 
6,925 strokes; 400,767 patients) was 1.08 (1.00 to 1.16) and psoriatic arthritis (three 
studies180,181,187 217 strokes; 12,051 patients) was 1.27 (0.98 to 1.64) (Figure 4.3).   
 
Figure 4.3  Any stroke in psoriasis and psoriatic arthritis (PsA) 
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Stroke subtypes: ischaemic and haemorrhagic 
Stroke incidence of ischaemic and haemorrhagic stroke by rheumatic diseases is 
summarised in Table 4.4.   
 
Table 4.4 Stroke incidence rates by stroke subtype among different rheumatic diseases 
Rheumatic disease Included 
studies 







Mean IR, per 
100,000 person-
years (95% CI) 
References 
Ischaemic 
Rheumatoid Arthritis 6 3,611 1,193,249 178 to 1,077 303 (269–337) 163,178,195–198 
Gout 1 5,391 767,725 702 702 (650–754) 164 
Ankylosing Spondylitis 1 111 76,494 145 145 (121–169) 178 
Reiter’s 1 13 7,436 175 175 (149–201) 178 
Psoriasis / PsA None      
Polyarteritis Nodosa 1 46 18,106 254 254 (223–285) 178 
Ploymyalgia 1 1,777 362,912 489 489 (446–532) 178 
SLE 7 995 271,076 208 to 2,530 367 (329–404) 162,166,174,178,1
99–201 
Scleroderma 1 44 11,264 391 391 (352–430) 178 
Sjogren’s 1 68 28,600 238 238 (208–268) 178 
Osteoarthritis None      
General population     141 (127–156) 202 
Haemorrhagic 
Rheumatoid Arthritis 3 562 1,096,594 43 to 118 51 (37–65) 163,178,196 
Gout 1 1,864 767,725 242 242 (211–272) 164 
Ankylosing Spondylitis 1 42 76,494 55 55 (40–69) 178 
Reiter’s 1 2 7,436 27 27 (17–37) 178 
Psoriasis / PsA None      
Polyarteritis Nodosa 1 5 18,106 28 28 (18–38) 178 
Polymyalgia 1 204 362,912 56 56 (41–71) 178 
SLE 4 164 223,027 35 to 118 74 (57–91) 162,166,174,178 
Scleroderma 1 8 11,264 71 71 (54–87) 178 
Sjogren’s 1 5 28,600 17 17 (9–25) 178 
Osteoarthritis None      
General population     12 (9–17) 202 
PsA = psoriatic arthritis, SLE = systemic lupus erythematosus.  Mean IR = Mean incident rate based on a weighted mean 
(weight based on study size, ie, person-years observed) 
 
Sufficient data to perform meta-analysis of stroke risk (rate ratios) among stroke 
subtypes versus the general population were only available for RA and SLE.  In RA 
versus the general population, the pooled odds of ischaemic stroke (3,481 strokes; 
86,280 patients) and haemorrhagic stroke (562 strokes; 84,419 patients) were 1.64 
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(95% CI 1.32 to 2.05) and 1.68 (1.11 to 2.53) respectively (Figures 4.4 and 4.5).  In 
SLE versus the general population, the pooled odds of ischaemic stroke (945 strokes; 
55,699 patients) and haemorrhagic stroke (164 strokes; 44,062 patients) were 2.11 
(1.66 to 2.67) and 1.82 (1.07 to 3.09) respectively (Figures 4.4 and 4.5).   
 
Figure 4.4  Forest plot – Ischaemic stroke in rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE) versus general population 
 
 
Figure 4.5  Forest plot – Haemorrhagic stroke in rheumatoid arthritis (RA) and 
systemic lupus erythematosus (SLE) versus general population  
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Subtypes of ischaemic stroke 
For SLE, two studies166,199 provide incidence rate data for ischaemic stroke subtypes: 
among 490 SLE patients166, 13 had cortical strokes (equivalent to 271 cortical strokes 
per 100,000 person-years) and four had lacunar strokes (83 per 100,000) from 4,802 
person-years follow-up;  among 232 SLE patients199, 20 had large artery strokes (1,150 
per 100,000), 17 had small vessel strokes (997 per 100,000) and four had 
cardioembolic strokes (230 per 100,000) from 1,739 person-years follow-up.  There 
were limited comparative data from the general population but Sacco et al.203 report 
annual incidence rates for lacunar stroke as 33 per 100,000 population.  There were 
insufficient data to pool rate ratios among ischaemic stroke subtypes. 
 
Age, rheumatic disease and stroke 
The pooled odds of any stroke (11,879 strokes; 340,548 patients)158,161–166,174,189 across 
five rheumatic diseases (data were available for RA, SLE, psoriasis, ankylosing 
spondylitis and gout) versus the general population was 1.38 (95% CI 1.21 to 1.57) 
(Figure 4.6).   When split by age, the pooled odds were 1.79 (1.46 to 2.20) for age <50 
years, 1.49 (1.07 to 2.06) for age 50-65 and 1.14 (0.94 to 1.38) for age 65 and above 
(Figure 4.6).  The age categories were significantly different (χ2 test for subgroups, 
p=0.007).  A study-by-study review of stroke by age categories across stroke in general 
and by ischaemic and haemorrhagic stroke subtypes is given in Table 4.5. 
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Figure 4.6  Forest plot – Any stroke in rheumatic diseases by three age categories 
 
 
Table 4.5 Summary of stroke risk findings by age: stroke in general and by subtype 
Stroke type Finding 
Any stroke Lindhardsen et al.158 report a rate ratio for stroke among male RA patients versus the general 
population as 3.61 (95% CI 2.05–6.36) for those aged < 50 years, 1.70 (1.34–2.15) for those 
aged 50-65 years and 1.21 (1.05–1.40) for those aged 65 years and older.  A similar trend 
was seen among women. 
Solomon et al.159 report a rate ratio for any cardiovascular event including stroke among 18-
49 year-old RA patients versus the general population as 3.3 (95% CI 2.4–4.5), 2.2 (1.9–2.5) 
for those aged 50-64 years, 1.9 (1.7 to 2.1) for those aged 65-74 years and 1.6 (1.5–1.7) for 
those aged 75 years and older. 
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Ward161 reports twice as many strokes among 18-44 year old women with SLE compared 
with the general population (rate ratio 2.05; 95% CI 1.17–2.93) whereas in those aged 45-64 
years and ≥ 65 years there was no such significant increase in stroke rates. 
Among 13,689 SLE patients followed for over 5 years, Wang et al.162 found stroke risk 
relative to the general population to diminish over the lifecourse.  Hazards ratios were: 31.1 
(95% CI 14.2–68.3) in 18-24 year olds, 15.1 (9.3–24.5) in 25-34 year olds, 5.3 (3.8–7.5) in 
35-44 year olds, 2.3 (1.7–3.1) in 45-54 year olds, 2.2 (1.6–3.0) in 55-64 year olds with no 
risk difference in those 65 years and older (0.97, 0.7–1.3). 
Bessant et al.160 assessed stroke risk in 202 SLE patients (92% female; mean age 42 years) 
using software (with Framingham data) against hypothetical age- and sex-matched controls.  
Patients had a higher 10-year risk of stroke versus control data (p<0.0001).  When stratified 
by age, patients under 40 years continued to be at significantly higher risk but patients over 
40 years showed no difference to controls.   
Szabo et al.165 found the excess risk for stroke in ankylosing spondylitis (AS) over the 
general population was highest among younger AS patients (example: females aged 20-39 
years had a risk ratio of 1.69 (95% CI 1.23–2.33) while females aged 40-59 years and ≥60 
years had non-significant risk ratios of 1.15 and 1.14 respectively). 
Ahlehoff et al.189 report reducing stroke risk with increasing age in mild psoriasis over the 
general population: 18-50 years (1.61 (95% CI 1.32–1.97)), 51-70 years (1.22 (95% CI 




Among prevalent RA, Holmqvist et al.163 report a hazard ratio for ischaemic stroke versus 
the general population to be 0.81 (95% CI 0.43–1.54) for those aged 16–52 years, 1.47 
(1.13–1.90) for those aged 53–62 years, 1.36 (1.14–1.62) for those aged 63–71 years and 
1.25 (1.12–1.41) for those aged 72–94 years.  The hazard ratios for haemorrhagic stroke 
among the same age bands were:  1.76 (0.85–3.63), 1.00 (0.61–1.65), 0.82 (0.53–1.25) and 
1.75 (1.34–2.29) respectively.   
Mok et al.166 report significantly higher levels of ischaemic stroke in young SLE patients (in 
each 10-year age band up to 50 years) versus the general population, but the difference 
becomes non-significant in each 10-year age band in those over 50 years.  Young SLE 
patients (below 40 years) had significantly higher rates of haemorrhagic stroke versus the 
general population, but data were limited with no cases of haemorrhagic stroke in those over 
40 years. 
From 25,704 SLE patients hospitalised in the US between 2001–2002, Krishnan174 found 
313 strokes (206 as the primary diagnosis) giving an age- and sex-adjusted risk estimate for 
stroke in young (< 50 years) SLE patients of 1.5 (95% CI 1.3–1.8).  SLE patients had higher 
stroke risk for all stroke subtypes except in subarachnoid haemorrhage where a trend to 
lower risk was observed (OR 0.57, 95% CI 0.34–0.96).  The study was limited to those aged 
< 50 years. 
Seminog and Goldacre164 report the relative risk for ischaemic stroke among gout patients 
versus the general population as 4.68 (95% CI 2.89–7.18) in those aged 20–44 years, 2.68 
(95% CI 2.51–2.86) in those aged 45–69 years and 1.56 (95% CI 1.51–1.61) in those over 
70 years.  The relative risk for haemorrhagic stroke was 7.49 (95% CI 4.67–11.40) in those 
aged 20–44 years, 3.02 (95% CI 2.72–3.34) in those aged 45–69 years and 1.49 (95% CI 
1.41–1.58) in those over 70 years. 
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Structural MRI brain imaging findings  
Numerous MRI studies of the brain in rheumatic diseases were reviewed.  Most were 
small, many investigated neurologically symptomatic patients only (e.g., comparing 
neurolupus with SLE), and few controlled for age and known vascular risk factors. 
Of the larger studies (>50 patients) that provided information on features of SVD, there 
were consistent reports of WMH and brain atrophy in rheumatic disease patients (n=13 
studies (11 in SLE) involving 1,411 patients) (Table 4.6)61,62,204–214.   
However, only five studies61,62,205,206,209 compared rheumatic disease patients (n=414 
patients) to non-rheumatic healthy controls, and three of these were from the same 
research group and so only ~224 patients contribute data versus healthy controls.  Two 
studies report on WMH:  Hamed et al.62 found no difference in WMH between 55 
patients with RA and 40 healthy controls, although they excluded seven patients with 
white matter disease before comparing the remaining 48 patients, and they did not 
report on whether a grading system or a volumetric calculation was used to assess the 
WMHs.  Harboe et al.61 report more WMH in 62 patients with SLE versus 62 age- and 
sex-matched healthy controls (6.0 v 4.1, p=0.05; Scheltens’ score). 
Longitudinal data were also limited.  Appenzeller et al.206 followed 75 SLE patients 
over almost two years and found significant brain atrophy particularly in the corpus 
callosum (baseline versus follow-up scan, p=0.001).  Additionally, predictors of new 
or increased WMH included antiphospholipid antibodies, SLE damage scores and 
higher dose of corticosteroids207. 
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Table 4.6 Summary of structural MRI brain imaging findings in rheumatic diseases 
 




Kaichi, 2013204 SLE 256 39.0 Significantly more patients with APS had lacunar 
infarcts in the deep white matter (p<0.01) (but not the 
basal ganglia), cortical infarcts in the MCA territory 
(p<0.01), bilateral borderzone infarcts (p<0.01) and 
basal ganglia lesions (p=0.01) versus SLE patients 
without APS.  WMH (rated with Fazekas) did not 
differ between SLE patients with and without APS. 
Steup-Beekman, 
2013211 
SLE 155 27.5 Among n=102 with NPSLE, 47% had a normal MRI.  
WMH were found in 31/102 (30%) and atrophy in 
20/102 (20%). 
Akasbi, 2012210 SS 51  Dichotomised 51 Sjögren’s Syndrome patients into 
those with WMH (n=25) and those without (n=26) 
using Wahlund scale.  Those with WMH were older 
(70.3 v 58.3; p=0.004) and had higher frequency of 
cardiovascular risk factors. 
Hamed, 201262 RA 55 45.6 Removed 7 patients with probable white matter 
disease, then compared n=48 patients with 40 healthy 
controls and found no difference in T2 or FLAIR 
‘hyperintense signals’ (p=0.245).  Unclear how the 
hyperintensities were measured. 
Katsumata, 
2010212 
SLE 191 32.0 Compared those with (n=57) and without (n=134) 
neurolupus.  Abnormal MRI were more often found 
in those with neurolupus (RR 1.7, 95% CI 1.1–2.7).  
Large abnormal signals (>10mm) were only seen in 
the neurolupus group (n=7) whereas small abnormal 
signals were seen in both groups. 
Harboe, 200861 SLE 62 44.3 SLE patients have more fatigue (p<0.0001) and 
WMH compared with healthy controls (p=0.05).  




SLE 71 32 Compared SLE patients with and without APS.  
WMH were found in more than 40% of patients from 
both groups (non-significant). 
Appenzeller, 
2008207 




33.3 At baseline, 50% of patients had WMH: mean 
volume 197 mm3 (FLAIR images).  WMH were 
associated with age (p=0.01), total corticosteroid 
dose (p=0.001) and damage from SLE (p=0.002).  
Predictors for new or increased WMH at follow-up 
(median 24 months) were past CNS involvement, 
antiphospholipid antibodies, SLE damage score and 
higher dose of corticosteroid dose.  
Appenzeller, 
2007206 
SLE 75 32.3 SLE patients have reduced white and grey matter 
volumes versus healthy controls (p=0.001).  On 
follow-up, there is progressive white and grey matter 
atrophy in patients (p=0.001) 
Appenzeller, 
2006209 
SLE 107 32.2 SLE patients have smaller hippocampal volumes 
versus controls (p<0.001). At follow-up (n=60 
patients, mean 19 months) there was significant 
reduction in hippocampal volume over baseline 
volumes.  Cognitive impairment was associated with 
hippocampal volume loss (r=0.89; p=0.001). 
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Appenzeller, 
2005205 
SLE 115 33.5 Cerebral and corpus callosum volumes were 
significantly smaller in SLE patients versus controls 
(p<0.001).  Patients with cognitive impairment had 
significantly reduced cerebral and corpus callosum 
volumes compared with SLE patients without 
cognitive impairment (p=0.001). 
Jennings, 
2004213 
SLE 85 40.4 115 scans in 85 SLE patients in which 39 (34%) were 
normal, 70 (60%) had WMH, 50 (43%) had brain 
tissue loss, 24 (21%) had infarcts and 6 (5%) had 
haemorrhage. 
Sanna, 2000214 SLE 68 38.0 Among 68 patients, 24 showed overt 
neuropsychiatric manifestations; none had acute 
presentation at time of scanning.  Abnormal MRI was 
found in 30/68 (44%).   Neuropsychiatric 
manifestations are significantly associated with 
serum antibody against anti-glial fibrillary acidic 
protein.   
APS = antiphospholipid syndrome.  FLAIR = fluid attenuated inversion recovery.  MCA = middle cerebral 
artery.  NPSLE = neuropsychiatric systemic lupus erythematosus.  RA = rheumatoid arthritis.  SLE = 
systemic lupus erythematosus.  SS = Sjogren’s syndrome.  WMH = white matter hyperintensities 
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Discussion 
Brain damage from any type of stroke, from ischemic and hemorrhagic stroke, and 
‘silent’ vascular damage such as WMHs is increased in most rheumatic diseases.  Most 
data are for stroke in general, but ischemic and hemorrhagic stroke were also increased 
in our new pooled analyses of RA and SLE, as were silent vascular disease markers.  
RA, SLE, AS, gout and to a lesser degree psoriasis carry a higher risk of stroke over 
the general population. Stroke incidence varies across  rheumatic diseases (Table 4.4) 
and appear higher than the general population (for example Rothwell et al.202 report 
annual incidence rates for ischaemic and haemorrhagic stroke as 141 (95% CI 127 to 
156) and 12 (9 to 17) per 100,000 population, respectively). 
Rheumatic disease patients aged under 50 have a particularly high stroke risk 
compared with the general population.  There was no additional stroke risk in 
osteoarthritis.  Other rheumatic diseases are understudied. While increased stroke risk 
may reflect impact on lifestyle through the physical effects of rheumatic diseases, the 
possibility that increased systemic inflammation affects the brain directly is suggested 
by the higher stroke risk in inflammatory versus non-inflammatory arthropathies. A 
better understanding of stroke in rheumatic disease would help focus clinical practice 
on prevention of vascular brain damage, including early lifestyle interventions and any 
vascular prevention role for anti-inflammatory agents, in these patients.  
This is the first analysis to quantify stroke subtype rates and risk in rheumatic disease, 
including by age.  Our results are comparable with Holmqvist et al’s.55 meta-analysis 
of 10 cohort studies of stroke and its subtypes in SLE, including that stroke risk is 
increased in the under 50’s, but we expand the analysis by including other rheumatic 
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diseases.  We were limited by the different methods used in the primary studies, 
although we attempted to correct for this by using random effects meta-analysis.  
Consistency of reporting of stroke rates is a recognised problem and future studies 
should attempt to standardise their methods215.   
The increase in risk of vascular disease in RA and SLE is perhaps expected, but we 
also note the almost doubling of stroke in gout (1.71, 1.68 to 1.75; n=9,951 strokes, 
n=202,033 patients) over the general population perhaps due to the relationship 
between gout and metabolic syndrome or to uric acid’s independent association with 
ischaemic and haemorrhagic stroke subtypes216.  
The review’s strengths include data from large population-based studies, although we 
only included English language studies.  We could not adjust for vascular risk factors 
or treatments, limiting generalisability, and cannot exclude the possibility of study 
bias.  Patients with rheumatic disease are often assiduously monitored (due to the 
disease and treatments) and so might have minor neurological problems investigated 
more compared to the general population.  
Data on ischaemic stroke subtypes were limited to two studies in SLE166,199.  Many 
more studies reported on SVD features among patients with several rheumatic 
diseases.  While the small size and disparate reporting precluded meta-analysis, the 
general impression was of more vascular lesions in rheumatic diseases.   
The increased stroke risk at earlier ages uses data from 340,548 patients (11,879 
strokes).  The excess risk was almost double that of the general population, highest in 
those <50 years, and declined steadily to approach that of the general population above 
age 65.  However there was heterogeneity in study reporting and inconsistencies in age 
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categories (despite guidance to use mid-decade age bands215).  The clear trend for 
higher stroke risk <50 years suggests that atherosclerosis is unlikely to be the sole 
pathogenic driver.  Systemic inflammation may play a role.  The increased risk at 
younger ages might reflect more rheumatic disease activity before the inflammation is 
well controlled.  
The risk of any stroke, ischaemic or haemorrhagic stroke, and MRI findings seem 
worse in inflammatory arthropathies (RA, SLE, AS, gout, psoriatic arthritis) than non-
inflammatory arthropathies (OA), although we acknowledge the inflammatory 
component to OA which limits interpretation of our results which dichotomises the 
arthropathies on the basis of inflammatory/non-inflammatory.  Inflammation is a risk 
factor for stroke217 and plasma markers of inflammation (CRP, TNF-a, IL-6) are 
associated with stroke127 and increased WMH burden.  Antiphospholipid (APL) 
antibodies increase the risk of thrombus: in rheumatic populations, strokes (and pre-
clinical brain abnormalities such as WMH) are more common in those with APL than 
those without204,207,208.  In those with stroke, APL are associated with stroke218 and 
increase the stroke risk fivefold in those <50 years219.  Conversely, Mikdashi et al.199 
found no association between baseline anti-cardiolipin antibodies and future stroke 
among 238 SLE patients followed for 8 years (although 44 (18%) developed ischaemic 
stroke, and the authors did not control for anticoagulant/antiplatelet use) while 
cholesterol and hypertension predicted stroke, indicating that traditional stroke risk 
factors should be managed rigorously. Petri et al.220 found homocysteine, a marker of 
endothelial dysfunction, to be an independent risk factor for stroke in SLE.  Therefore 
inflammation generated in the rheumatic diseases may be at least in part responsible 
for the marked stroke risk and overt brain lesions, and increased risk at younger ages.   
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A large well conducted brain imaging population study with detailed stroke 
phenotyping is needed to fully characterise stroke subtypes including SVD in 
rheumatic patients.  A clear picture of increased stroke risk in younger patients is 
established indicating a need to a) unravel the extent to which inflammation, lifestyle, 
anti-rheumatic treatments and risk factors (traditional as well as new) contribute to 
stroke risk and b) whether aggressive management of these risk factors including 
inflammation, can ameliorate the stroke risk.  Imaging features such as WMH might 
assist in identifying rheumatic disease patients who are at particularly high risk of 
stroke, as do WMH in the general ageing population21. 
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Chapter 5: Cerebrovascular disease including stroke subtypes in 




Arthritis patients die prematurely from cardiovascular disease156.  RA is an 
independent risk factor154,155 in this regard, while Chapter 4 showed that SLE and other 
inflammatory arthropathies also increase stroke risk.  Chapter 4 provided new data on 
the excess risk of stroke by stroke subtypes over the general population in RA 
(ischaemic, OR 1.64 (1.32 to 2.05); haemorrhagic, OR 1.68 (1.11 to 2.53)) and SLE 
(ischaemic, OR 2.11 (1.66 to 2.67); haemorrhagic, OR 1.82 (1.07 to 3.09)).  Less is 
known about other arthropathies.  Less is known about the relationship between 
arthropathies and ischaemic stroke subtypes such as lacunar stroke.     
A proportion of excess stroke risk in arthritis could relate to higher systemic 
inflammatory activity.  Different types of arthritis (eg, RA / SLE representing 
inflammatory arthritis versus osteoarthritis / osteoporosis representing non-
inflammatory arthritis) could be studied to assess the contribution of inflammatory 
disease mechanisms between stroke subtypes.  Inflammation plays a major role in all 
stages of atherosclerosis (and hence large vessel stroke)43–45 and is seen pathologically 
in the intracranial arteriolar walls and perivascular tissue in small vessel disease (SVD) 
stroke46.  However, while inflammation in atheroma might be a direct result of the 
atheromatous process, the origin of the inflammation in the brain microvessels in SVD, 
whether intrinsic or secondary to systemic inflammation, is unknown.  
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Most studies investigate single arthropathies.  Only one prior study178 has looked at 
stroke risk among a range of arthropathies concurrently in one study.  No studies have 
grouped a range of arthropathies into inflammatory versus non-inflammatory subtypes 
to assess burden of stroke or stroke subtypes between these groups. 
In Chapter 4 we saw that stroke risk (for any stroke) in rheumatic patients was greatest 
among younger people, particularly <50 years.  No studies have grouped a range of 
arthropathies and compared stroke subtypes by age versus stroke subtypes in the 
general population.  Identifying increased risk across the lifecourse is clinically 
important, might unveil mechanistic or lifestyle insights and has implications for 
stroke prevention.  Early management of stroke risk factors is important to help avoid 
accumulating damage that might precipitate an acute cerebrovascular event. 
We used comprehensive data from a large regional rheumatology service linked to 
Scottish national hospital records to: (1) assess the number of strokes, including 
subtypes, in relation to several common rheumatic diseases; (2) group the arthropathies 
into inflammatory and degenerative (non-inflammatory) categories to see if there is a 
higher burden of all stroke or of stroke subtypes among the inflammatory group; (3) 
investigate age at stroke to confirm if stroke in inflammatory versus degenerative 
arthropathies occurred at a younger age in this data and (4) set our findings in context 
by comparing to stroke incidence rates and age at stroke from the general population. 
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Methods 
This is a cohort study, with ascertainment of rheumatic cases identified in an audit and 
extraction of data on antecedent vascular events in the preceding 15 years. 
Prospective audit of rheumatology attendees 
We undertook an audit of new referrals and follow-up patients attending outpatient 
clinics at the rheumatic diseases unit within NHS Lothian over a 24 month period from 
January 2011 to December 2012.  Demographic details, clinical diagnoses, anti-
rheumatic treatments and other relevant information were collected. A national data 
linkage search for cerebrovascular events was conducted for the patients in the audit. 
National data linkage search 
Every person in Scotland that is registered with a general practitioner (GP) or who has 
attended a hospital is given a unique reference number known as a Community Health 
Index (CHI) number. We sent the rheumatology patient CHI numbers to NHS Services 
Scotland to query its national hospital admissions database, SMR-01, to find episodes 
relating to cerebrovascular disease.  The SMR-01 database records every general acute 
inpatient and day case admission in Scotland as part of the National Data Catalogue 
(http://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/).  SMR-01 was 
upgraded in 1997 to cater for the introduction of version 10 of the International 
Classification of Diseases (ICD-10) classification system and so we searched over 15 
years, from May 1997 to December 2012.  We were interested in any of 11 codes (see 
below) of relevance to stroke.  There is no ability to record ischaemic stroke subtypes 
in ICD-10.   
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ICD-10 codes 
G45 – Transient ischaemic attack       
I60 – Subarachnoid haemorrhage       
I61 – Intracerebral haemorrhage       
I62 – Other non-traumatic intracerebral haemorrhage (eg, subdural)   
I63 – Cerebral infarction        
I64 – Stroke, not specified as haemorrhage or infarction    
I65/66 – Occlusion and stenosis, not resulting in cerebral infarction   
I67 – Other cerebrovascular disease      
I68 – Cerebrovascular disease classified elsewhere     
I69 – Sequelae of cerebrovascular disease      
 
Research ethics 
The CHI numbers were removed after the database query so all analyses were on 
anonymised data.  Both the NHS Lothian and NHS Services Scotland Caldicott 
Guardians approved the release of data under reference XRB13145.  As such, research 
ethics committee approval was not required. 
Grouped rheumatic categories 
We grouped 18 rheumatic diagnoses into eight categories: RA (rheumatoid arthritis), 
seronegative (psoriatic arthritis, ankylosing spondylitis, reactive arthritis (Reiter’s)), 
vasculitis (polymyalgia rheumatica and temporal arteritis, Churg Strauss vasculitis, 
polyarteritis nodosa, Takayasu disease), mixed (systemic lupus erythematosus, 
Sjogren’s, scleroderma, mixed connective tissue disease), crystal (gout, pseudogout), 
osteoarthritis, osteoporosis and other.  ‘Other’ was used when a diagnosis was 
provisional awaiting test results or was unclear.  
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We also grouped patients into inflammatory (all diagnoses except osteoarthritis and 
osteoporosis) and non-inflammatory (i.e., degenerative: osteoarthritis and 
osteoporosis) arthropathies.  Some patients had a single rheumatic diagnosis of 
“Other” and therefore could not be dichotomised.  Where a patient had multiple 
rheumatic diagnoses, we defined ‘non-inflammatory’ as requiring all diagnoses to be 
non-inflammatory. 
Grouped stroke categories 
‘All strokes’ were defined as any of: cerebral infarcts, intracerebral haemorrhage 
(ICH), subarachnoid haemorrhage, transient ischaemic attack (TIA), non-traumatic 
subdural bleeds or unspecified strokes.  ICH, subarachnoid haemorrhage and non-
traumatic subdural bleeds were grouped into one ‘bleeds’ category for some analyses.  
Comparison to population data and statistics 
A patient rather than an event is the unit of analysis in this study.  We calculated stroke 
incidence rates and placed stroke by subtype into 10-year age bands and compared 
these data with data from the general population202,221.   We assessed differences in 
proportions by χ2 test and differences in means for continuous data with Student’s t 
test using the statistical programming language R version 3.0.1 (http://www.r-
project.org/)141.  We used logistic regression to adjust for age and sex when comparing 
cerebrovascular event versus no event among different groups.  We considered a p 
value of <0.05 as significant.  
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Results 
Audit and database query 
The audit recorded 6,681 visits between January 2011 and December 2013, which we 
linked to national cerebrovascular events covering 15 years.  We excluded repeat visits 
during the audit period (n=31 patients), visits from new patients that did not result in 
a rheumatic diagnosis (n=19) and coding errors (n=18) which left 6,613 patients 
available for analysis.  The linkage query returned 37,619 records, being any 
hospitalisation for any purpose in our rheumatic patients and there were 347 
cerebrovascular disease event episodes among 224/6,613 (3.4%) patients (66% 
women).  Of 224 patients with a cerebrovascular event, 63 (28%) had multiple events 
and 53 (24%) had more than one rheumatic diagnosis (Figure 5.1) 
 
Figure 5.1 Schematic of audit data and national linkage search  
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There were 4,527/6,613 (68.5%) women in the audit.  The mean age of those attending 
clinic was 56 years (range 14–95 years).  The mean age at cerebrovascular event was 
63.7 ± 12.9 years (Table 5.1).   
 
Table 5.1 Overview cerebrovascular events among 224 rheumatology patients 
 All Women Men 
Number of persons (%) 6,613 4,527 (68.5%) 2,086 (31.5%) 
Age at clinic visit (years)  56.0 56.5 55.0 
Number having an event (%) 224 149 (66.5%) 75 (33.5%) 
Proportion* 3.4% 3.3% 3.6% 
Age at event (years) 63.7 63.7 63.6 
* Number of rheumatology patients with an Event as a proportion of all rheumatology patients 
 
Inflammatory versus non-inflammatory 
We classified 4,088/6,613 (62%) rheumatology patients as inflammatory and 
664/6,613 (10%) as non-inflammatory.  Of these, 157/4,088 (3.8%) and 28/664 (4.2%) 
had cerebrovascular events (Table 5.2).   
 
Table 5.2 Cerebrovascular events among rheumatology patients split by inflammatory 
and non-inflammatory arthritis (excludes 1,861 “Others”) 
 Inflammatory Non-
inflammatory 
P value Others 
Patients with event 157 28 0.72 39 
Patients with no event 3,931 636 --- 1,822 
Total 4,088 664 --- 1,861 
Proportion of patients with event 3.8% 4.2% ---  
Mean age at event (years) 64.0 61.5 0.23  
Mean age at clinic visit (years) 68.2 66.9 0.51  
Others could not be dichotomised inflammatory/non-inflammatory 
 
Almost a third (1,861/6,613 (28%)) of patients had a single rheumatic diagnosis of 
“Other” and could not be classified as inflammatory / non-inflammatory, including 39 
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patients with cerebrovascular events.  There were no significant differences in age at 
event (p=0.23) or the proportion (p=0.72) of rheumatology patients having a 
cerebrovascular event between arthropathies grouped as inflammatory (n=4,088) 
versus non-inflammatory (n=664) (Table 5.2). 
Inflammatory arthritis was not associated with cerebrovascular events before and after 
(Table 5.3) adjusting for age and sex.  Age was predictive of events: a year’s increase 
in age resulted in a 6% increase in likelihood of having an event (Table 5.3).  
 
Table 5.3 Logistic regression showing odds ratios for three parameters in estimating 
cerebrovascular event versus no event 
 OR 95% CI 
Inflammatory arthritis 0.93 0.62 to 1.44 
Age (year) 1.06 * 1.05 to 1.08 
Male sex 1.28 0.93 to 1.75 
CI = confidence interval, OR = odds ratio.  Compares odds of having a cerebrovascular event 
versus no event in n=4,088 inflammatory and n=664 non-inflammatory patients.  * p<0.0001.  
 
RA versus osteoarthritis 
We repeated the analysis comparing only patients with a single diagnosis of either RA 
(n=1,768) or osteoarthritis (n=583) and found no statistical difference in age between 
the groups, no difference in the proportion of any cerebrovascular event, and no 
difference in any ischaemic or haemorrhagic stroke versus no event.   
Grouped rheumatic categories 
The proportion of cerebrovascular events by grouped rheumatic categories were: RA 
3.8%, crystal 4.4%, seronegative 2.0%, vasculitis 6.3%, mixed 1.7%, osteoarthritis 
3.6% and osteoporosis 9.0% (Table 5.4).    
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Table 5.4 Cerebrovascular events among rheumatology patients by grouped category 
 No event Event Event as % 
Inflammatory 
     RA 1,700 68 3.8% 
     Crystal 109 5 4.4% 
     Seronegative 751 15 2.0% 
     Vasculitis 193 13 6.3% 
     Mixed 293 5 1.7% 
     Sub-total 3,046 106 3.4% 
Non-inflammatory 
     Osteoarthritis 562 21 3.6% 
     Osteoporosis 50 5 9.0% 
     Sub-total 612 26 4.1% 
Other 1,822 39 2.1% 
Total 5,480 171 3.0% 
 
Stroke subtypes 
There were 151 patients with some form of stroke: 54 infarcts, 30 TIAs, 7 ICHs, 14 
subarachnoid haemorrhages, 5 non-traumatic subdural bleeds and 41 unspecified 
strokes (Table 5.5).  There were no statistically significant differences in the numbers 
of infarcts or bleeds among inflammatory versus non-inflammatory arthropathies as a 
proportion of all strokes (p=1.0) nor as a function of the entire cohort (p=0.79).   
Grouping unspecified strokes with ischaemic strokes did not alter these results.   
Table 5.5 All stroke and stroke subtypes 




     Infarcts 54 37 6 11 
     TIA 30 21 3 6 
     Unspecified 41 32 4 5 
     Sub-total 125 90 13 22 
Haemorrhagic 
     ICH 7 5 1 1 
     Subarachnoid 14 11 1 2 
     Subdural 5 3 1 1 
     Sub-total 26 19 3 4 
Any stroke 151 109 16 26 
Numbers are patients.  * Other = Unable to assign to inflammatory/non-inflammatory.  ICH = 
intracerebral haemorrhage. TIA = transient ischaemic attack. 
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General population comparison of stroke incidence rates and age at stroke 
The number of any strokes equated to 152 strokes per 100,000 person-years.  Lee et 
al.221 and Rothwell et al.202 report stroke incidence in the UK as ranging from 104–227 
per 100,000 person-years.  The mean age at event in our data was 63.7 ± 12.9 years 
with events peaking in the 55–64 years age band (Table 5.6 and Figure 5.2).  
Table 5.6 Stroke subtypes by 10-year age bands across all rheumatic diagnoses 
 25 to 34 35 to 44 45 to 54 55 to 64 65 to 74 75 to 84 85+ 
Ischaemic 
     Infarcts  3 8 15 13 15  
     TIA  4 3 13 6 3 1 
     Unspecified 2 2 5 13 9 8 2 
     Sub-total 2 9 16 41 28 26 3 
Haemorrhagic 
     ICH  1  4 2   
     Subarachnoid  6 3 2 2 1  
     Subdural   2 1 1 1  
     Sub-total  6 5 7 5 2  
Total 2 15 21 48 33 28 4 
Numbers are patients.   ICH = intracerebral haemorrhage, TIA = transient ischaemic attack. 
 
 
Figure 5.2 Stroke subtypes by 10-year age bands. Panel (A) among rheumatic 
patients in south-east Scotland; panel (B) among the general population202  
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Discussion 
This was a large national retrospective data linkage study involving 6,613 patients with 
various rheumatic diagnoses attending a regional specialist rheumatology clinic.  We 
found 224 cerebrovascular events (3.4%). 
Although our stroke incidence rate is within the range expected from the general 
population, the strokes occurred on average two decades earlier than in the general 
population.  There was no difference in the proportion of strokes occurring between 
patients classified as inflammatory versus non-inflammatory, although a third of the 
data could not be used as the diagnoses were incomplete. 
We classified a patient as ‘non-inflammatory’ only if there was a diagnosis of 
osteoarthritis, osteoporosis or both in patients with two diagnoses but verified our 
results by repeating the analysis by comparing only patients with a single diagnosis of 
either RA or osteoarthritis. Moreover, there was no association of any event with RA 
after controlling for age and sex.  RA is generally considered a more aggressive disease 
requiring assiduous monitoring than osteoarthritis, with RA patients less likely to miss 
a clinic visit.  Meanwhile osteoarthritis is a very common disorder so perhaps only the 
more severe osteoarthritis referrals and follow-ups may be represented in our data.  
Furthermore increasing the non-inflammatory denominator could lead to detection of 
a difference in events between RA and osteoarthritis, although it would take a roughly 
doubling of the non-inflammatory denominator in our data to show any difference. 
We captured a range of strokes.  However, mild strokes and TIAs are generally not 
admitted to hospital in NHS Lothian but instead followed-up as outpatients in 
specialist neurovascular clinics and consequently are not captured in the national 
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database which requires an admission or in-patient day case visit. Hence TIA and mild 
strokes are likely to be under-represented in this analysis whereas haemorrhagic stroke 
which is more often severe is probably more completely captured.  It was not possible 
to link to data on stroke outpatient records. 
We did not review individual clinical records nor the results from imaging and so are 
unable to verify if the cerebrovascular events were coded correctly in the national 
database, however studies have validated the use of administrative data in stroke 
research222. We are unable to comment on modifiable risk factors such as smoking, 
diabetes, hypertension, relative lipid levels, high homocysteine, sedentary lifestyles, 
etc.  A proportion of stroke risk in rheumatic patients may be a function of the 
inevitable lifestyle restrictions: joint pain, swelling, lack of motivation and depression 
limit activity and exercise, potentially increasing stroke risk through weight gain, 
higher blood pressures, etc. 
We included osteoporosis with osteoarthritis when creating a non-inflammatory group 
since patients with osteoporosis are followed-up by rheumatology, although we note 
this is primarily a metabolic bone disease. 
We did not have date of rheumatic diagnosis nor date of commencement of treatments 
and could not analyse duration of rheumatology disease and cerebrovascular events.  
The retrospective design is limiting; this was not an inception cohort from 1997 and 
thus those with rheumatic diseases that died from stroke between 1997 and 2011 will 
not have been captured in the data. 
Our incidence rates are crude (the nature of this linkage study does not allow for true 
“observed years at risk” to be known) and comparison with general population data is 
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merely illustrative. Our overall rates are slightly higher than Lee et al.221 but lower 
than Rothwell et al.202, possibly as the number of minor strokes we found from the 
linkage data will be under-stated. 
Not all prior studies have associated rheumatic disease with an increased risk of stroke.  
In meta-analysis, Levy et al.223 found no additional risk of stroke (n=79 any type 
strokes) in 2,235 RA patients versus the general population (OR 1.14, 95% CI 0.86 to 
1.51), although a larger more recent meta-analysis did find an association (pooled 
stroke incident rate ratio 1.91 (95% CI 1.73 to 2.12))170.  In Chapter 4 it was shown 
that the increased risk of ischaemic and haemorrhagic stroke in RA was 1.64 (1.32 to 
2.05) and 1.68 (1.11 to 2.53) respectively. 
Stroke occurred early: our data were clustered around the 55–64 years age band, two 
decades younger than the average age of stroke in the general population202.  Other 
studies161,164,166,178,189 have reported a trend towards increased stroke risk earlier in life 
among rheumatic patients, including our own findings (Chapter 4).  Ours is the first 
study to group several different rheumatic diseases to compare age of stroke by 
subtype versus stroke subtypes in the general population.  
The persistent, non-resolving inflammatory mechanisms present in many rheumatic 
diseases could accelerate stroke processes resulting in stroke earlier in life (perhaps 
before the inflammation is brought under control), although we found no difference in 
the proportion of strokes between arthropathies grouped as inflammatory versus non-
inflammatory, nor between RA and osteoarthritis when analysed separately – although 
the non-inflammatory patients captured here may be more severe than non-
inflammatory arthritis patients in general and we lost power through not including 
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many patients classified as ‘Other’.  Those having a cerebrovascular event classified 
as inflammatory were slightly (non-significantly) older than those classified as non-
inflammatory (64 v 61.5 years). The use of logistic regression to adjust for age and sex 
did not alter our findings.  Either a larger sample is needed to detect a difference, or 
non-inflammatory arthropathies, particularly those severe enough to be referred to a 
specialised rheumatology service, are equally subject to more stroke risk.  Moreover, 
uncontrolled osteoarthritic joint pain might itself trigger an inflammatory cascade with 
systemic consequences, including effects on the brain.  
Implications and future work 
Rheumatologists should consider the possibility of cerebral involvement in all 
rheumatology patients (not solely those with presumed vulnerability such as RA, SLE 
and vasculitis patients), and note that stroke is more likely early in life compared to 
stroke in the general population.  Assiduous risk factor management to help reduce the 
risk of stroke is essential and could be beneficial if started early. Rheumatology 
patients are often encouraged to engage in exercise as it is helps their rheumatic 
condition, however doing so will also reduce stroke risk.    Brain imaging studies 
involving rheumatic patients are likely to be helpful in understanding the brain’s 
involvement in, and response to, rheumatic diseases.  Large, prospective, longitudinal 
studies that follow the brain in patients starting different forms of anti-inflammatory 
treatments would be useful. More studies involving the lesser studied rheumatic 
diseases, including the non-inflammatory arthropathies, are also needed. 
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Chapter 6: A pilot MRI neuroimaging study of patients diagnosed with 
systemic lupus erythematosus (“the SLE study”): background, 
rationale and methods  
 
Introduction 
SLE is a chronic inflammatory autoimmune disease, mostly affecting women, which 
is associated with an increased risk of stroke55,56 for reasons which are incompletely 
understood (reviewed in Chapter 4).  SLE patients also complain of fatigue, ‘brain 
fog’, cognitive impairment and other neurological involvement224.  At least three 
prospective studies (n=1,385) document rates of at least one episode of psychiatric 
disturbance over several years of around 40%, as well as headaches, cognitive 
disturbance and neurological symptoms that fall short of stroke211,225,226.  These 
symptoms are disabling, unpleasant and contribute substantially to the burden of 
disease.  
Fatigue60 is a common but unexplained feature of SLE which increases distress and 
lost work days.  Fatigue in SLE has been associated with an increased burden of brain 
WMH in one study61, suggestive of a biological basis for fatigue.  Cognitive decline 
in SLE patients has also been reported59.  Cognitive decline also occurs with WMH in 
SVD, therefore SVD might explain both cognitive decline and fatigue in SLE, possibly 
linked through inflammation. 
Cerebral small vessel disease 
SVD is an intrinsic disorder of the brain’s perforating arterioles18.  Features range from 
asymptomatic WMH and other brain imaging biomarkers19 of SVD to symptomatic 
lacunar stroke, which accounts for a quarter of all ischaemic strokes.  SVD is a major 
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cause of cognitive impairment and dementia, and also results in depression and gait 
and balance problems18.  
In sporadic SVD, inflammation and cell infiltrates are seen in the perforating arteriolar 
walls and microglial activation is seen in the perivascular tissue on pathology46,47.  The 
source of the inflammation is not known, whether intrinsic or systemic, but is 
associated with raised plasma markers of inflammation in healthy older subjects48. C-
reactive protein (CRP), one of the main clinical measures of inflammation, was 
associated with lacunar infarcts in a recent large (n=519) study, independent of age 
and vascular risk factors49.  Factors that contribute to damage of the endothelial lining 
of brain vasculature such as immune complex formation and complement 
activation/deposition and occur in SLE, might trigger cerebrovascular inflammation in 
SLE.  We hypothesized that one explanation for increased stroke risk in patients with 
SLE could be via the effects of systemic inflammation on cerebral small vessel 
integrity.   
White matter microstructural damage 
As brain white matter is disrupted in SVD we also hypothesized that patients with 
SLE, but no overt neurological dysfunction, would show subclinical white matter 
damage.  Diffusion tensor magnetic resonance imaging (DT-MRI) and quantitative 
tractography are techniques that can map the brain’s white matter tracts (bundles of 
individual white matter fibres known as axons) and provide biomarkers for 
microstructural integrity. Water molecules preferentially diffuse along the principal 
fibre direction in healthy white matter, while loss of structural integrity, which has a 
deleterious effect on brain function, increases free water movement. The magnitude 
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and directionality of water molecule diffusion can be quantified within segmented 
tracts using biomarkers such as mean diffusivity (MD) and fractional anisotropy 
(FA),227 with low MD and high FA indicating structurally intact white matter.  A study 
in a large sample (n=420) of older people in their early seventies showed that white 
matter tract integrity measured using quantitative tractography is a global property of 
the brain227. That is, lower FA in one tract tends to be associated with lower FA in all 
other tracts, and the first unrotated principal component (considered to be a general 
factor of white matter integrity) explained 38% of the variance across white matter 
tracts. Additionally, in that study, the general factor of white matter integrity was 
related to general cognitive ability. 
Nine small (average n=24 patients) studies57,228–235 showed microstructural white 
matter tract damage in SLE and neuropsychiatric SLE (NPSLE) versus healthy 
controls. However, none of these studies in SLE investigated whether subvisible DT-
MRI-detected brain damage associates with fatigue or cognitive function. 
Hypothesis 
We hypothesized that patients diagnosed with SLE have brain MRI evidence of SVD, 
and this could be the biological basis for fatigue and cognitive decline, and might 
explain increased stroke risk.   
Pilot study 
This cross-sectional brain MRI study (“the SLE study”) was a pilot study designed to 
test our hypothesis, establish and test working practices and protocols (e.g., to see if 
the SLE patients would tolerate the MRI exam, and to see if our techniques for image 
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analysis would work well in this cohort) and to generate data which could be used to 
inform and power a future multi-centre study.  A grant application to fund the study 
was developed (by the author of this thesis, supported by his supervisor) and submitted 
to the charity Lupus UK and granted in November 2013 (award letter in Appendix B). 
This pilot study is part of work to improve understanding of how inflammation affects 
the brain vessels and tissue and relates to symptoms, with the aim ultimately of 
improving prevention and treatment. The detection of early changes in the brain could 
influence the management of patients with SLE to prevent disabling neurological 
symptoms and progressive brain damage. This knowledge will also contribute to 
understanding of how inflammation affects the brain to improve prevention and 
treatment of SVD-related lacunar stroke, cognitive decline and dementia.   
Aims 
In addition to piloting this brain study in SLE patients, our aims were to: 
[these results are presented in Chapter 7] (1) measure and compare imaging 
biomarkers of SVD in patients with SLE with sex- and age-matched healthy 
controls and patients with mild stroke including small vessel type; (2) compute a 
total burden of SVD score and determine associations with vascular risk factors, 
plasma biomarkers of inflammation, endothelial dysfunction and coagulability, and 
SLE disease activity and damage; 
and: 
[these results are presented in Chapter 8] (3) compare water diffusion biomarker 
values measured in a number of major white matter tracts using quantitative 
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tractography with sex- and age-matched healthy controls; (4) assess associations 
between MD and FA and other variables as well as the relationship with age; (5) 
identify if fatigue or cognitive function in SLE were related to DT-MRI 
parameters, SLE disease activity or plasma biomarkers of inflammation, 
endothelial dysfunction and coagulability and; (6) consider the totality of the data 
on DTI-MRI in SLE and NPSLE by meta-analysing the current and all prior 
studies. 
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Methods 
 
SLE patients  
We prospectively recruited patients with SLE – including patients already recruited to 
the Scottish Lupus Exchange database (SLEx) (UK Clinical Trials ID 15489) – who 
attended a specialist SLE clinic in NHS Lothian between April and December 2014.  
The SLEx is new national network of rheumatologists and a patient registry project 
formed in 2008 and funded initially to 2018 that longitudinally monitors SLE disease 
activity, progression and treatments.  The SLEx is co-ordinated from Dundee 
University and includes participating centres in Fife, Grampian, Greater Glasgow and 
Clyde, Highland, Lanarkshire, Lothian and Tayside.  The mission for SLEx is stated 
as: 
‘SLEx aims to raise awareness and understanding of SLE and other related 
connective tissue diseases and to promote high standard clinical care and 
scientific research of these conditions in Scotland and further afield’. 
All patients were seen by a consultant rheumatologist.  SLE was diagnosed according 
to updated American College of Rheumatology 1997 criteria236.  A person is said to 
have SLE if they meet four from 11 of the following clinical criteria: malar rash; 
discoid rash; photosensitivity; oral ulcers; arthritis; serositis; renal disorder; 
neurologic disorder; haematologic disorder; immunologic disorder; antinuclear 
antibodies (further details are presented in Appendix C that draws from the earlier 
1982 guidelines237, which remain essentially unchanged in the 1997 update other than 
a revision to criterion 10 “immunologic disorder”).  
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Regulatory approvals and informed consent  
The author of this thesis completed the ethical approval process using the Integrated 
Research Application System (https://www.myresearchproject.org.uk/) and the 
project received research ethics committee (REC) approval (South-East Scotland REC 
01, 14/SS/0003; approval letter in Appendix D) and local R&D approval (NHS 
Lothian; approval letter in Appendix E).  A protocol was developed (by the author of 
this thesis, supported by his supervisor; Appendix F) and all participants were sent an 
information sheet about the study (Appendix G).  Written informed consent (Appendix 
H) was obtained from all participants. 
Inclusion and exclusion criteria 
We included adult (aged 18+ years) patients with a diagnosis of SLE who were able 
to self-consent.  We excluded those unable to undergo MRI (e.g., patients fitted with 
a cardiac pacemaker) and those with prior significant head injury or known 
neurological disease such as multiple sclerosis.  We avoided scanning during 
concurrent acute illness like infection to avoid the acute phase immune response which 
would influence inflammatory markers.   
Overview of data collection for SLE patients 
We developed a data collection form (Appendix I) for demographic and other 
variables, measured SVD and DT-MRI imaging biomarkers (detailed below) and used 
validated tools (detailed below) to assess fatigue, anxiety, depression, current 
cognitive function and premorbid intelligence.  The tests were chosen for their ease of 
use, practicality, validity and relevance to medical care and patients.  Therefore the 
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cognitive tools did not test every aspect of cognitive function and intelligence in 
minute detail but focussed on collecting information in major domains in ~20 mins. 
We measured plasma markers of inflammatory activity and endothelial dysfunction, 
SLE disease activity and accumulated systemic damage (detailed below).  An 
overview of the data collected is presented in Figure 6.1. 
 
Figure 6.1 Data collection on the SLE study. 
 
ACER = Addenbrooke’s cognitive examination – revised, BILAG = British Isles lupus assessment 
group 2004, CRP = C reactive protein, dsDNA = double stranded DNA, ESR = erythrocyte 
sedimentation rate, FA = fractional anisotropy, FSS = fatigue severity scale, HADS = hospital anxiety 
and depression scale, HDL = high density lipoprotein, IL-6 = interleukin-6, MD = mean diffusivity, 
MoCA = Montreal cognitive assessment, MMSE = mini mental state examination, NART = national 
adult reading test, SLEDAI = sytemic lupus erythematosus disease activity index, SLICC = systemic 
lupus international collaborating clinics, TNF-a = tumour necrosis factor alpha, vWF = von Willebrand 
factor.  
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Healthy controls 
We obtained control data from healthy volunteers aged between 25 and 65 years, 
recruited by poster campaign at the same health region.  Healthy volunteer subjects 
were recruited if they were native English speakers, were not on any long term 
medication, had not been diagnosed with diabetes or hypertension, had not undergone 
previous cranial surgery, had alcohol consumption levels within the UK national safety 
guidelines and were able to undergo brain MRI. The study was funded by the National 
Institute for Health (grant R01 EB004155-03), approved by the Lothian Research 
Ethics Committees REC (05/S1104/45) and subjects gave written informed consent. 
Stroke controls 
We also compared the SLE patients with patients with first-ever mild (non-disabling) 
stroke including of small vessel (lacunar) type, recruited from the same health region 
via the regional stroke service.  The study, known as Mild Stroke Study 2 (MSS 2), 
was funded by the Wellcome Trust (grant WT088134/Z/09/A), approved by the South-
East Scotland REC 01 (09/S1101/54) and subjects gave written informed consent.  A 
stroke specialist determined the ischaemic stroke subtype (lacunar or mild cortical) 
using the Oxfordshire Community Stroke Project (OCSP)15 clinical classification and 
confirmed by imaging.  Similar tests were used for assessing premorbid cognition and 
mood. 
Vascular risk factors – SLE patients 
Medical histories including cardiovascular risk factors such as smoking status, prior 
cerebrovascular events, hypertension and diabetes were recorded in SLE patients.  
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Height and weight were measured and body mass index (BMI) calculated using the 
NHS online tool (http://nhs.uk/Tools/Pages/Healthyweightcalculator.aspx).  We 
measured blood pressure three times using an Invivo Research Inc 3150 MRI-
compatible patient monitor (before the MRI scan, after the scan and at the end of the 
study visit) to derive an average blood pressure reading, and we also identified patients 
on hypertension medication from medical notes.  We dichotomised patients as 
hypertensive or not, and also classified them with the British Hypertension Society 6-
point scale, from optimal to severe238. 
SLE activity and damage scores – overview  
SLE disease activity was assessed by an experienced rheumatology nurse specialising 
in SLE who interviewed each patient and had access to all medical data and blood 
results using the Systemic Lupus Erythematosus Disease Activity Index 2000 
(SLEDAI-2K)239 and British Isles Lupus Assessment Group 2004 (BILAG)240 tools. 
Accumulated permanent damage was assessed with the Systemic Lupus International 
Collaborating Clinics (SLICC)241,242 tool.  
SLE activity and damage scores – further details 
The SLEDAI-2K (Appendix J) is a 24-item checklist of important factors in disease 
activity from which the assessor decides whether each manifestation is present or 
absent in the preceding 10 days243.  The scores are weighted such that more serious 
manifestations like seizures and other central nervous system disorders are given more 
prominence in the final score.  Higher scores reflect more current disease activity.  The 
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maximum theoretical score is 105 but in practice patients rarely score more than 45 
and scores higher than eight are considered active disease244.  
The BILAG (Appendix K) consists of 97 questions (known as “items”) over nine 
systems (known as “categories”: constitutional, mucocutaneous, central nervous 
system, musculoskeletal, cardiovascular/respiratory, abdominal, renal, ophthalmic and 
haematological) and is based on “intention to treat”240,245.  The answers to the questions 
are entered into the web-based i-BLIPS (British Lupus Integrated Prospective System) 
system and include responses on Likert scales, Yes/No answers and the input of 
serological values.  The i-BLIPS software determines a “score” that summarises the 
involvement of each of the nine category systems as follows: A (Action), B (Beware), 
C (Content), D (Once involved but no longer active) and E (Never involved).  The 
most active score in each system, grade A, is defined as “the individual clinical 
features, or combination of features, which would lead to the prescription of 
medium/large doses of corticosteroids (>20mg prednisolone or equivalent) and/or 
starting or increasing immunosuppressive drugs or high-dose anticoagulation”240. 
Scores are not intended to be summed into a global measure, although Yee et al.246 
showed the validity of a numeric conversion of the scores as follows: A=12, B=8, C=1, 
D=0 and E=0.  We created numerical values from the nine individual system scores 
following the approach of Yee et al.246 and then summed these to create a global 
BILAG disease activity score per patient. 
The damage index SLICC (Appendix L) was used to assess permanent damage.  
SLICC measures accumulated damage across 12 organ systems arising since the onset 
of SLE where damage is defined as “irreversible change in an organ or system that has 
been present for at least six months”247.  Use of the six month time frame allows for 
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permanent damage to be distinguished from active inflammation.  Damage may be the 
consequence of active SLE disease, therapy, comorbid disease or any combination of 
these247.  Higher scores reflect more accumulated damage.  
Fatigue 
The Fatigue Severity Scale (FSS)58 was used to assess fatigue (Appendix M).  The FSS 
asks nine questions with responses scored on a 7-point Likert scale (1 strongly disagree 
to 7 strongly agree).  Higher scores indicate more severe fatigue.  The mean (± SD) 
from normal healthy adults in the standardisation sample was 2.3 (± 0.7)58.  In the 
present study, participants were asked to assess how they felt within the prior week.  
Cognitive assessments 
The Hospital Anxiety and Depression Scale (HADS)248 was used to assess levels of 
anxiety and depression (Appendix N).  The HADS is a short (about 2 minutes to 
complete) self-administered validated249 questionnaire, designed to assess anxiety and 
depression.  It asks 14 questions; the scores allow a patient to be categorised as ‘case’, 
‘borderline case’ and ‘non-case’ for each of anxiety and depression.  We received 
permission from the publishers of HADS, GL Assessment Ltd, to use this tool.  We 
used this in preference to the Beck’s Depression Inventory (used in MSS 2) because it 
can be completed independently. 
Three validated screening tools were used to assess cognitive function: the Montreal 
Cognitive Assessment (MoCA)250, Addenbrooke’s Cognitive Examination – Revised 
(ACER)251 and Mini Mental State Examination (MMSE)252 (Appendices O, P and Q), 
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while the National Adult Reading Test (NART)253 was used to adjust for premorbid 
intelligence (Appendix R).  Further details follow. 
The MoCA was designed as a rapid screening tool for mild cognitive impairments.  It 
assesses different domains of cognition (e.g. attention, executive function, orientation, 
etc.) and is scored out of a maximum of 30 points.  A score of 26 and above is 
considered normal.  Copyright permission is not required. 
The ACER is a brief cognitive test that assess five domains (attention/orientation, 
memory, verbal fluency, language and visuospatial abilities).  The total score is 100 
and higher scores indicate better cognitive functioning with scores below 88 leading 
to a suspicion of dementia.  Administration takes about 15 minutes.  Copyright 
permission is not required.   
The MMSE tests a number of mental abilities, including memory, attention and 
language.  The maximum score is 30 and scores of 27 or above are considered normal 
while scores of between 10 and 26 warrant further investigation for mild-to-moderate 
Alzheimer’s disease, and below 10 indicates severe Alzheimer’s.  We received 
permission from the publishers of MMSE, PAR Inc, to use this tool. 
The NART is a validated254 estimate of childhood peak premorbid intelligence as it 
appears broadly resilient to age-related cognitive decline.  The NART assesses ability 
to read aloud 50 irregular words that do not follow common grapheme-phoneme and 
stress rules254; the words can only be pronounced correctly if the person has a prior 
knowledge of the word.  The maximum score is 50 correctly pronounced words.  
Reading ability is used as it is highly correlated with general IQ in the normal 
population.  By adding NART as a term in the linear models (see Statistical analysis 
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below), we can adjust for premorbid intelligence, allowing us to assess changes in 
cognitive function from an inferred peak.    
MRI 
All subjects were scanned at 1.5T on a research-dedicated MRI scanner with an 8-
channel phased-array head coil (GE, Milwaukee, WI).  The scan protocol included an 
axial T2, axial gradient-recalled echo (GRE), axial fluid-attenuated inversion recovery 
(FLAIR), sagittal T2, high-resolution coronal 3D T1 volume, and whole brain DT-
MRI sequences. The DT-MRI sequence consisted of three T2-weighted and 32 
diffusion-weighted (b = 1000 s mm -2) axial single-shot spin-echo echo-planar imaging 
volumes (field of view 240  240 mm, matrix 128  128, TR 13.75 s, TE 78.4 ms). 
Each volume comprised 56 contiguous 2.5 mm thick axial slices with 1.875 mm in-
plane resolution. The scan protocol took ~50 mins.  Detailed scanning parameters are 
presented in Table 6.1. 
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Table 6.1 Scanning parameters for the SLE study 







FSPGR 2 FSPGR 12 
ORIENTATION  AX AX AX SAG COR AX AX AX 
TE  140 102 14  MIN FULL MIN MIN FULL MIN FULL 
TR  9400 8750 1420 3000  13750   
TI/prep time  2350    500    
FOV  24 24 24 24 24 24 24 24 
SLICE THICK.  5 2.5 2.5 1 1.3 2.5 2.5 2.5 
SLICE GAP  0 0 0 0 0 0 0 0 
Acq. MATRIX  384 x 256 384 x 384 384 x 256 320 x 320 192 x 192 96 x 96 128 x 128 128 x 128 
Padded (R x C)  512 x 512  512 x 512 512 x 512 512 x 512 256 x 256 128 x 128 256 x 256 256 x 256 
Pixel width  0.47 0.47 0.47 0.47 0.94 1.875 0.94 0.94 
Pixel height  0.47 0.47 0.47 0.47 0.94 1.875 0.94 0.94 


















FREQ. DIR  AP AP AP  SI RL AP AP 
BAND WIDTH  15.63 20.83 12.50  15.63  27.78 27.78 
NEX  1 1 1 1 1 1 1 1 
FLIP ANGLE    20  8  2 12 










TIME of ACQ. 0:10 6:16 5:59 6:09 5:13 8:12 8:15 00:49 00:49 
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Image review and visual rating of the MRI scans 
All MRI scans were reviewed by a consultant neuroradiologist blind to all other data.  
Imaging features of SVD were defined per STRIVE guidelines19.  
We defined WMH as punctate or diffuse areas in the white matter and deep grey matter 
of the cerebral hemispheres or in the brainstem that were 3 mm or larger in diameter, 
and hyperintense with respect to normal-appearing white and grey matter on T2 and 
FLAIR images.  Deep and periventricular WMHs were coded 0 to 3 using the 
Fazekas137 scale and summed to give a total WMH score (0 to 6) per subject.   
Visible (enlarged) perivascular spaces (PVS) are seen as round (<3mm) or linear 
depending on the scan plane in relation to the orientation of the vessel255 and their 
intensity is that of cerebrospinal fluid on T2-weighted MRI.  They were assessed in 
the basal ganglia and centrum semiovale and scored as 0 (none), 1 (1–10 PVS), 2 (11–
20), 3 (21–40) and 4 (>40) using a validated scale138,255.   
Lacunes256 were defined as deep infarcts – distinguished from PVS due to their larger 
size (3–20 mm) – and their presence, including location in the brain, was noted. We 
used the GRE scans and the simplified Brain Observer Microbleeds Scale139 to count 
microbleeds.   
Cerebral atrophy was defined as enlargement of the ventricles (deep atrophy) and 
enlargement of the sulci (superficial atrophy) and scored accordingly by classifying 
each participant on a validated 6-point scale257 against a template of normal reference 
brains.  Figure 6.2 (overleaf) summarises the MRI features of SVD. 
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Total SVD score 
A total SVD score (range 0–4)258,259 was calculated from individual imaging features 
by awarding points as follows: 1 for any lacunes, 1 for any microbleeds, 1 for moderate 
to severe PVS in the basal ganglia (grade 2–4) and 1 for WMHs (deep tissue: Fazekas 
score 2 or 3 and/or periventricular: Fazekas score 3).  The total SVD score correlated 
with both WMH volume (see below) (r = 0.61, p<0.0001) and summed total Fazekas 
score (r = 0.65, p<0.0001).  
 
Figure 6.2 MRI findings for lesions related to SVD.  Shows examples (upper row) and 
schemaic representation (middle row) of MRI features related to SVD, with a summary 
of imaging characteristics (lower row) for individidual lesions.  DWI = diffusion-
weighted imaging, FLAIR = fluid-attenuated inversion recovery, GRE = gradient-
recalled echo, SWI = susceptability-weighted imaging.  Reproduced from Wardlaw et 
al. Lancet Neurol 2013;12:822–38 with permission from the publishers Elsevier Ltd 
(license number 3832420235618 dated 19 March 2016). 
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Quantitative analysis of the MRI scans 
All pre-processing and image analyses of the structural images was performed by the 
author of this thesis.  All steps involved in generating the tractography data were 
performed by Dr Mark Bastin, Brain Research Imaging Centre. 
Pre-processing 
All images were converted from the Digital Imaging and Communications in Medicine 
(DICOM) international standard file format for medical images 
(http://dicom.nema.org) to the Neuroimaging Informatics Technology Initiative 
(NIfTI-1) format (http://nifti.nimh.nih.gov/nifti-1) using MRICRON 
(https://www.nitrc.org/projects/mricron).  The axial T2-weighted scan was chosen as 
the target scan for registering the other scans to as it has the best resolution and so is 
the best representation of brain anatomy.  Each subject’s FLAIR, GRE and 3D T1 
coronal scans were registered to the T2 using FLIRT260 in FSL 
(http://www.fmrib.ox.ac.uk/fsl).  Registered scans were manually inspected for 
accuracy, e.g., to ensure the scan orientation followed standard radiological 
convention (and were not ‘flipped’ during pre-processing).   
Volumetric imaging measures – ICV, CSF, BTV and WMH 
Intracranial (ICV), cerebrospinal fluid (CSF), brain tissue (BTV) and white matter 
hyperintensities (WMH) volumes were measured using Analyse 11.0 
(http://analyzedirect.com) and in-house software ‘MCMxxxVI’, which is freely 
available from http://sourceforge.net/projects/bric1936/?source=directory.  These 
methods which have been developed locally have been validated256,261.   
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First, using the Object Extractor Tool in Analyse 11.0, the brain (i.e., all soft tissues 
including brain parenchyma, CSF, vessels and meninges within the inner skull and 
limited inferiorly by the tip of the odontoid peg at the foramen magnum) was extracted 
from the GRE scan.  Next the region of interest (ROI) tool was used to manually 
correct erroneous structures and the final ‘object’ saved as the ICV.  The volume of 
the ICV (in ml) was noted.  Next, the GRE and FLAIR were fused in the red-green 
colour space (using the Register Tool in Analyse 11.0) for being used afterwards with 
MCMxxxVI for quantifying WMH volumes. 
Using MCMxxxVI, CSF, venous sinuses and meninges, considered together as ‘non-
brain’ intracranial features, were extracted.  The software uses minimum variance 
quantisation140 on the colour fused image from the prior step. The resultant ‘non-brain’ 
binary masks were subtracted from the ICV to provide a measure of BTV. 
Finally, WMH were automatically extracted using MCMxxxVI, as described 
previously140, then visually inspected for accuracy and to avoid erroneous 
classification, and falsities were manually corrected accordingly.  The corrected WMH 
were considered final, and volumes in ml were recorded. 
Prior to statistical analyses (e.g., correlation between WMH volumes and other data), 
the effect of head size was corrected for by dividing WMH volume by ICV volume.  
The WMH volume correlated strongly with the total Fazekas score (r = 0.83, 
p<0.0001).   
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Volumetric imaging measures – atrophy 
In addition to the visual brain atrophy rating (see above), the BTV:ICV ratio was also 
used as a volumetric measure of atrophy; lower values reflect lower brain tissue 
volume.  The BTV:ICV ratio correlated with the atrophy scores (deep r = –0.72, 
p<0.0001 and superficial r = –0.74, p<0.0001).   
Tractography 
The DT-MRI scans were used to assess white matter microstructural integrity by 
measuring mean diffusivity (MD) and fractional anisotropy (FA). All tractography 
analysis was performed blind to all other data.  MRI data were converted from DICOM 
to NIfTI-1and pre-processed with FSL tools in order to extract the brain, eliminate 
bulk patient motion and eddy current-induced artefacts, and estimate the diffusion 
tensor parameters MD and FA.  The underlying connectivity data was generated using 
a 2-fibre model and 5000 streamlines to reconstruct white matter tracts of interest. 
Major white matter tracts were identified using probabilistic neighbourhood 
tractography (PNT), an automatic tract segmentation method based on modelling tract 
topology, as implemented in the TractoR package for fibre tracking analysis 
(http://www.tractor-mri.org.uk). PNT works by optimizing the choice of tractography 
seed point by estimating the best matching tract from a series of candidate tracts 
generated from a neighbourhood of native space voxels (7 × 7 × 7) placed around a 
voxel transferred from standard space against a pre-defined reference tract. The 
topological tract model is then used to reject any false positive connections, thereby 
significantly improving tract segmentation. The tracts assessed were the genu and 
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splenium of corpus callosum, bilateral corticospinal tracts, cingulum bundles, ventral 
cingulum bundles, left and right arcuate and inferior longitudinal fasciculi. For each 
subject, the seed point that produced the best match tract to the reference for each of 
the pathways was determined, with the resulting tractography mask applied to each 
subject’s MD and FA volume. Tract-averaged MD and FA values, weighted by the 
connection probability, were calculated from these masks.  To ensure that the 
segmented tracts were anatomically plausible, a researcher visually inspected all 
masks and excluded tracts with aberrant or truncated pathways. 
Plasma markers 
All participants had blood drawn on the day of MRI scanning, which provided data on 
levels of the pro-inflammatory cytokine interleukin-6 (IL-6), endothelial dysfunction 
(von Willebrand factor antigen (vWF Ag) and two measures of vWF activity: factor 
VIIIc (fVIIIc) and ristocetin cofactor (RCOF)), endothelial toxicity (homocysteine), 
cholesterol (total, high- (HDL) and low-density (LDL) lipoprotein) and anti-
phospholipid antibodies (anti-cardiolipin Immunoglobulin G (IgG) and M (IgM)). 
Bloods were analysed in a fully-accredited, major NHS laboratory 
(http://www.edinburghlabmed.co.uk) that handles thousands of samples per day. 
We also had access to blood data from recent clinic visits (most within one month, all 
within six months; and all analysed in the same lab) including SLE disease activity 
(C3, C4 and anti-double stranded DNA) and routine inflammatory markers (CRP and 
erythrocyte sedimentation rate (ESR)).  Additionally, interferon beta (IFN) signatures 
were measured at the University of Manchester by analysis of messenger ribonucleic 
acid in a subset of 25 (49%) patients.    
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Statistical analysis 
The distributions of relevant variables were checked graphically for normality 
(histograms and quantile-quantile plots) and presented as means (± SD) or medians 
(Q1–Q3) as appropriate.  A p value of <0.05 was considered significant with the 
following caveat.  In the interests of transparency, we report results from all analyses 
regardless of the p value as this aids interpretation of the entire study and we did not 
adjust the p values for multiple comparisons262.  Thus, in some analyses, a p value of 
<0.01 or less might be more appropriately used for significance to account for 
multiplicity.  All analyses were performed in R, version 3.0.1 (http://www.r-
project.org/)141.  Additional specific methods are noted hereunder. 
SVD (results in Chapter 7) 
We tested the association between the total SVD score and the Fazekas score and, 
separately, the WMH volume.  We compared age and sex pairwise (SLE to healthy 
controls; SLE to stroke) by Student’s t test and χ2 test respectively.  The individual 
features of SVD were compared for differences across the three groups by the Kruskal-
Wallis test (a non-parametric analysis of variance) and a posttest comparison was used 
to identify the source of the difference. 
We used ordinal logistic regression to test for associations between the total SVD score 
(range 0–4) and vascular risk factors (age, BMI, cholesterol and hypertension but not 
diabetes as no SLE patients had diabetes); plasma biomarkers of inflammation (IL6, 
ESR and CRP); endothelial dysfunction (vWF) and toxicity (homocysteine); 
rheumatology scores (SLEDAI-2K, BILAG and SLICC); SLE disease duration; 
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plasma markers of SLE activity (C3, C4 and anti-double stranded DNA); anti-
phospholipid antibodies and brain atrophy.  Results are presented as odds ratios (OR) 
with 95% CIs.   
DT-MRI (results in Chapter 8) 
Principal components analysis (PCA) was used to create general factors of MD and 
FA.  PCA is a data reduction technique used to remove redundancy from several 
measured variables by replacing them with a smaller set of derived (latent) variables. 
PCA borrows concepts from linear algebra (such as eigenvalues, eigenvectors and 
singular value decomposition) in order to uncover hidden relationships in data that 
might otherwise not be obvious from other statistical techniques.  Some measured 
variables contribute more weight to the general factor; this is assessed via inspection 
of each measurement’s loading, i.e., its correlation with the general factor.   Tract-
averaged MD and FA were compared between SLE patients and healthy controls using 
Student’s t test.  We plotted MD and FA against age and tested for a difference in slope 
between patients and controls with an interaction term in a linear regression model.  
Mean fatigue in patients was compared with a normal reference range58 using the 
Welch two-sample t test. Linear regression was used to examine the association 
between fatigue and other variables by univariate analyses.  Multiple linear regression 
was used to adjust for age alone, then age plus disease duration plus current steroid 
use.  PCA was also used to create a general factor of cognitive function (g)263 from the 
three cognitive tools (MoCA, ACER, MMSE).  Linear regression was used to examine 
the association between g and various potential explanatory variables by univariate 
analyses.  Multiple linear regression was used to adjust for age alone, then age plus 
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disease duration plus current steroid use plus NART (to adjust for a person’s prior 
(peak) cognitive function before the deleterious effect of age and SLE disease duration, 
if any).  For all regression models, we checked multicollinearity, independence, 
constancy of variance and normality in the residuals.  
Literature review and meta-analysis of DT-MRI studies (results in Chapter 8) 
We searched MEDLINE and EMBASE (from 1990) on 15th January 2015 using the 
terms “diffusion-tensor imaging” and “diffusion-weighted imaging” in conjunction 
with the terms “lupus”, “systemic lupus erythematosus” and “neuropsychiatric 
systemic lupus erythematosus”.  Acronyms and different combinations of the main 
search terms were also used.  We checked reference lists of relevant papers for 
additional studies.  We extracted data on study population (demographics, sample size, 
disease duration), imaging parameters, part of the brain measured (whole brain, 
specific tracts) and the reported diffusion measures.  Standardised mean differences 
were calculated using the Cochrane Collaboration’s Review Manager 5 software and 
used to compare DT-MRI findings in the meta-analysis.    
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Chapter 7: Cerebral small vessel disease burden is increased in SLE. 
Results and discussion from the SLE study 




Of 55 consecutive patients with SLE, 51 participated of mean age 48.8 ± 14.3 years 
(range 20 to 76 years), including 47 women (92%), and compared with 51 healthy 
controls (39 women (76%, p=0.06)) and 51 stroke patients (47 women, p=0.99).  Of 
the four SLE patients that did not participate two had previous MRI claustrophobia 
and two gave no reason.  Clinical data and blood results given in Tables 7.1 and 7.2.   
Table 7.1 Subject charactersitics 
 N (%) or mean ± SD or 
median (Q1–Q3) 
N (%) or mean ± SD or 
median (Q1–Q3) 
p value 
 SLE (n=51) Stroke (n=51)  
Females (n) 47 (92%) 47 (92%) 0.99 
Age (years) 48.8 ± 14.3 55.3 ± 8.9 0.008 
Disease duration (months) 50 (24–148) NA NA 
Members of SLEx registry 31 (61%) NA NA 
NPSLE 4 (8%) NA NA 
BMI (kg / m2) 29 (6.5) NA NA 
Current smoker 6 (12%) 28 (54.9%) <0.0001 
Hypertension 9 (18%) 32 (62.7%) <0.0001 
Diabetes None 2 (3.9%) NA 
Past medical history of stroke 1 (1.9%) 51 NA 
Current steroids 18 (35%) NA NA 
Fatigue (score) 5.0 ± 1.7 NA NA 
MMSE (score) 28 (27–30) NA NA 
MoCA (score) 26 (24–28) NA NA 
ACER (score) 91 (87–94) NA NA 
SLICC (score) 0 (0–1) NA NA 
SLEDAI-2K (score) 2 (0–4) NA NA 
BILAG (score) 2 (1–9) NA NA 
ACER = Addenbrooke’s Cognitive Examination – Revised, BMI = body mass index, BILAG = British Isles Lupus 
Assessment Group, MMSE = Mini Mental State Examination, MoCA = Montreal Cognitive Assessment, NPSLE = 
neuropsychiatric SLE, NA = not applicable, SLE = systemic lupus erythematosus, SLEx = Scottish Lupus Exchange 
Regitry, SLEDAI-2K = systemic lupus erythematosus Disease Activity Index 2000, SLICC = Systemic Lupus International 
Collaborating Clinics 
 
  111 
Table 7.2 Blood results for 51 SLE patients  
 N (%) or mean ± SD 
or median (Q1–Q3) 
Reference range 
Rheumatological 
C3 (mg / dL) (n=47) 1.2 ± 0.32  0.81–1.57 
C4 (mg / dL) (n=47) 0.19 ± 0.09 0.13–0.39 
Anti-ds-DNA (IU / mL) (n=47) 15 (8.5–33) 0–20 
Inflammatory  
ESR (mm / hr) (n=49) 13 (6–21) 3–15  
CRP (mg / L) (n=46) 2 (1–8) 0–5  
IL-6 (pg / mL) (n=40) 1.72 (1.12–2.37)  
IFN (RQ value)  (n=25) 6.7 (0.60–18.5)  
Endothelial dysfunction 
vWF Ag (IU / mL) (n=46) 1.71 ± 0.66 0.42–1.22 
vWF fVIIIc (IU / mL) (n=46) 1.38 ± 0.45 0.5–1.5  
vWF RCOF (IU / mL) (n=46) 1.37 ± 0.41 0.42–1.22 
Homocysteine (umol / L) (n=45) 17 (15–21) 0–20  
Lipids 
Total cholesterol (mmol / L) (n=49) 5.02 ± 0.95 <5.2 
HDL cholesterol (mmol / L) (n=47) 1.42 ± 0.41 >1 
LDL cholesterol (mmol / L) (n=46) 2.96 ± 0.84 <3.3 
Antibodies 
Anti-cardiolipin IgG (GPL) (n=50) 3.35 (2.20–5.60) 0–13.3 
Anti-cardiolipin IgM (MPL) (n=50) 1.65 (1.10–3.30) 0–9.8  
Lupus anticoagulant (n=47) 5 positive Positive/Negative 
Anti-ds-DNA = anti-double stranded DNA, CRP = C-reactive protein, ESR = erythrocyte sedimentation 
rate, HDL = high density lipoprtein, IFN = interferon, IgG = immunoglobulin isotype G, IgM = 
immunoglobulin isotype M, IL-6 = interleukin-6, LDL = low density lipoprotein, vWF Ag = von 
Willebrand factor antigen, vWF fVIIIc = von Willebrand factor factor VIIIc, vWF RCOF = von 
Willebrand factor ristocetin co-factor 
 
 
Healthy controls were of similar age (44.9 ± 11.1 years, p=0.12) while the stroke 
patients were on average six years older (55.3 ± 8.9 years, p=0.008).  Four SLE patients 
had neuropsychiatric SLE (NPSLE), six were current smokers, nine had hypertension, 
none had diabetes and one had a prior ischaemic stroke.  Eighteen were prescribed 
steroids at the time of assessment.  There were significantly more smokers and 
hypertensives in the stroke group.  The inflammatory markers ESR and CRP were 
raised in 22/49 (45%) and 17/45 (38%) of SLE patients versus these tests’ normal 
reference ranges.  Homocysteine was raised in 37/45 (82%) SLE patients. 
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WMH, PVS, lacunes and microbleeds 
Periventricular and deep WMHs were seen in 49/51 (96%) and 36/51 (70%) SLE 
patients respectively.  All SLE patients had visible PVS.  Lacunes were seen in five 
(10%) and microbleeds in two (4%) SLE patients.   
SVD imaging biomarkers in SLE versus healthy controls and stroke patients 
Compared to healthy controls, SLE patients had a greater total SVD score (Table 7.3) 
sustained across each 10-year age band (Figure 7.1), including more deep but not 
periventricular WMHs.  Compared to stroke patients, the SLE patients also had higher 
SVD score, mostly due to having more PVS, and similar deep and periventricular 
WMHs.  SLE patients had more superficial, but not deep, atrophy versus healthy 
controls.  There was no difference in either deep or superficial atrophy score between 
SLE and stroke patients.  Individual SVD features by age are given in Figure 7.2. 
 



















Lacunes 0 (0–2) 0 (0–3) 0 (0–0) 0.02   0.01 
Microbleeds 0 (0–1) 0 (0–15) 0 (0–0) 0.15    
PVS BG (score 0–4) 2 (1–4) 1 (0–3) 1 (1–2) <0.0001 <0.0001 <0.0001  
PVS CS (score 0–4) 3 (1–4) 1 (0–4) 1 (0–3) <0.0001 <0.0001 <0.0001 0.001 
WMH periventricular (score 0–3) 1 (0–3) 1 (0–3) 1 (1–2) 0.48    
WMH deep (score 0–3) 1 (0–3) 1 (0–3) 0 (0–2) <0.0001  0.01 0.0007 
WMH (total Fazekas score 0–6) 2 (1–6) 2 (0–6) 1 (1–4) 0.02  0.05 0.03 
Total SVD score (score 0–4) 1 (0–3) 0 (0–4) 0 (0–2) <0.0001 0.02 <0.0001 0.0006 
Deep atrophy (score 1–6) 1 (1–5) 1 (1–4) 1 (1–4) 0.14    
Superficial atrophy (score 1–6) 1 (1–4) 1 (1–3) 1 (1–4) 0.006  0.004  
Values are medians (range).  The p value compares the individual SVD features across the three groups by Kruskal-Wallis 
test. Posttest comparisons identifies where differences exists.  Blank cells = non-sgnificant pairwise relationship.  BG = 
basal ganglia, CS = centrum semiovale, PVS = perivascualr spaces, SVD = small vessel disease, SLE = systemic lupus 
erythematosus, WMH = white matter hyperintensities.  
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Figure 7.1 Total SVD score (mean plus 95% CI) by age distribution in SLE, stroke 
and healthy controls  
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Figure 7.2 Scores of individual features of SVD in (a) periventricular WMH, (b) 
deep WMH, (c) basal ganglia PVS and (d) and centrum semiovale PVS by age 
among SLE, stroke and healthy controls  
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Association between total SVD score and other variables 
In SLE, the total SVD score was associated with age (OR 1.05, 95% CI 1.01–1.09), 
hypertension (1.82, 1.13–2.93), higher levels of MD (2.58, 1.32–5.06) and lower levels 
of FA (0.42, 0.22–0.80).  The association with hypertension did not remain after 
adjusting for age (Table 7.4).  Higher SVD burden was inversely associated with 
fatigue (older people had less fatigue) but not when adjusted for age. The total SVD 
score was not associated with SLE activity (by SLE activity scoring tools or blood 
markers of activity), accumulated damage (SLICC) nor SLE disease duration. The 
total SVD score was not associated with CRP.  However, we excluded one SLE patient 
from our analysis of CRP as they reported a tooth infection in the week prior to their 
scan (CRP of 155, i.e., a considerable outlier).  When this patient was included, CRP 
was associated with total SVD score (1.05, 1.01–1.09), but since this result depends 
on one patient’s data it is not reliable.  More PVS in the centrum semiovale were 
associated with higher levels of HDL cholesterol (14.88, 2.76–80.09; Table 7.5) which 
remained significant after adjusting for age and BMI (16.99, 2.98–96.66).  No other 
individual SVD feature showed significant associations with other variables (vascular 
risk factors, SLE activity or blood markers) (PVS and WMH shown in Table 7.5). 
 
NPSLE 
Patients diagnosed with NPSLE (n=4) had more deep WMH compared with SLE 
(p=0.04, Table 7.6) but data were limited.  
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Table 7.4 Univariate and multivariable associations between total SVD score and 
other variables in SLE patients 
 Unadjusted Age adjusted Adjusted for age and 
SLE disease duration 
 OR 95% CI OR 95% CI OR 95% CI 
Vascular risk factors 
Age (years) 1.05 1.01 – 1.09 * -- -- 1.05 1.00 – 1.10 * 
Hypertension (classified) 1.82 1.13 – 2.93 * 1.58 0.95 – 2.63 1.58 0.95 – 2.63 
BMI (kg / m2) 0.97 0.89 – 1.06 0.95 0.87 – 1.04 0.95 0.87 – 1.04 
Disease duration (months) 1.00 0.99 – 1.01 1.00 0.99 – 1.00 -- -- 
Current smoker (Yes/No) 0.91 0.15 – 5.29 1.19 0.19 – 7.32 1.22 0.19 – 7.55 
Ever smoked (Yes/No) 2.06 0.63 – 6.80 2.00 0.67 – 6.62 2.01 0.60 – 6.76 
Steroids (Yes/No) 0.63 0.18 – 2.16 0.62 0.18 – 2.14 0.62 0.18 – 2.13 
Neurological 
Fatigue 0.68 0.47 – 0.98 * 1.04 0.99 – 1.08 1.00 0.99 – 1.00 
Anxiety 0.97 0.87 – 1.08 1.02 0.90 – 1.14 1.02 0.90 – 1.14 
Depression 0.97 0.85 – 1.09 1.01 0.88 – 1.15 1.01 0.88 – 1.15 
MMSE 0.94 0.63 – 1.38 1.05 0.69 – 1.58 1.07 0.69 – 1.67 
MoCA 1.06 0.89 – 1.26 1.11 0.92 – 1.33 1.12 0.93 – 1.36 
ACER 1.01 0.94 – 1.09 1.02 0.95 – 1.11 1.03 0.95 – 1.12 
Rheumatology scores 
SLEDAI-2K 1.01 0.78 – 1.30 1.01 0.78 – 1.31 1.01 0.78 – 1.31 
BILAG 0.95 0.85 – 1.07 0.98 0.87 – 1.11 0.99 0.87 – 1.11 
SLICC 1.14 0.68 – 1.91 0.93 0.53 – 1.62 0.88 0.48 – 1.65 
DTI biomarkers 
MD across 12 tracts (n=47) 2.58 1.32 – 5.06 ** 2.32 1.16 – 4.64 * 2.53 1.22 – 5.22 * 
FA across 12 tracts (n=47) 0.42 0.22 – 0.80 ** 0.47 0.24 – 0.93 * 0.43 0.21 – 0.88 * 
Bloods 
C3 (mg / dL) (n=47) 1.06 0.15 – 7.56 1.06 0.14 – 8.11 1.14 0.14 – 8.93 
C4 (mg / dL) (n=47) 1.07 0.52 – 2.20 1.14 0.55 – 2.35 1.17 0.56 – 2.47 
Anti-ds-DNA (IU / mL) (n=47) 0.99 0.98 – 1.01 0.99 0.98 – 1.00 0.99 0.98 – 1.01 
ESR (mm / hr) (n=49) 1.03 0.99 – 1.06 1.02 0.98 – 1.06 1.02 0.98 – 1.06 
CRP (mg / L) (n=45) 0.99 0.92 – 1.08 0.99 0.92 – 1.08 1.00 0.92 – 1.08 
IL-6 (pg / mL) (n=40) 0.99 0.71 – 1.40 1.02 0.72 – 1.43 1.02 0.72 – 1.43 
IFN (RQ value)  (n=24) 1.04 0.94 – 1.14 1.04 0.95 – 1.14 1.04 0.93 – 1.16 
vWF Ag (IU / mL) (n=46) 1.21 0.48 – 3.00 0.88 0.33 – 2.30 0.87 0.33 – 2.31 
vWF F8c (IU / mL) (n=46) 2.50 0.66 – 9.45 2.30 0.62 – 8.57 2.31 0.62 – 8.61 
vWF RCOF (IU / mL) (n=46) 2.00 0.46 – 8.56 1.24 0.26 – 5.83 1.25 0.26 – 5.91 
Homocysteine (umol / L) (n=45) 1.03 0.94 – 1.12 1.01 0.92 – 1.11 1.01 0.92 – 1.11 
Tot cholesterol (mmol / L) (n=49) 1.55 0.84 – 2.87 1.37 0.72 – 2.59 1.38 0.73 – 2.62 
HDL cholesterol (mmol / L) (n=47) 1.35 0.32 – 5.74 1.41 0.33 – 6.04 1.39 0.32 – 6.02 
LDL cholesterol (mmol / L) (n=46) 1.72 0.85 – 3.49 1.47 0.71 – 3.01 1.50 0.71 – 3.14 
Anti-cardiolipin IgG (GPL) (n=50) 0.92 0.77 – 1.09 0.93 0.78 – 1.11 0.93 0.78 – 1.10 
Anti-cardiolipin IgM (MPL) (n=50) 1.00 0.95 – 1.06 0.98 0.93 – 1.04  0.98 0.93 – 1.04 
Lupus anticoagulant (n=47) 0.42 0.06 – 2.73 0.30 0.04 – 2.18 0.30 0.04 – 2.15 
* p<0.05, ** p<0.01 
ACER = Addenbrooke’s Cognitive Examination – Revised, BMI = body mass index, BILAG = British Isles Lupus 
Assessment Group, BTV = brain tissue volume, CRP = C-reactive protein, DTI = diffusion tensor imaging, ESR = 
erythrocyte sedimentation rate, FA = fractional anisotropy, HDL = high density lipoprotein, LDL = low density 
lipoprotein, MD = mean difussivity, MMSE = Mini Mental State Examination, MoCA = Montreal Cognitive Assessment, 
IFN = interferon beta, IL-6 = interleukin-6, ICV = intracranial volume, SLEDAI-2K = systemic lupus erythematosus 
Disease Activity Index, SLICC = Systemic Lupus International Collaborating Clinics, vWF Ag = von Willebrand factor 
antigen, vWF F8c = von Willebrand factor VIII, vWF RCOF = von Willebrand factor ristocen co-factor 
  117 
Table 7.5 Unadjusted univariate associations between individual SVD features and 
other variables in SLE patients 
 PVS BG PVS CS WMH (Total Fazekas) 
 OR 95% CI OR 95% CI OR 95% CI 
Vascular risk factors 
Age (years) 1.02 0.98 – 1.06 1.03 0.99 – 1.07 1.13 1.07 – 1.20 *** 
Hypertension (classified) 1.36 0.90 – 2.05 1.25 0.84 – 1.86 1.88 1.20 – 2.94 ** 
BMI (kg / m2) 0.97 0.89 – 1.05 0.98 0.91 – 1.07 1.03 0.95 – 1.25 
Disease duration (months) 1.00 0.99 – 1.00 1.00 0.99 – 1.00 1.00 0.99 – 1.00 
Current smoker (Yes/No) 0.87 0.19 – 3.92 0.50 0.11 – 2.34 1.87 0.37 – 9.40 
Ever smoked (Yes/No) 0.82 0.30 – 2.23 0.77 0.27 – 2.18 2.63 0.87 – 7.89 
Steroids (Yes/No) 0.48 0.17 – 1.41 0.74 0.25 – 2.24 1.44 0.47 – 4.36 
Rheumatology scores 
SLEDAI-2K 1.10 0.88 – 1.37 1.04 0.80 – 1.35 1.00 0.78 – 1.29 
BILAG 0.96 0.86 – 1.07 0.93 0.84 – 1.04 0.96 0.86 – 1.07 
SLICC 0.86 0.55 – 1.35 0.92 0.57 – 1.49 1.42 0.88 – 2.28 
Bloods 
C3 (mg / dL) (n=47) 0.35 0.06 – 1.98 1.08 0.22 – 5.29 0.70 0.13 – 3.71 
C4 (mg / dL) (n=47) 0.85 0.45 – 1.62 1.16 0.64 – 2.09 0.79 0.42 – 1.49 
Anti-ds-DNA (IU / mL) (n=47) 1.00 0.99 – 1.02 1.00 0.99 – 1.01 1.00 0.99 – 1.01 
ESR (mm / hr) (n=49) 1.02 0.98 – 1.05 0.99 0.96 – 1.02 1.03 0.99 – 1.06 
CRP (mg / L) (n=45) 1.00 0.99 – 1.03 1.02 0.98 – 1.06 1.02 0.99 – 1.04 
IL-6 (pg / mL) (n=40) 1.04 0.79 – 1.37 0.94 0.71 – 1.24 0.98 0.74 – 1.29 
IFN (RQ value)  (n=24) 0.93 0.86 – 1.00 0.97 0.91 – 1.05 0.98 0.90 – 1.06 
vWF Ag (IU / mL) (n=46) 0.96 0.43 – 2.17 1.56 0.67 – 3.60 1.30 0.56 – 2.99 
vWF F8c (IU / mL) (n=46) 1.39 0.40 – 4.84 2.58 0.69 – 9.64 1.89 0.54 – 6.63 
vWF RCOF (IU / mL) (n=46) 1.07 0.29 – 3.89 1.62 0.42 – 6.21 1.34 0.31 – 5.76 
Homocysteine (umol / L) (n=45) 0.97 0.89 – 1.04 1.02 0.94 – 1.11 1.07 0.98 – 1.16 
Tot cholesterol (mmol / L) (n=49) 1.75 0.98 – 3.12 1.40 0.80 – 2.46  1.31 0.73 – 2.35 
HDL cholesterol (mmol / L) (n=47) 3.30 0.86 – 12.6 14.8 2.76 – 80.0 *** 0.95 0.23 – 3.99 
LDL cholesterol (mmol / L) (n=46) 1.89 0.96 – 3.71 1.11 0.58 – 2.12 1.38 0.70 – 2.73 
Anti-cardiolipin IgG (GPL) (n=50) 1.00 0.86 – 1.16 0.94 0.80 – 1.09 0.88 0.75 – 1.04 
Anti-cardiolipin IgM (MPL) (n=50) 1.02 0.97 – 1.08 1.02 0.97 – 1.07 0.99 0.94 – 1.04 
Lupus anticoagulant (n=47) 0.79 0.14 – 4.67 1.23 0.22 – 6.84 0.60 0.11 – 3.22 
** p<0.01 *** p<0.0001 
BMI = body mass index, BILAG = British Isles Lupus Assessment Group, BTV = brain tissue volume, CI = confidence 
interval, CRP = C-reactive protein, DTI = diffusion tensor imaging, ESR = erythrocyte sedimentation rate, HDL = high 
density lipoprotein, LDL = low density lipoprotein, IFN = interferon beta, IL-6 = interleukin-6, ICV = intracranial volume, 
OR = odds ratio, PVS BG = perivascular spaces in basal ganglia, PVS BG = perivascular spaces in centrum semiovale, 
SLEDAI-2K = systemic lupus erythematosus Disease Activity Index, SLICC = Systemic Lupus International Collaborating 
Clinics, vWF Ag = von Willebrand factor antigen, vWF F8c = von Willebrand factor VIII, vWF RCOF = von Willebrand 
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Table 7.6 Imaging biomarkers of SVD in SLE and NPSLE patients 
 Median (Q1–Q3) Median (Q1–Q3) p value 
 SLE NPSLE  
N 47 4  
Lacunes 0 (0–0) 0 (0–0) 0.52 
Microbleeds 0 (0–0) 0 (0–0) 0.71 
PVS BG (score 0–4) 2 (2–3) 2.5 (1.5–3.0) 0.76 
PVS CS (score 0–4) 3 (3–4) 3.0 (1.5–4.0) 0.72 
WMH periventricular (score 0–3) 1 (1–1) 1.5 (0.5–2.5) 0.43 
WMH deep (score 0–3) 1 (0–1) 1.5 (1.0–2.5) 0.04 * 
WMH (total Fazekas score 0–6) 2 (1–2) 3.0 (1.5–5.0) 0.22 
Total SVD score (score 0–4) 1 (1–2) 1.5 (1.0–3.5) 0.43 
Deep atrophy (score 1–6) 1 (1–2) 1.5 (1.0–2.5) 0.49 
Superficial atrophy (score 1–6) 1 (1–1) 1.5 (0.5–2.0) 0.59 
* p<0.05 
BG = basal ganglia, CS = centrum semiovale, NPSLE = neurpsychiatric SLE, PVS = 
perivascualr spaces, SVD = small vessel disease, SLE = systemic lupus erythematosus, 
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Discussion 
We show that patients with SLE have more SVD markers, notably PVS and deep 
WMH, than sex- and age-matched healthy controls and mild stroke patients from the 
same health region.  Deep WMH were worse in four patients with NPSLE.  Our 
patients were not selected on the basis of neurological involvement and only 4/51 were 
diagnosed with NPSLE.  There were more lacunes, higher PVS and WMH scores in 
SLE patients versus healthy controls.  Moreover, despite the stroke patients being 
slightly older with far more smokers and hypertensives, the SLE patients had more 
PVS and an equal burden of WMH.  The higher burden of SVD, particularly PVS as 
a marker of inflammation, provides a possible explanation for increased stroke risk 
and suggests that systemic inflammation is associated with microvascular brain 
damage in SLE patients even in the absence of neurological symptoms even though 
there was no association between SVD markers and plasma inflammatory markers or 
disease duration, activity and damage scores. 
Several cross-sectional studies (reviewed in Chapter 4), including ~1,200 SLE patients 
reported features of SVD, such as WMHs and atrophy, but many of these studies 
focused on NPSLE patients, while few compared SLE to healthy controls (instead 
most compared SLE to NPSLE, or SLE to patients with antiphospholipid syndrome), 
none compared SLE to mild stroke patients which allows for comparison with 
clinically overt SVD, and none included the range of SVD features assessed here with 
validated scoring tools.   Longitudinally, a 20-year MRI follow-up study showed 
increased number and volume of WMHs and brain volume loss in most of 30 SLE 
patients studied, but may have reflected mainly ageing effects264. In a shorter follow-
up study of 75 SLE patients, predictors of new or increased WMH included 
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antiphospholipid antibodies, SLE damage scores and higher dose of corticosteroids 
and there was more grey and white matter volume loss versus controls206,207. 
PVS on neuroimaging (in SLE or any other cohort) could reflect inflammatory 
activity265.  PVS are not normally seen on brain imaging with MRI at 1.5 Tesla (as 
used in our study) but we note the higher spatial resolution of higher field strength 
MRI scanners will increase detection and complicate interpretation, until such time 
when sufficient control data from the normal population becomes available.  This 
could also complicate assessment of associations with inflammation.  PVS were 
associated with the inflammatory marker CRP in a large cohort (n=634) of community-
dwelling older people (ß=0.12, p=0.048)48.  In our study, the total SVD score and PVS 
were not associated with any blood measure of inflammation (ESR, CRP, IL-6) or with 
clinical SLE disease activity or disease burden score.  However, we note about 40% 
of patients had raised ESR and CRP. Moreover, our cross-sectional study design did 
not permit us to associate inflammatory flares over time with the evolution, or not, of 
PVS.  We did not select patients on the basis of SLE activity and cannot exclude the 
possibility that blood markers of inflammation (captured during a flare-up) will 
associate with PVS in a larger or longitudinal study. Chung et al. also found no 
association between systemic inflammation (measured using a novel marker, GlycA) 
and SLE activity, despite the presence of systemic inflammation266. 
Perivascular inflammation of the small cerebral vessels is a prominent finding in 
SLE267 at autopsy as well as in sporadic SVD46.  Some studies have noted PVS208,268 
on brain imaging in SLE patients (n=122), but data are limited and none compared the 
total PVS load with a non-SLE comparator group.  In a recent, but smaller (n=11), 
post-mortem study of vascular changes in SLE, a third of subjects had 
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microthromboemboli, glial hyperplasia, neuronal loss, microaneurysms, lacunar 
infarcts and microbleeds which correlated with neuroimaging, including recent 
subcortical infarcts, lacunes, WMHs and atrophy; stroke and cognitive impairment 
were more frequent findings amongst these patients compared to the SLE patients that 
did not have histology evidence of SVD269.  
We note an association between higher levels of HDL cholesterol and more PVS in 
the centrum semiovale which remained significant after adjusting for age and BMI.  
Additionally, there was a trend towards an association between total, HDL and LDL 
cholesterol and PVS in the basal ganglia (p values 0.05 to 0.07).  High HDL cholesterol 
is traditionally considered protective against cardiovascular disease including 
ischaemic stroke, but a recent meta-analysis showed that drugs designed to boost HDL 
had no effect on improving cardiovascular outcomes270.   Additionally, a gene variation 
in some people impairs HDL uptake, making them susceptible to cardiovascular 
disease despite high HDL271.  In a cohort study272 of 210 SLE patients followed for 29 
months, functional HDL (a novel marker of inflammation) was associated with carotid 
plaques (OR 9.1, 95% CI 3.3–24.6).  Meanwhile, higher HDL is associated with 
increased risk of haemorrhagic stroke in the general population (relative risk 1.17 
(95% CI 1.02–1.35); 7,960 strokes, 1.4M participants)273. The reason why cholesterol 
might relate to PVS in SLE is unknown and could be spurious given our study’s lack 
of power, but HDL can become dysfunctional resulting in inflammation274,275 and 
endothelial dysfunction276. 
The inverse relationship between higher SVD burden and lower levels of fatigue was 
explained by age – the older SLE patients (that had more SVD features) were less 
fatigued. 
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Our data further validates the concept of a ‘total SVD score’258,259 as a simple surrogate 
marker for total brain damage due to SVD.  The association of deep and superficial 
atrophy on univariate analysis, but not in adjusted analyses, is in agreement with Staals 
et al.258 and suggests atrophy should remain complementary, but not core, in the 
assessment of SVD as atrophy co-associates with age.  Our volume measure of atrophy 
(the BTV:ICV ratio) was also associated with total SVD burden.  Hypertension was 
also associated with the total SVD score, but, unlike Staals et al.,258 smoking (current 
or ever) was not, although our study was underpowered and only 12% of our patients 
smoked compared with a third of theirs. 
NPSLE patients had more deep WMH than SLE patients (as expected since NPSLE 
implies more clinically overt brain damage), but the number of patients with NPSLE 
in our study was small which limits generalizability. 
Further work 
Larger longitudinal studies are needed to fully appreciate the significance of SVD in 
SLE, for example to elucidate the contribution of SLE activity, diet and lifestyle, SLE 
treatments or some other variable in causing accelerated brain damage in these 
patients.  This pilot study clearly demonstrates the feasibility of such a study.  Of 55 
consecutive patients invited to participate, 51 agreed to take part (93% uptake).  All 
the participants tolerated the MRI scanner environment (there were no cases of 
claustrophobia among the 51 participants that took part in the study) and completed 
the full exam (~50 mins).  Venepuncture failed in a handful of participants.  Our MRI 
sequences (including the diffusion tensor sequences (see next Chapter) and methods 
for image analysis could be used in a larger multi-centre study.  
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Chapter 8: Fatigue and cognitive function in SLE: associations with 
white matter microstructural damage. A diffusion tensor MRI study, 
literature review and meta-analysis. Results and discussion from the 
SLE study 




Fifty-one patients with SLE were recruited of mean age 48.8 ± 14.3 years (range 20 to 
76 years), including 47 women (92%) which is consistent with community prevalence.  
Clinical, fatigue and cognitive data are given in Table 8.1.  MD, FA and NART scores 
were available for 51 age- and sex-matched healthy controls of mean age 44.9 ± 11.1 
years, including 39 women (76%).  A third of patients (18/51 (35%)) were currently 
prescribed corticosteroids.   
Table 8.1 Subject charactersitics 
SLE patients, n = 51 N (%) or mean ± SD or 
median (Q1–Q3) 
Reference data from controls or standard ranges 
Female 47 (92%) 39 (76%);  p=0.06 
Age (years) 48.8 ± 14.3 44.9 ± 11.1;  p=0.12 
Disease duration (months) 50 (24.5–148)  
Members of SLEx registry 31 (61%)  
NPSLE 4 (8%)  
BMI (kg / m2) 29 (6.5) 20-25 normal, 25-30 overweight, 30-35 obese, 35+ clinically obese 
Current smoker 6 (12%)  
Hypertension 9 (18%) ≥140/90 mm Hg 
Fatigue (score) 5.0 ± 1.7 2.3 ± 0.7;  p<0.0001 
Anxiety (score) 6 (3–12 ) 0-7 non-case, 8-10 borderline, 11+ case 
Depression (score) 8 (6–12) 0-7 non-case, 8-10 borderline, 11+ case 
Current steroids 18 (35%)  
MoCA (score) (n=50) 26 (24–28)  0–30.  Normal ≥26  
ACER (score) (n=50) 91 (87–94) 0–100.  Normal ≥88 
MMSE (score) (n=50) 28 (27–30) 0–30.  Normal ≥27 
NART (score) (n=50) 34 (27–39) 40 (34–42);  p=0.0008 
ACER = Addenbrooke’s Cognitive Examination – Revised, BMI = body mass index, MoCA = Montreal Cognitive 
Assessment, MMSE = Mini Mental State Examination, NART = National Adult Reading Test, SLE = systemic lupus 
erythematosus, SLEx = Scottish systemic lupus erythematosus exchange registry 
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General factors for MD and FA 
DT-MRI failed in four patients so the analyses are based on 47 patients.  In SLE, the 
general factors MD and FA accounted for 40% and 27% of the variance among tracts, 
respectively. A similar level of variance was explained in the control group.  Factor 
loadings of each tract are given in Table 8.2.  An image illustrating whole brain white 
matter tractography from a representative patient along with a group map illustrating 
two tracts (the genu and splenium of corpus callosum) is shown in Figure 8.1. 
 
Table 8.2 Factor loadings for white matter tracts 
 SLE (n=47) Controls (n=47) 
 MD FA MD FA 
Genu 0.68 0.61 0.68 0.33 
Splenium 0.01 -0.34 0.22 0.21 
Left cingulum 0.77 0.67 0.73 0.76 
Right cingulum 0.87 0.60 0.79 0.76 
Left CST 0.73 0.55 0.65 0.34 
Right CST 0.43 0.56 0.77 0.18 
Left ILF 0.76 0.48 0.57 0.64 
Right ILF 0.28 0.08 0.19 0.40 
Proportion of shared variance 0.40 0.27 0.38 0.25 
CST = corticospinal tract, FA = fractional anisotropy, MD = mean diffusivity, ILF = 
inferior longitudinal fasciculus 
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Figure 8.1 Whole brain tractography and two major tracts.  The top row shows maps of 
whole brain white matter structure from a representative patient. White matter tracts running 
predominantly anterior/posterior are coloured green, superior/inferior blue and right/left red. 
The lower row shows group maps (all patients superimposed on each other) of two major 
tracts, the genu (left image) and splenium (right) of corpus callosum for all 47 patients. Note 
the close correspondence of these tracts, indicated by the lighter red/yellow colours, which 
allows the integrity of the same structure to be measured across the cohort. 
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Comparing MD and FA to healthy controls 
MD was significantly higher in all tracts (p<0.0001 for all tracts) in SLE patients 
versus controls (Table 8.3). FA was significantly higher in SLE patients than controls 
in the genu (p<0.0001) and left corticospinal tract (p<0.0001), and significantly lower 
in the splenium (p=0.008), and left (p=0.04) and right (p=0.01) cingulum bundles 
(Table 8.3).   Overall, the expected increase in MD and decrease in FA with age 
appeared accelerated in SLE patients versus controls (Figure 8.2).  However, the 
patients’ and controls’ regression slopes (for both MD and FA) did not differ when 
tested via an interaction term in a linear regression model. 
Table 8.3 Comparison of MD and FA values for white matter tracts between SLE 
patients and healthy controls 
 SLE (n=47) Controls (n=47) p value Cohen’s d 
Female n (%) 43 (91.5%) 41 (87.2%) p=0.74  NA 
Age (years) 48.5 ± 13.7 44.6 ± 11.5 p=0.14  NA 
MD (10-6 mm2 /s) 
Genu 833.18 ± 68.13 751.29 ± 57.36 p<0.0001  1.33 
Splenium 1072.33 ± 162.98 761.49 ± 129.37 p<0.0001  2.19 
Left cingulum 740.69 ± 44.08 624.21 ± 35.41 p<0.0001  3.01 
Right cingulum 721.06 ± 43.33 619.70 ± 35.74 p<0.0001  2.62 
Left CST 729.25 ± 30.76 667.24 ± 39.4 p<0.0001  1.82 
Right CST 740.96 ± 30.18 683.32 ± 35.31 p<0.0001  1.79 
Left ILF 781.68 ± 49.53 728.42 ± 66.48 p<0.0001  0.96 
Right ILF 818.16 ± 136.72 703.82 ± 63.03 p<0.0001  1.29 
Average 804.6 ± 39.8 692.4 ± 32.2 p<0.0001  3.20 
FA (unitless, values lie in the range 0 to 1) 
Genu 0.49 ± 0.06 0.42 ± 0.04 p<0.0001  1.42 
Splenium 0.52 ± 0.07 0.55 ± 0.06 p=0.008 -0.57 
Left cingulum 0.44 ± 0.05 0.46 ± 0.04 p=0.04 -0.45 
Right cingulum 0.42 ± 0.04 0.44 ± 0.03 p=0.01 -0.57 
Left CST 0.49 ± 0.04 0.44 ± 0.04 p<0.0001  1.26 
Right CST 0.47 ± 0.04 0.48 ± 0.04 p=0.24 -0.25 
Left ILF 0.45 ± 0.05 0.43 ± 0.04 p=0.08  0.36 
Right ILF 0.42 ± 0.05 0.43 ± 0.04 p=0.59 -0.11 
Average 0.46 ± 0.02 0.46 ± 0.02 p=0.25 0.24 
CST = corticospinal tract, FA = fractional anisotropy, ILF = inferior longitudinal fasciculus, MD = 
mean diffusivity. 
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Figure 8.2 General factors for (A) mean diffusivity and (B) fractional anisotropy in 
relation to age among SLE patients and healthy controls 
 
MD and FA – associations with other variables 
In univariate analyses, higher MD was associated with older age (r = 0.32, p=0.03), 
less fatigue (r = –0.35, p=0.01), more brain atrophy (all three measures of atrophy, see 
Table 8.4), more accumulated SLE damage on SLICC scoring (r = 0.32, p=0.03), 
worse performance on MoCA (r = –0.30, p=0.04) and poorer general cognitive 
function (g) (r = –0.31, p=0.04) (Table 8.4).  MD was not associated with any of the 
plasma markers (Table 8.5).  The association between higher MD and SLICC damage 
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did not remain when adjusted for age.  The association between higher MD and 
cognitive function (MoCA and g) remained after adjustment for age.  
In univariate analyses, lower FA was associated with older age (r = –0.38, p=0.01), 
longer disease duration (r = –0.31, p=0.03), more atrophy on volumetric measurement 
(r = 0.34, p=0.02), more accumulated SLE damage on SLICC scoring (r = –0.36, 
p=0.01), worse performance on the MMSE test (r = 0.29, p=0.04) and higher HDL 
cholesterol levels (r = –0.34, p=0.02) (Tables 8.4 and 8.5).   
Table 8.4 Univariate relationships between MD and FA with other variables in SLE  
 MD FA 
 B r p value B r p value 
Age (years) 0.023 0.32 0.03 -0.027 -0.38 0.01 
BMI (kg / m2) 0.024 0.16 0.28 -0.022 -0.15 0.32 
Anxiety -0.022 -0.11 0.45 -0.012 -0.06 0.69 
Depression -0.040 -0.18 0.22 -0.000 -0.00 0.99 
Disease duration (months) 0.001 0.23 0.11 -0.002 -0.31 0.03 
Fatigue -0.207 -0.35 0.01 0.031 0.05 0.72 
Brain measures 
FA (n=47) <0.0001 -0.80 <0.0001 NA NA NA 
MD (n=47) (10-6 mm2 /s) NA NA NA <0.0001 -0.80 <0.0001 
ICV (mm3) <0.0001 -0.12 0.40 <0.0001 0.27 0.06 
L hippocampus volume (mm3) -0.000 -0.19 0.19 0.000 0.16 0.28 
R hippocampus volume (mm3) -0.000 -0.19 0.19 0.000 0.24 0.09 
Deep atrophy 0.297 0.31 0.03 -0.190 -0.19 0.19 
Superficial atrophy 0.389 0.36 0.01 -0.281 -0.26 0.07 
BTV:ICV -0.088 -0.38 0.01 0.078 0.34 0.02 
Rheumatology scores 
SLICC 0.292 0.32 0.03 -0.325 -0.36 0.01 
SLEDAI-2K -0.014 -0.03 0.85 0.004 0.01 0.95 
BILAG -0.025 -0.12 0.40 0.014 0.07 0.63 
Cognitive function 
MoCA -0.109 -0.30 0.04 0.042 0.12 0.44 
ACER -0.033 -0.21 0.15 0.025 0.16 0.27 
MMSE -0.178 -0.25 0.08 0.207 0.29 0.04 
g -0.348 -0.31 0.04 0.261 0.23 0.12 
NART -0.029 -0.27 0.07 0.014 0.13 0.38 
Bold p<0.05.  ACER = Addenbrooke’s Cognitive Examination – Revised, B = beta coefficient, BMI 
= body mass index, BILAG = British Isles Lupus Assessment Group, BTV = brain tissue volume, g = 
gneral factor of cognitive function, FA = fractional anisotropy, ICV = intracranial volume, MD = 
mean difussivity, MoCA = Montreal Cognitive Assessment, MMSE = Mini Mental State 
Examination, NART = National Adult Reading Test, r = correlation coefficient, SLE = systemic 
lupus erythematosus, SLEDAI-2K = systemic lupus erythematosus Disease Activity Index 2000, 
SLICC = Systemic Lupus International Collaborating Clinics 
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Table 8.5 Univariate relationships between MD and FA with plasma markers in SLE  
 MD FA 
 B r p value B r p value 
Rheumatological 
C3 (mg / dL) (n=47) 0.287 0.09 0.53 -0.415 -0.14 0.37 
C4 (mg / dL) (n=47) 1.226 0.11 0.48 -1.048 -0.09 0.56 
Anti-ds-DNA (IU / mL) (n=47) -0.004 -0.17 0.25 0.003 0.15 0.32 
Inflammatory  
CRP (mg / L) (n=45) -0.031 -0.24 0.13 0.017 0.13 0.41 
ESR (mm / hr) (n=49) -0.003 -0.05 0.75 0.008 0.13 0.39 
IL-6 (pg / mL) (n=40) -0.133 -0.20 0.23 0.166 0.26 0.12 
IFN (RQ value)  (n=24) 0.038 0.35 0.11 -0.022 -0.28 0.19 
Endothelial dysfunction 
vWF Ag (IU / mL) (n=46) 0.087 0.05 0.73 0.265 0.17 0.27 
vWF fVIIIc (IU / mL) (n=46) 0.052 0.02 0.88 0.370 0.17 0.27 
vWF RCOF (IU / mL) (n=46) 0.028 0.01 0.95 0.397 0.13 0.39 
Homocysteine (umol / L) (n=45) -0.004 -0.03 0.86 0.002 0.01 0.93 
Lipids 
Tot cholesterol (mmol / L) (n=49) 0.218 0.21 0.16 -0.303 -0.29 0.05 
HDL cholesterol (mmol / L) (n=47) 0.575 0.23 0.14 -0.833 -0.34 0.02 
LDL cholesterol (mmol / L) (n=46) 0.207 0.17 0.28 -0.233 -0.19 0.22 
Antibodies 
Anti-cardiolipin IgG (GPL) (n=50) -0.040 -0.13 0.37 0.017 0.06 0.69 
Anti-cardiolipin IgM (MPL) (n=50) 0.010 0.08 0.56 -0.015 -0.13 0.39 
Lupus anticoagulant (n=47) -0.104 -0.03 0.83 -0.157 -0.05 0.75 
Bold p<0.05.  B = beta coefficient, CRP = C-reactive protein, ESR = erythrocyte sedimentation 
rate, IFN = interferon beta, IL-6 = interleukin-6, r = correlation coefficient, SLE = systemic lupus 
erythematosus, vWF Ag = von Willebrand factor antigen, vWF fVIIIc = von Willebrand factor 
VIII, vWF RCOF = von Willebrand factor ristocen co-factor 
 
Fatigue 
Fatigue in SLE was significantly higher than the expected normal range58 (5.0 ± 1.7 v 
2.3 ± 0.7, p<0.0001).  In univariate analyses, higher levels of fatigue were associated 
with higher depression (r = 0.47, p=0.0004), higher anxiety (r = 0.41 p=0.002), higher 
BMI (r = 0.36, p=0.01), lower MD (r = –0.35, p=0.01), lower IFN (r = –0.54, p=0.006) 
and lower vWF (RCOF (r = –0.34, p=0.02) and fVIIIc (r = –0.30, p=0.04)) (Tables 
8.6 and 8.7).  Except vWF (RCOF) all associations remained after adjusting for age 
(Table 8.8).  Except vWF (RCOF) and IFN all associations remained after adjusting 
for age, disease duration and steroids (Table 8.8).  
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Table 8.6 Univariate relationships between fatigue (FSS) and cognitive function (g) 
with other variables in SLE patients  
 Fatigue Cognitive function (g) 
 B r p value B r p value 
Age (years) -0.028 -0.24 0.09 -0.011 -0.16 0.27 
BMI (kg / m2) 0.093 0.36 0.01 -0.025 -0.16 0.25 
Anxiety 0.132 0.41 0.002 -0.019 -0.10 0.48 
Depression 0.174 0.47 0.0004 -0.030 -0.13 0.35 
Disease duration (months) 0.001 0.10 0.48 -0.003 -0.41 0.003 
Fatigue NA NA NA -0.026 -0.04 0.75 
Brain measures 
FA (n=47) -0.088 0.05 0.73 0.202 0.23 0.12 
MD (n=47) (10-6 mm2 /s) -0.580 -0.35 0.01 -0.271 -0.31 0.03 
ICV (mm3) 0.000 0.19 0.17 -0.000 -0.07 0.61 
Left hippocampus volume (mm3) 0.000 0.04 0.76 0.000 0.28 0.05 
Right hippocampus volume (mm3) 0.000 0.13 0.37 0.000 0.24 0.10 
Deep atrophy -0.217 -0.13 0.35 -0.232 -0.25 0.08 
Superficial atrophy -0.308 -0.16 0.24 -0.274 -0.25 0.07 
BTV:ICV 0.059 0.15 0.28 0.051 0.22 0.12 
Rheumatology scores 
SLICC 0.016 0.01 0.94 -0.202 -0.22 0.13 
SLEDAI-2K 0.091 0.12 0.39 -0.038 -0.08 0.55 
BILAG 0.080 0.24 0.09 -0.018 -0.09 0.50 
Cognitive function 
MoCA -0.005 -0.01 0.94 NA NA NA 
ACER -0.022 -0.09 0.51 NA NA NA 
MMSE -0.002 -0.00 0.99 NA NA NA 
g -0.078 -0.04 0.75 NA NA NA 
NART -0.002 -0.00 0.95 0.069 0.64 <0.0001 
Bold p<0.05. ACER = Addenbrooke’s Cognitive Examination – Revised, B = beta coefficient, 
BMI = body mass index, BILAG = British Isles Lupus Assessment Group, BTV = brain tissue 
volume, g = gneral factor of cognition, FA = fractional anisotropy (general factor from 12 tracts), 
ICV = intracranial volume, MD = mean difussivity (general factor from 12 tracts), MoCA = 
Montreal Cognitive Assessment, MMSE = Mini Mental State Examination, NART = National 
Adult Reading Test, r = correlation coefficient, SLE = systemic lupus erythematosus, SLEDAI-2K 
= systemic lupus erythematosus Disease Activity Index 2000, SLICC = Systemic Lupus 
International Collaborating Clinics 
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Table 8.7 Univariate relationships between fatigue (FSS) and cognitive function (g) 
with plasma markers in SLE patients  
 Fatigue Cognitive function (g) 
 B r p value B r p value 
Rheumatological 
C3 (mg / dL) (n=47) 0.680 0.12 0.41 -0.133 -0.04 0.76 
C4 (mg / dL) (n=47) -0.755 -0.04 0.80 -1.331 -0.12 0.41 
Anti-ds-DNA (IU / mL) (n=47) 0.002 0.06 0.70 0.003 0.12 0.41 
Inflammatory  
CRP (mg / L) (n=45) 0.065 0.29 0.05 0.001 0.00 0.95 
ESR (mm / hr) (n=49) -0.002 -0.02 0.90 -0.007 -0.11 0.43 
IL-6 (pg / mL) (n=40) 0.062 0.07 0.66 -0.234 -0.43 0.006 
IFN (RQ value)  (n=24) -0.091 -0.54 0.006 -0.026 -0.33 0.12 
Endothelial dysfunction 
vWF Ag (IU / mL) (n=46) -0.521 -0.20 0.18 -0.799 -0.51 0.0003 
vWF fVIIIc (IU / mL) (n=46) -1.168 -0.30 0.04 -0.512 -0.22 0.13 
vWF RCOF (IU / mL) (n=46) -1.426 -0.34 0.02 -0.889 -0.35 0.02 
Homocysteine (umol / L) (n=45) -0.005 -0.02 0.90 -0.025 -0.16 0.29 
Lipids 
Tot cholesterol (mmol / L) (n=49) 0.015 0.01 0.95 0.027 0.02 0.86 
HDL cholesterol (mmol / L) (n=47) -0.310 -0.07 0.63 -0.003 -0.00 0.99 
LDL cholesterol (mmol / L) (n=46) -0.194 -0.09 0.54 0.051 0.04 0.78 
Antibodies 
Anti-cardiolipin IgG (GPL) (n=50) 0.079 0.15 0.28 -0.000 -0.00 0.99 
Anti-cardiolipin IgM (MPL) (n=50) -0.021 -0.13 0.37 -0.008 -0.08 0.55 
Lupus anticoagulant (n=47) 1.297 0.23 0.11 -0.678 -0.19 0.21 
Bold p<0.05.  B = beta coefficient, CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, 
g = general factor of cognition, IL-6 = interleukin-6, r = correlation coefficient, SLE = systemic 
lupus erythematosus, vWF Ag = von Willebrand factor antigen, vWF fVIIIc = von Willebrand factor 




One patient was excluded from the analysis of cognitive results as English was not his 
first language.  On average, patients met the minimum levels required for normal 
cognition by the three individual tests (Table 8.1).  However, 19/50 (38%) (MoCA), 
13/50 (26%) (ACER) and 5/50 (10%) (MMSE) patients scored below the tests’ 
commonly-used cut-offs indicating clinical levels of cognitive impairment.  The mean 
NART score in SLE was significantly lower than age-matched healthy controls (34 v 
40, p=0.0008).  
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In univariate analyses, poorer cognitive function (g) was associated with longer SLE 
disease duration (r = –0.41, p=0.003) and higher MD (r = –0.31, p=0.03) (Table 8.6).  
Poorer cognitive function (g) was also associated with higher vWF (Ag (r = –0.51, 
p=0.0003) and RCOF (r = –0.35, p=0.02)) and higher IL-6 (r = –0.43, p=0.006) (Table 
8.7).  Except MD, all associations remained after adjusting for age (Table 8.8).  After 
adjusting for age, disease duration, steroids and NART, only higher IL-6 (p=0.02) 
remained independently and significantly associated with poorer cognitive function 
(Table 8.8).   
 
Table 8.8 Multiple linear regression models of fatigue and cognitive function in SLE 
patients 
 Unadjusted Age adjusted Fully adjusteda 
 B SE B p 
value 
B SE B p 
value 
B SE B p 
value 
Fatigue 
BMI (kg / m2) 0.093 0.034 0.01 0.106 0.033 0.003 0.102 0.033 0.004 
Anxiety 0.132 0.041 0.003 0.119 0.044 0.01 0.127 0.044 0.006 
Depression 0.175 0.046 0.0004 0.162 0.048 0.001 0.170 0.047 0.001 
MD (10-6 mm2 /s) -0.580 0.234 0.02 -0.556 0.249 0.03 -0.610 0.253 0.02 
IFN (RQ value) -0.090 0.030 0.006 -0.091 0.029 0.005 -0.080 0.040 0.06 
vWF (fVIIIc) (IU / mL) -1.168 0.550 0.04 -1.121 0.539 0.04 -1.111 0.533 0.04 
vWF (RCOF) (IU / mL) -1.426 0.599 0.02 -1.212 0.623 0.06 -1.154 0.616 0.07 
Cognitive function 
Disease duration (months) -0.003 0.001 0.003 -0.003 0.001 0.005 -0.001 0.000 0.07 
MD (10-6 mm2 /s) -0.271 0.126 0.04 -0.264 0.135 0.06 -0.012 0.108 0.91 
vWF (Ag) (IU / mL) -0.800 0.204 0.0003 -0.794 0.215 0.0006 -0.286 0.208 0.18 
vWF (RCOF) (IU / mL) -0.889 0.358 0.02 -0.848 0.380 0.03 -0.296 0.317 0.36 
IL-6 (pg / mL) -0.234 0.080 0.006 -0.241 0.080 0.005 -0.151 0.063 0.02 
a Fatigue adjusted for age, disease duration and steroids; Cognitive function adusted for age, disease duration, 
steroids and NART.    
B = beta coefficient, IL-6 = interleukin-6, MD = mean difussivity, NART = national adult reading test, SE B = 
standard error for beta coefficient, vWF Ag = von Willebrand factor antigen, vWF fVIIIc = von Willebrand factor 
VIII, vWF RCOF = von Willebrand factor ristocen co-factor 
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Literature review and meta-analysis 
The search uncovered 19 papers of which 10 were excluded as not relevant (no 
measure of MD or FA in SLE or NPSLE).  We meta-analysed results in three groups: 
(1) SLE versus healthy controls, (2) NPSLE versus healthy controls and (3) SLE versus 
NPSLE. 
A total of nine57,228–235 prior studies were reviewed (n=214 patients; n=24 average per 
study) and added to the current study for meta-analysis (Table 8.9 and Figures 8.3–
8.6).  Four studies229–232 did not provide data to permit inclusion in the forest plots and 
are summarised with the other studies in Table 8.9 only. 
In general, among most tracts, the MD was significantly increased (standardised mean 
difference (SMD) 1.07 (95% CI, 0.62 to 1.52)) and FA non-significantly reduced 
(SMD –0.16 (–0.48 to 0.17)) in SLE patients versus healthy controls (Figures 8.3 and 
8.4). A similar pattern was seen in NPSLE versus healthy controls.  Data comparing 
SLE to NPSLE directly were limited: only one study231 provided data on MD, and 
whereas three studies228,229,231 reported on FA, there were no data suitable for pooling 
although the general observation was little difference in water diffusion measures 
between SLE and NPSLE (Table 8.9). 
  134 




Field Technique n (mean 
age in 
years) 
Comparison Measurement Region Findings 
SLE versus healthy controls 
Zhang, 2007 DTI, 26 1.5T MTR and ADC histogram, 
and ROI 
34 (47) SLE v HC FA and MD Whole brain and 
Various regions 
 MD in brain in SLE 
 FA in SLE in most regions 
 MD in SLE in most regions 
Emmer, 2010 DTI, 6 3T TBSS 12 (42) SLE v HC FA Various tracts  FA in SLE in most tracts 
Jung, 2010 DTI, 12 1.5T TBSS 16 (37) SLE v HC FA and MD Various tracts No difference in FA 
No difference in MD 
Schmidt-Wilcke, 
2014 
DTI, 15 3T TBSS & TFCE 19 (38) SLE v HC FA Voxels and clusters 
across WM 
 FA in SLE in prefrontal WM  
Zimny, 2014 DTI, 25 1.5T ROI 13 (34) SLE v HC FA 14 WM tracts  FA in SLE in most tracts (see FP) 
Wiseman, 2015 DTI, 32 1.5T Quantitative tractography 47 (48) SLE v HC FA and MD 8 WM tracts  FA in SLE in most tracts (see FP) 
 MD in SLE in all tracts (see FP) 
NPSLE versus healthy controls 
Bosma, 2003 DWI, 3 1.5T ADC histogram 11 (35) NPSLE v HC mean ADC Whole brain  mean ADC in brain in NPSLE 
Welsh, 2007 DWI, 3 1.5T ADC histogram 17 (43) NPSLE v HC mean ADC Whole brain and 
segmented tissues 
 mean ADC in brain in NPSLE 
 mean ADC in GM & WM in NPSLE 
Hughes, 2007 DTI, 9 1.5T ROI 8 (43) NPSLE v HC FA and MD Various regions  FA in NPSLE in various regions 
 MD in NPSLE in various regions 
Jung, 2010 DTI, 12 1.5T TBSS 17 (39) NPSLE v HC FA and MD Various tracts  FA in NPSLE in some tracts 
 MD in NPSLE in most tracts 
Zivadinov, 2013 DTI, 39 3T Voxel based tissue segment 26 (48) NPSLE v HC MD NAWM  MD in NAWM in NPSLE 
Schmidt-Wilcke, 
2014 
DTI, 15 3T TBSS 19 (39) NPSLE v HC FA Voxels and clusters 
across WM 
 FA in SLE in prefrontal WM 
Zimny, 2014 DTI, 25 1.5T ROI in WM tracts 22 (35) NPSLE v HC FA 14 WM tracts  FA in NPSLE in most tracts (see FP) 
SLE versus NPSLE 
Jung, 2010 DTI, 12 1.5T TBSS 16 (37) SLE v NPSLE FA and MD Various tracts  FA in SLE in 2 tracts 
 MD in SLE in 3 tracts 
Schmidt-Wilcke, 
2014 
DTI, 15 3T TBSS 19 (38) SLE v NPSLE FA Voxels and clusters 
across WM 
No difference in FA between SLE and 
NPSLE 
Zimny, 2014 DTI, 25 1.5T ROI 13 (34) SLE v NPSLE FA 14 WM tracts Generally no difference in FA between 
SLE and NPSLE (see FP) 
ADC = average diffusion coefficient, FA = fractional anisotropy, FP = forest plot, GM = grey matter, MD = mean diffusivity, MTR = mean transit ratio, NPSLE = neuropsychiatric SLE, NAT = 
normal appearing tissue, NAWM = normal appearing white matter, ROI = region of interest, SLE = systemic lupus erythematosus, TBSS = tract based spatial statistics, WM = white matter 
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Figure 8.3 SLE versus healthy controls, outcome: mean diffusivity  
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Figure 8.4 SLE versus healthy controls, outcome: fractional anisotropy  
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Figure 8.5 NPSLE versus healthy controls, outcome: mean diffusivity 
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Figure 8.6 NPSLE versus healthy controls, outcome: fractional anisotropy  
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Discussion  
The main findings in the present study, the largest to date on DT-MRI in SLE adding 
~25% more data, and the only one to use quantitative tractography, were that: (i) MD 
was higher in eight major white matter tracts in SLE versus healthy controls; (ii) MD 
and FA were associated with several expected variables (age, atrophy) but also more 
permanent damage as measured by SLICC score and lower cognitive function in 
univariate analyses; (iii) fatigue in patients was higher than a normal reference range 
and associated with higher anxiety, depression and BMI.  Poorer current cognitive 
function was associated with SLE disease duration and there was an independent 
association with higher levels of the pro-inflammatory biomarker IL-6. 
The direction of the regression slopes relating MD (rising) and FA (declining) with 
age were as expected but steeper in SLE patients versus controls, indicating 
accelerated decline in white matter microstructure with age.  However, when we tested 
the slopes using an interaction term in a linear regression model there was no 
significant difference between patients and controls and a larger sample will be needed 
to confirm accelerated ageing.  Nonetheless, significantly higher MD levels were 
found in all white matter tracts in SLE patients versus healthy controls which are in 
accordance with the literature review of nine prior studies that used diffusion imaging.  
This indicates a diffuse increase in brain water mobility in SLE, possibly indicating a 
subtle decline in white matter microstructural integrity.  We recently demonstrated 
increased stroke risk in SLE versus the general population with greatest risk in those 
<50 years; again possibly indicative of accelerated ageing56 (see Chapter 4) and the 
results here are also consistent with our findings in Chapter 7 of more markers of SVD 
in SLE patients versus healthy controls. 
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In SLE, higher fatigue was also associated with lower MD, although this likely reflects 
higher fatigue scores being more common in younger participants.  A much larger 
study will be required to determine if fatigue in SLE is associated with reduced MD 
levels for a given age.  Higher fatigue was also associated with lower IFN, lower vWF 
(fVIIIc and RCOF) and approached significance with higher CRP.   
The finding that higher fatigue was associated with lower MD was unexpected, 
although the most fatigued were also the youngest which partly explains our finding 
as younger people have lower MD.  No other studies have examined MD with fatigue 
in SLE.  In a prior study of ankylosing spondylitis patients with high fatigue (n=20; 
method = Tract-based Spatial Statistics (TBSS)) there was reduced FA values in 
several tracts (inferior fronto-occipital fasciculi, superior/inferior longitudinal 
fasciculi and corticothalamic tracts) versus healthy controls.277  Conversely, patients 
diagnosed with granulomatosis with polyangiitis (n=28; method = TBSS) were 
dichotomised into 14 with and 14 without fatigue: fatigued patients had increased FA 
in the let fornix and bilateral posterior cingulum bundles which the authors suggest 
may reflect plasticity secondary to normal activation of these tracts.278  
A possible explanation of our fatigue-MD finding apart from age was steroid use.  We 
have previously shown steroids reduce MD values in oedematous brain acutely in 
patients with brain tumours279.  Corticosteroids are commonly prescribed in the 
treatment of SLE, although we did not quantify current/lifetime dose and so could not 
directly relate our DT-MRI findings to steroid dose as a continuous variable.  
However, fatigue remained inversely associated with MD in the multivariable model 
that included age and current steroids as a dichotomised variable. 
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Higher levels of fatigue were associated with higher BMI in the current study, as has 
been established previously280.  Higher levels of fatigue were also associated with 
lower levels of endothelial dysfunction (vWF).  The plasma marker that had the highest 
association with fatigue was IFN, independent of age.  Fatigue is a common side effect 
of IFN therapy although none of the current SLE study participants were on IFN 
thereapy; meanwhile, prior studies of endogenous IFN in SLE did not show 
associations with fatigue.281,282 
Lower levels of current cognitive function were associated with longer SLE disease 
duration and higher MD and between 10% and 38% of patients had cognitive test 
scores indicating clinical levels of cognitive impairment.  Our finding that lower levels 
of cognitive function were associated with higher MD is in agreement with Bosma et 
al.226 who examined 24 patients diagnosed with NPSLE, although when we adjusted 
for age the association disappeared (as people get older MD tends to rise).  Bosma and 
colleagues also correlated lower levels of neurological functioning (essentially motor 
skills) with higher levels of magnetization transfer MRI parameters. 
Poorer current cognitive function was also associated with higher levels of the pro-
inflammatory cytokine IL-6, independent of age and prior cognitive abilities. We used 
a high-sensitivity enzyme-linked immunosorbent assay (R&D Systems, Abingdon, 
UK) with sensitivity of 0.16 pg/mL.  The PROSPER283 study (randomised controlled 
trial; n=5,653) associated higher IL-6 with worse executive function (p<0.001), 
independent of age.  At follow-up (mean 39 months), higher IL-6 was independently 
associated with an increased rate of cognitive decline in both executive function 
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(p=0.002) and memory (p=0.002)283.  The mean age of participants in the PROSPER 
study was 75 years, considerably older than the mean age of participants in the current 
study, yet the similarity in findings could indicate that SLE patients are experiencing 
aged-related effects on the brain at younger ages.  The PROSPER study corrected for 
educational level but not premorbid intelligence using NART. 
Other variables associated with cognitive function on univariate analysis became 
nonsignificant when NART was added to the regression models.  The apparent current 
cognitive impairment is thus mostly explained by premorbid IQ, although 
inflammation also played a role in this data. 
Strengths of the present study include use of a continuum of fatigue and cognitive 
scores rather than dichotomised data, the 32 diffusion-encoding gradient directions in 
the DT-MRI exam which increases the precision of the imaging data, a large sample 
size relative to existing DT-MRI studies (although we note our sample is still small, 
limiting study power) in SLE and use of quantitative tractography rather than ‘region 
of interest’ or ‘voxel-based’ methods. The quantitative tractography method employed 
here, PNT, has the advantage that it segments white matter tracts automatically in 
native space, avoiding brain distortion by use of registration to standard space and 
thereby providing objective measures of tract microstructure that can be correlated 
with phenotypic data.  Additionally, our study did not solely focus on patients that 
were neurologically symptomatic or diagnosed with NPSLE but instead included a 
range of SLE patients making our findings relevant to the wider SLE patient 
population.  In the multiple linear regression models we corrected for age, disease 
duration, and where current cognitive function was the outcome (dependent variable), 
NART, to adjust for an inferred prior (peak) IQ. 
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We did not administer tasks to assess reaction times, information processing speed or 
motor skills and so we are unable to comment on these aspects of neurological 
function.  Although subjects were asked to consider their fatigue over the prior week, 
they were seen at different times of the day and this could have impacted the self-
reported fatigue scores via diurnal variation. 
The main observation from the literature review and meta-analysis (increased MD and 
decreased FA in SLE versus controls) was in agreement with findings in this study.  
Studies of other inflammatory autoimmune diseases show a similar pattern of findings, 
for example, in Sjögren Syndrome (n=19; method = TBSS) there was increased MD 
and decreased FA in several tracts compared to controls284. 
Conclusion 
Patients with SLE have more microstructural brain white matter damage for age than 
the general population, but this does not explain increased fatigue or lower cognition 
in SLE.  Lower MD in the most fatigued may reflect younger age which should be 
explored in larger studies.  Fatigue associates with BMI, anxiety and depression.  
Worse current cognitive function in SLE is related to lower prior cognitive ability 
although inflammation also plays a detrimental role and the independent association 
with raised IL-6 should be explored in larger datasets. 
The findings are consistent with the increased SVD burden shown in the previous 
chapter and adds evidence of microstructural brain damage to overt SVD features in 
SLE.  This likely contributes to the ‘brain fog’ described by most SLE patients.  Larger 
studies are needed and these are clearly feasible based on this pilot study, as has been 
described in concluding paragraph to Chapter 7.  
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Chapter 9: General discussion 
 
This aims of this thesis were to: 
 investigate plasma biomarkers of coagulation, fibrinolysis, endothelial 
dysfunction, and inflammation in lacunar stroke versus other ischaemic stroke 
subtypes and non-stroke controls; 
 assess relationships between plasma biomarkers and SVD features such as WMH; 
 review associations between stroke, including stroke subtypes, and rheumatic 
diseases, and to determine if rheumatic diseases increase the risk of specific stroke 
subtypes or ‘silent’ vascular disease on neuroimaging; and, 
 via the conduct of a pilot MRI neuroimaging study: 
o assess the burden of SVD among patients with the inflammatory disease 
SLE versus a cohort of stroke patients (i.e., clinically overt SVD) and 
non-stroke healthy controls; 
o assess relationships between total SVD burden and plasma biomarkers of 
SLE disease activity, inflammation, endothelial dysfunction, cholesterol 
and autoantibodies; 
o investigate evidence of SVD burden in the brain including 
microstructural damage in SLE including relationships with cognition, 
fatigue, SLE disease activity and inflammatory markers. 
We have shown an increase in SVD burden in the inflammatory rheumatic disease 
SLE (Chapter 7) and an association with stroke at younger ages in RA, SLE and other 
inflammatory rheumatic diseases (Chapter 4) which has been unexplained to date.  The 
increased SVD burden, seen mainly as enlarged PVS on scanning, is consistent with 
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perivascular inflammation and provides mechanistic evidence that systemic 
inflammation may affect endothelial function and lead to brain damage.  The aims and 
main findings on a chapter-by-chapter basis are summarised below, followed by a 
general discussion, including comments on the difficulties encountered and 
implications for future research. 
In Chapter 2, we systematically reviewed the literature for studies comparing plasma 
biomarkers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in 
lacunar stroke versus non-stroke controls or other ischemic stroke subtypes.  Markers 
of coagulation/fibrinolysis (t-PA, PAI, fibrinogen, D-dimer) were higher in lacunar 
stroke patients versus non-stroke controls.  There was no difference in the levels of t-
PA and PAI between lacunar stroke and non-lacunar stroke.  Fibrinogen and D-dimer 
were significantly lower in lacunar stroke compared to other ischemic stroke subtypes.  
Markers of endothelial dysfunction (homocysteine, vWF, E-selectin, P-selectin, 
ICAM, VCAM) were higher or had insufficient or conflicting data in lacunar stroke 
versus non-stroke.  Compared to other ischemic stroke subtypes, homocysteine did not 
differ in lacunar stroke, while vWF was significantly lower in lacunar stroke.  
Available data did not permit meta-analysis of E-selectin, P-selectin, ICAM and 
VCAM but the general impression was of no difference in these biomarkers between 
stroke subtypes.  Markers of inflammation (CRP, TNF-α, IL-6) were higher in lacunar 
stroke versus non-stroke.  Compared to other ischemic stroke subtypes, there was no 
difference (CRP) or insufficient or conflicting data (TNF-α) to lacunar stroke.  IL-6 
was significantly lower in lacunar stroke versus other ischaemic stroke subtypes.  We 
concluded that more studies comparing lacunar stroke to non-lacunar stroke 
specifically, rather than to non-stroke controls, are needed.   The available data in the 
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review were limited and did not exclude the possibility that peripheral inflammatory 
processes including endothelial dysfunction are associated with lacunar stroke and 
SVD127. 
In Chapter 3, we used data from a prospective study of patients presenting with non-
disabling lacunar or cortical ischaemic stroke.  Biomarkers of inflammation, 
endothelial dysfunction and haemostasis were measured and compared between the 
two stroke groups.  We calculated WMH volume and modelled it as a function of age, 
sex, hypertension and smoking (the baseline model).  We fitted exploratory models 
using plasma biomarkers as additional predictor variables to assess model 
improvement over baseline.  The lacunar group had lower t-PA levels in adjusted 
analyses compared with the cortical group.  There were no significant differences in 
the other plasma biomarkers.  The direction of the t-PA finding was consistent with 
our updated meta-analysis (new total 300 lacunar strokes), although the overall effect 
remained non-significant.  The baseline regression model explained 29% of the 
variance in WMH volume.  Inflammatory biomarkers showed minor improvement 
over the baseline model, but the other plasma biomarkers did not improve the baseline 
model.  We concluded that plasma t-PA levels appear to differ between lacunar and 
cortical stroke subtypes, independent of age, sex and vascular risk factors and may 
reflect endothelial dysfunction, but found no difference in the other plasma 
biomarkers.  Except for a minor additional predictive effect of inflammatory markers, 
plasma biomarkers did not relate to WMH severity in this small stroke population285. 
In Chapter 4, we reviewed associations between stroke and rheumatic disease, 
including incidence rates and pooled rate ratios for stroke subtypes versus the general 
population.  We also assessed risk by age and determined if rheumatic diseases 
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increased the risk of ‘silent’ vascular disease on neuroimaging.  Prior published meta-
analyses and new pooled analyses of any stroke in RA, SLE, ankylosing spondylitis, 
gout and psoriasis showed an excess risk of stroke over the general population.  New 
meta-analyses of stroke subtypes in RA and SLE also showed an excess risk of stroke 
over the general population.  Stroke risk across rheumatic diseases was highest in those 
aged <50 years and reduced relatively with ageing as the general population caught up 
with the increased risk.  We concluded risk of any stroke is higher in most rheumatic 
diseases than in the general population, particularly in patients aged <50 years.  
In Chapter 5, we used data from an audit of a large regional rheumatology service 
which we linked to Scottish national hospital records to assess the number of strokes, 
including subtypes, across several common rheumatic diseases. We grouped the 
arthropathies into inflammatory and degenerative (non-inflammatory) categories to 
see if there was a higher burden of all stroke or of specific stroke subtypes among the 
inflammatory group, investigated age at stroke to confirm if stroke in inflammatory 
versus degenerative arthropathies occurred at a younger age in these patients, and set 
our findings in context by comparing to stroke incidence rates and age at stroke from 
the general UK population.  There were 347 cerebrovascular disease event episodes 
among 224/6,613 (3.4%) patients.  We classified 4,088/6,613 (62%) rheumatology 
patients as inflammatory and 664/6,613 (10%) as non-inflammatory.  Of these, 
157/4,088 (3.8%) and 28/664 (4.2%) had cerebrovascular events.  Inflammatory 
arthritis was not associated with cerebrovascular events before and after adjusting for 
age and sex.  Age was predictive of cerebrovascular events: a year’s increase in age 
resulted in a 6% increase in likelihood of having an event. The mean age at stroke 
event in the rheumatic disease population overall was 63.7 ± 12.9 years with a peak in 
  148 
events in the 55–64 years age band, which is two decades earlier than in the UK general 
population.  We concluded that there was no difference in the proportion of strokes 
occurring between patients classified as inflammatory versus non-inflammatory, but 
that strokes in rheumatic diseases occur at younger ages than is normally expected, 
consistent with our finding of accelerated stroke risk in rheumatic patients in Chapter 
4.  
In Chapter 6 we described the background and rationale for pilot MRI neuroimaging 
study of patients diagnosed with the inflammatory autoimmune disease SLE, and in 
Chapters 7 and 8 gave the results to the study.  We hypothesized that patients 
diagnosed with SLE would have evidence of SVD on brain MRI, and this could be the 
biological basis for fatigue and cognitive decline, and might explain increased stroke 
risk.  We sought to provide evidence that systemic inflammation can be associated 
with cerebral perivascular inflammation in SVD.   
Of 55 consecutive patients with SLE invited to participate, 51 (93%) agreed and were 
compared with 51 healthy controls and 51 stroke patients.  Compared to healthy 
controls, SLE patients had a greater total SVD score sustained across each 10-year age 
band, including more deep but not periventricular WMHs.  Compared to stroke 
patients, the SLE patients also had higher SVD score, mostly due to having more PVS.  
The total SVD score was not associated with SLE activity, accumulated systemic 
damage, nor SLE disease duration in this small sample.  We concluded that patients 
with SLE have more SVD markers, notably PVS and deep WMH, than sex- and age-
matched healthy controls and mild stroke patients from the same health region.   
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In tractography analyses, MD was significantly higher in all tracts in SLE patients 
versus controls, which was consistent with our meta-analysis of the literature (n=10 
studies; n=261 SLE patients).  We concluded that patients with SLE have more 
microstructural brain white matter damage for age than the general population which 
may explain the consistently (though subtly) altered cognitive function, but does not 
explain increased fatigue in SLE.  The findings of more microstructural damage was 
consistent with the increased SVD burden, and added evidence of microstructural brain 
damage to overt SVD features in SLE.  This may contribute to the ‘brain fog’ described 
by most SLE patients and also recognised (anecdotally) to be a complaint amongst 
older patients with sporadic SVD.  We show that a larger study would be very feasible 
based on our pilot study. 
General discussion – vascular / atherothrombotic 
Stroke is a preventable and treatable disease286.  Recent advances such as better public 
awareness that stroke is a medical emergency and the signs to look for, use of aspirin, 
thrombolysis, multidisciplinary rehabilitation and specialised acute stroke units have 
improved outcomes for patients, but the burden of stroke is still high, probably because 
society is ageing and people – at the population level – take a laissez-faire attitude to 
altering diet and sedentary habits, at least until – at the individual level – a warning 
sign is delivered.  Dietary choices influence stroke risk.  Eating more fruit and 
vegetables confers protection from stroke in general287.  Plant-based foods are also 
high in fibre7,8 and potassium288 which have been associated with lowering stroke risk 
by up to a fifth. 
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The conventional risk factors for stroke (hypertension, smoking, hyperlipidemia, 
diabetes, hyperhomocysteinemia) are modifiable in those willing, able and dedicated 
enough to take control of their heath, although some risk factors are unavoidable 
(increasing age) and there are a proportion of people that have systemic inflammatory 
diseases (e.g. RA and SLE) that increase stroke risk and accelerate atherosclerosis, 
although here too lifestyle choices may attenuate risk by dampening the inflammation.   
The conventional risk factors for stroke do not fully account for stroke incidence, and 
some people that have had a stroke do not have any of these risk factors and so 
alternative mechanisms need to be considered.  Such alternative mechanisms might 
act alone in some strokes, but in most cases the likely mode of operation is interaction 
with the traditional stroke risk factors to precipitate or accelerate stroke.   
Atherosclerosis is now known to be a chronic inflammatory disease44,289 involving 
innate and adaptive immunity (macrophages, T cells and mast cells)44,217,289–291, 
triggered by high levels of circulating cholesterol, which also accumulates in the 
arterial wall. In the smaller vessels there is intimal thickening217.  The fat trapped in 
the vascular system (why this happens is not known, but is probably one mechanism 
the body uses to neutralise too much circulating cholesterol) becomes oxidised and 
phagocytosed by macrophages leading to fat-laden macrophages (foam cells).  Lipid 
oxidation upregulates adhesion molecules and promotes transmigration of immune 
cells from the circulation and into the vascular wall.  Subendothelial accumulation of 
lipids (fatty streaks) and foam cells develop a protective fibrous ‘cap’ which can be 
infiltrated by activated T cells, which produce pro-inflammatory mediators and 
enzymes, and, in cases of plaque rupture, thrombosis – which is followed by platelet 
activation and aggregation, and coagulation.   
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While the accumulation of lipids in the arterial wall is considered a long term 
phenomenon that develops over time, even a single meal292 high in animal fat has been 
linked to an immediate vascular stiffening, inhibiting normal vasodilation, and has also 
been found in Asian males293.  The endotoxins present in animal fat and protein survive 
cooking, stomach acid and enzyme digestion, and trigger an inflammatory response294.  
In mice, a systemic challenge with the bacterial endotoxin lipopolysaccharide 
exacerbates ischaemic brain damage and the severity of neurological deficit, while 
simultaneous administration of interleukin-1 receptor antagonist attenuated the 
effect38. Obese mice have worse outcomes295 and raised plasma concentrations of the 
pro-inflammatory cytokine IL-6296 after stroke compared to lean controls, highlighting 
the interaction of the peripheral inflammatory response on the brain.   
General discussion – SVD 
However, questions remain unanswered as to whether inflammation outside the brain 
plays a role in the microvascular damage that is well-documented in lacunar stroke or 
the development or worsening of SVD.  Systemic inflammation might predispose to a 
higher burden of SVD, possibly by increasing vascular endothelial injury in the 
perforating arterioles.  Indeed, this thesis has shown evidence of the association of 
systemic inflammation and SVD, for instance via the increased burden of enlarged 
PVS in SLE patients.  However, the only association we found with elevated markers 
of inflammation in lacunar stroke specifically was when lacunar stroke was compared 
to non-stroke healthy controls (raised levels of all of CRP, IL-6 and TNF-α; Chapter 
2) and we did not find an association between raised plasma inflammatory markers 
and lacunar stroke versus other ischaemic strokes in the systematic review127 or our 
study of two types of mild ischaemic stroke patients285.  This suggests that 
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inflammatory plasma marker elevation in lacunar stroke is likely to reflect the process 
of having a stroke, rather than that systemic inflammation or endothelial dysfunction 
following stroke is specific to lacunar stroke alone, although we cannot exclude the 
possibility that systemic inflammation prior to first ever stroke is specific to lacunar 
stroke.  Also, we cannot exclude the possibility that a raised inflammatory profile 
increases the risk of any stroke and that the subtype of stroke is determined more by 
other characteristics than the inflammation per se. 
The Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) study was 
nested within SPS3297, a multi-centre secondary prevention trial in stroke patients with 
small vessel stroke.  Among a number of inflammatory markers, the LIMITS 
investigators measured the inflammatory biomarkers CRP298 and IL-6299 a minimum 
of three weeks after stroke in 1,244 lacunar stroke patients and again about one year 
later.  CRP and IL-6 levels predicted the risk of recurrent stroke and other major 
vascular events, although the study did not have sufficient power to predict recurrent 
small vessel stroke specifically, and had no non-lacunar stroke control group. Whether 
inflammatory markers are causative of recurrent stroke, or merely co-associated 
modulators, needs to be better understood. 
The LIMITS study may be confounded because they studied patients that already had 
a stroke – and so the inflammatory profile will be raised because of the stroke, even 
though the LIMITS investigators attempted to control for this by drawing blood at least 
three weeks post-stroke in an effort to allow the acute inflammatory response to settle.  
Most plasma biomarker studies draw blood in the acute phase following stroke which 
is confounding because the immune response is active resulting in raised circulating 
markers of inflammation. Between-study heterogeneity on time to blood draw is an 
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issue in biomarker studies, but we dealt with this in our meta-analysis (Chapter 2) by 
grouping studies into acute and chronic, using 21 days as the cut point. In our study of 
mild ischaemic stroke subtypes (Chapter 3) we drew blood a minimum of one month 
after the strokes. 
Many imaging features of SVD that are detected on MRI, especially in older people, 
do not produce clinical symptoms, yet non-stroke ‘silent’ SVD is important because 
these SVD imaging features are associated with an increased risk of stroke and 
cognitive decline.  In a large cross-sectional study of neurologically normal non-stroke 
patients (n=519), Mitaki et al.49 showed CRP was associated with [silent] lacunar 
infarcts (n=54, p=0.02), microbleeds (n=26, p=0.03) and more severe deep (n=114, 
p=0.04) and periventricular WMH (n=43, p=0.04).  However, the authors used tertiles 
of CRP, and these associations reflected the comparison of the lowest tertile of CRP 
against the highest, which throws away the middle third of the data.  The authors then 
modelled presence or absence of each of the imaging feature of SVD (as outcome 
variables) using binary logistic regression with CRP as a continuous predictor variable 
(a much better approach as it uses the entire continuum of data) and found higher levels 
of CRP were associated with silent lacunar infracts after adjusting for age, sex, 
hypertension, diabetes, hyperlipidemia, smoking and alcohol (odds ratio 1.62, 95% CI 
1.12–2.33, p=0.009); the other imaging markers of SVD were not related to levels of 
CRP. The authors did not control for pre-existing inflammatory diseases, and the 
sample size (n=54 lacunar infarcts) is probably too small to be generalizable.  
Wersching et al.129 also found no association between CRP and WMH among 321 
stroke-free participants, although higher levels of CRP were associated with worse 
performance on cognitive testing after adjustment for age, education and 
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cardiovascular risk factors (ß = –0.095, p=0.02) and reduced FA (ß = –0.237, p<0.001) 
indicating cerebral microstructural damage in the absence of an association with 
inflammation.  Aribisala et al.48 found no association between inflammation (a latent 
factor comprising CRP, fibrinogen and IL-6) and WMH among 634 community-
dwelling older people of near-identical age, after adjustment for risk factors, although 
did show an association between inflammatory markers and increased PVS, and in 
turn, between increased PVS and increased WMH.  Shoamanesh et al.131 found no 
association between inflammatory biomarkers (CRP, IL-6 and TNF-α) and silent 
infarcts or extensive WMH in the stroke-free Framingham cohort (n=522) but did 
associate ICAM (a marker of endothelial activation) with these SVD features. 
In contrast, three large population studies of non-stroke subjects (n=1,841 in the 3C 
Dijon Study67, n=1,033 in the Rotterdam Scan Study128 and n=3,437 in the 
Cardiovascular Health Study300) found higher inflammatory biomarkers were 
independently associated with higher WMH, although the 3C-Dijon Study used an 
automated imaging processing technique to calculate WMH volume which might have 
miscalculated the volume of WMH by including scan artefacts while the 
Cardiovascular Health Study did not appear to use a validated WMH rating scale. 
These differing findings urgently need meta-analysis to get a more complete view of 
the association, or not, of plasma biomarkers of inflammation in silent SVD to 
augment our review of plasma biomarkers in clinically relevant SVD127 with 
consideration of the methodological strength of the underlying study designs. 
Inflammation, including systemic non-resolving inflammation, goes though periods of 
active flare and quiescence, which could explain why some studies find associations 
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and others do not.  Alternatively, differing inflammatory pathways may underlie SVD.  
A promising line of enquiring is endothelial dysfunction and perivascular 
inflammation.   Biomarkers of endothelial activation were associated with WMH in 
cross sectional analysis132 and with WMH progression69.  In the Framingham Heart 
Study131, ICAM was associated with silent infarcts and WMH after adjusting for age 
(n=522, odds ratio 1.7, 95% CI 1.1–2.5, p=0.02).  Flow-mediated dilatation studies 
have shown endothelial dysfunction in lacunar stroke versus non-stroke controls133.  
Biomarkers of endothelial dysfunction are associated with greater arterial stiffness in 
longitudinal studies301.  Perivascular inflammation of the small cerebral vessels is a 
prominent finding in SLE267 at autopsy as well as in sporadic SVD46.  Some studies 
have noted PVS208,268 on brain imaging in SLE patients (n=122).  Endothelial 
dysfunction is also implicated in SVD150.  After adjusting for age, sex and vascular 
risk factors, Aribisala et al.48 found inflammation was associated with PVS (ß=0.12, 
p=0.048).  In an interventional study302, there was a significant boost in arterial 
function in coronary artery disease patients placed on a low fat, plant-based diet for 12 
weeks versus age- and risk-factor matched controls.  In a double-blind randomized 
controlled trial, vitamin B supplementation (needed to detoxify homocysteine) slowed 
the rate of brain atrophy in people with mild cognitive impairment303 although the 
study only provides weak evidence as it was small (n=168) and lost 25% of participants 
to follow-up; a larger trial is required to confirm findings.  Petri et al.220 found 
homocysteine, a marker of endothelial dysfunction, to be an independent risk factor 
for stroke in SLE while Jeon et al.304 found an association between homocysteine and 
ischaemic stroke (n=825), including small vessel stroke, after adjustment for age, sex, 
hypertension, diabetes, smoking and alcohol consumption but not meat consumption 
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(odds ratio 1.04, 95% CI 1.01–1.07, p=0.005).  In our SLE study (Chapters 7 and 8) 
we show that 37/45 (82%) patients with SLE had elevated homocysteine. 
Comorbid inflammatory diseases 
None of the lacunar stroke and ‘silent’ SVD studies adjusted for comorbid 
inflammatory diseases.  Studying patients with chronic inflammatory diseases (at the 
cellular and epidemiological level) could provide useful mechanistic insights into 
lacunar stroke and SVD because the inflammation in these patients is active and, like 
stroke in general, probably interacts with traditional vascular risk factors to accelerate 
SVD.  Similarities between atherosclerosis and chronic inflammatory rheumatic 
diseases are seen, such as activation of macrophages and increased levels of circulating 
cytokines305,306.  The reason for early entry of immune cells into the perivascular tissue 
is not clear but the resultant release of inflammatory mediators can make the 
endothelium adherent and procoagulant (e.g. upregulation of tissue factor and PAI-1 
and downregulation of t-PA)217,307,308.  In Chapter 3 we saw lower levels of t-PA in 
lacunar stroke patients versus cortical stroke patients, although in meta-analyses 
(Chapter 2) the overall effect showed no difference in t-PA levels between these two 
ischaemic stroke subtypes even though the directionality of our finding was consistent.  
Knottnerus et al.150 found higher levels of t-PA in SVD patients that had extensive 
WMH versus those with an isolated lacunar infarct, suggesting differences in the levels 
of t-PA at different stages of SVD, or different mechanisms between these lacunar 
stroke subtypes, although there was no association between extensive WMH and t-PA 
levels when age was adjusted for.  Increased endothelial disturbance results in 
increased t-PA secretion but also increased levels of its inhibitor, tissue plasminogen 
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activator inhibitor (PAI), resulting in increased levels of circulating complexes with t-
PA143–145 which complicates, and potentially confounds, analyses.   The largest study 
to date to find lower levels of t-PA in small vessel stroke is the Sahlgrenska cohort, 
Sweden92:  among 600 patients with ischaemic stroke, including 124 with small vessel 
stroke, small vessel stroke patients had higher t-PA levels compared to non-stroke 
controls in the acute phase and at three months, but lower t-PA levels compared to 
other stroke subtypes which was consistent with our Chapter 3 findings285. 
Clearly, an over-active or non-resolving inflammatory immune response can disrupt 
the vascular system, including the small vessels.  Epidemiology studies have shown a 
risk reduction of cardiovascular disease when the pro-inflammatory cytokine TNF-α 
is blocked309.  Clinical trials of inflammation modification in atheromatous vascular 
disease are ongoing.  Methotrexate is a very common disease-modifying anti-
rheumatic and anti-inflammatory drug which has been used in the treatment of 
inflammatory rheumatic diseases such as RA and SLE for several years.  The CIRT 
(Cardiovascular Inflammation Reduction Trial) trial is an ongoing, randomised, 
double-blind, placebo-controlled trial of low dose methotrexate to see if it reduces 
heart attack, stroke or death in people with type II diabetes or metabolic syndrome that 
have had a heart attack.  This would be targeting large artery atheroma mainly.  The 
investigators are hoping to enrol 7,000 patients over the period 2013 to 2018.   
Atrial fibrillation (AF) contributes to ischaemic stroke.  Anticoagulation reduces 
stroke in AF patients, but not completely, and some treated patients still go on to have 
a stroke.  Colchicine is an anti-inflammatory drug used in the treatment of gout.  The 
CIAFS-1 (Colchicine in Atrial Fibrillation to Prevent Stroke) trial is a much smaller 
(enrolment target, n=60) ongoing, randomised, placebo-controlled trial of colchicine 
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to see if it reduces stroke in anticoagulated patients with AF.  Colchicine is also being 
tested in the CONVINCE (COlchicine for preventioN of Vascular Inflammation in 
Non-CardioEmbolic stroke) trial, a randomised clinical trial of low-dose colchicine for 
secondary prevention after stroke (EU Clinical Trials Register 2015-004505-16).  
Colchicine has shown efficacy in preventing coronary events when used with statins 
versus statins alone310.  Moreover, others289,311 suggest further studies are needed to 
evaluate the use of immune-directed therapies in atherosclerotic cardiovascular 
disease, including use of novel approaches to monitor inflammation at the site of 
disease (e.g., with 18F-fluorodeoxyglycose positron emission tomography or fluorine-
19 MRI), a sentiment that could be extended to cerebral SVD.   
In our pilot neuroimaging study, we showed that patients with the inflammatory 
autoimmune disease SLE had a higher burden of SVD, notably more enlarged PVS.  
Enlarged PVS were associated with inflammation (n=634) in prior work48 at our 
Centre.  We also meta-analysed the literature on stroke risk in SLE patients which 
showed a doubling of risk over the general population, although the data on lacunar 
stroke specifically were limited and insufficient for meta-analysis.  Clearly, patients 
with inflammatory rheumatic diseases exhibit a pro-inflammatory phenotype and are 
at increased stroke risk which may in part be mediated by accelerated microscopic 
damage as seen by increased SVD burden.  The peripheral inflammation in 
inflammatory rheumatic diseases could modulate stroke vulnerability via endothelial 
dysfunction or increase susceptibility to coagulability as well as lead to damage 
secondary to perivascular inflammation.  Stroke risk is also increased in other 
inflammatory diseases such as inflammatory bowel disease312,313 and SVD imaging 
features have been reported314,315 including microstructural damage derived from DT-
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MRI indices of water molecule diffusivity316.  Additionally, we showed that stroke risk 
in rheumatic diseases occurs earlier in life (in our meta-analysis in Chapter 4 and the 
national linkage search in Chapter 5), supporting the hypothesis that active 
inflammation promotes accelerated cerebrovascular disease including microvascular 
disease. 
Difficulties 
In Chapter 2 we conducted a systematic review and meta-analysis of 13 plasma 
biomarkers of four physiological processes in lacunar stroke versus non-lacunar stroke 
(to control for having any stroke) and non-stroke (to compare to the general 
population) and in Chapter 3 we compared eight biomarkers between lacunar and 
cortical stroke obtained from a stroke study conducted at our Centre134.  Choosing 
biomarkers is not straightforward.  The ones studied might be benign while valuable 
information might go undetected in those not studied.  There are also financial and 
technical limitations, for instance we did not study markers in CSF as CSF is rarely 
obtained in these patients.  We based our choices on prior literature, biological 
plausibility and advice from experts in inflammation and plasma markers.  We cannot 
exclude the possibility of missing associations because of our choice of biomarkers.  
Conversely, biomarkers that measure the same biological process tend to be correlated 
(e.g., IL-6 correlates with TNF-α) and so one might infer that if inflammation 
(measured by IL-6) correlates with a brain imaging feature of SVD, then TNF-α (or 
some other inflammatory marker not studied) probably does too via co-association.  
Sample size is often a problem – most biomarker studies are not large enough to find 
subtle but important associations.  Lastly, as the study in Chapter 3 was cross-sectional 
we are unable to comment on causation. 
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In Chapter 4 we reviewed cerebrovascular disease in rheumatic disease.  We focussed 
our analysis on the main rheumatic diseases – in order to capture the general theme – 
yet there are several more rheumatic diseases that could have been studied as well as 
non-rheumatoid inflammatory diseases such as Crohn’s that could have augmented the 
analysis, although arguably such diseases have sufficiently different pathogenic 
processes that they warrant their own review.   These topics could be addressed in 
future.  Additionally, it would be interesting to know if the aggressive pharmaceutical 
management of those with the most severe inflammation attenuated stroke risk or 
halted (or increased) the development of WMHs and other biomarkers of SVD, 
although extracting this level of detail from the literature could be challenging as it is 
generally not reported.  Data on ischaemic stroke subtypes was limited, and so we were 
only able to provide an estimate of lacunar stroke incidence rate and not pooled risk 
versus the general population (most studies do not subtype stroke and those that do use 
varying methods; this is a known problem).  A large brain imaging population study 
with detailed stroke phenotyping is needed to fully characterise stroke subtypes 
including SVD in rheumatic patients but would require a large sample and long term 
follow up to achieve reasonable power.   
In Chapter 5 we conducted a national data linkage study of rheumatology patients in 
NHS Lothian, with cerebrovascular disease events as the outcome measure.  The input 
data involved 6,613 patients but a third of the data could not be used as the diagnoses 
were incomplete.  We attempted to correct this by re-analysing the audit records for 
information that would allow us to classify the missing data (for example a single 
patient’s data entry might show no clear diagnosis but the notes field might say 
“probable RA” and we could have legitimately allocated this patient to the RA group) 
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but the scale of this task became insurmountable in the timeframe of this thesis.  Work 
is ongoing to rectify this problem so that the sample size, hence study power, can be 
increased before re-analysing the data. A future study would aim to allocate diagnosis 
at inception as closely as possible and follow-up to confirm or exclude each patient. 
In Chapters 6, 7 and 8 we report on our SLE study.  We encountered relatively few 
problems with this study.  DT-MRI failed in four patients which reduced our sample 
size from 51 to 47 for the tractography measurements.  We considered re-calling these 
four subjects but resource limitations precluded this, and it was a pilot study.  We used 
quick screening tools rather than a full psychological battery in our assessment of 
cognitive function in the SLE subjects but we justified this on the basis that this was a 
pilot project.  The tests were chosen for their ease of use, practicality, validity, wide 
evidence base and relevance to medical care and patients.  Therefore the cognitive 
tools did not test every aspect of cognitive function and intelligence in minute detail, 
but focussed on collecting information in major domains in ~20 mins.  A future larger 
study might rectify this shortcoming, especially as information processing speeds 
appear to be a specific neurological problem in SLE patients317 and this should be 
investigated in greater detail, including associations with brain imaging data. 
Final synthesis of main points and suggestions for future work  
This thesis set out to investigate the role of inflammation in cerebral SVD.  
Inflammation has been seen pathologically in the perforating arteriolar walls and 
perivascular tissue in SVD since the 1800s, but the origin of the inflammation, 
systemic or intrinsic or both, is unclear.  We have shown, for the first time, an increased 
burden of enlarged PVS as a marker of inflammation in a group of patients with a 
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systemic chronic inflammatory disease versus healthy controls and stroke patients with 
overt SVD, suggesting that inflammation is associated with changes consistent with 
SVD in the brain.  We did not show conclusive evidence for an association between 
raised clinical inflammatory markers and SVD, although this does not preclude an 
association because inflammatory markers are best detected during active flares 
(which is difficult as large samples are required), whereas brain imaging evidence of 
the resulting damage is easily detected as it is thought to persist and accumulate.  We 
also set out to clarify the association between inflammatory rheumatic diseases and 
stroke, including stroke subtypes and SVD, and although existing knowledge already 
suggests that rheumatic patients are at increased cardiovascular risk, we found that in 
general stroke occurred about two decades earlier in life than in patients without 
inflammatory rheumatic diseases, which is an important message to start stroke 
prevention strategies early. 
It remains to be discovered in detail to what extent systemic inflammation contributes 
to SVD initiation and progression in the presence/absence of vascular risk factors and 
other environmental influences, and how inflammation interacts with traditional risk 
factors to accelerate SVD in some people but not others.  Future studies should attempt 
to measure precisely and localise anatomically the exact location of the inflammation 
in the brain in SVD, possibly via use of advanced neuroinflammation imaging 
techniques (for a recent review of these techniques in dementia see Table 1 in Stefaniak 
and O’Brien52).  Such techniques offer the potential to deepen our understanding of 
how inflammatory cells contribute to brain damage within the cerebral 
microcirculation in different diseases. 
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Interventions that dampen inflammation (pharmaceutically or via diet and lifestyle) in 
SVD are needed to see if this reduces disease burden and prevents recurrent vascular 
events in those that have already had a lacunar stroke or who are otherwise at risk of 
SVD.  Brain imaging studies involving a range of different rheumatic patients are 
likely to be helpful in understanding how systemic inflammation affects the brain, e.g., 
in terms of localised or global dysfunction, and how the damage accumulates relative 
to systemic inflammation, including  inflammatory flares and remissions.  More work 
to raise public awareness of the potential damaging effects of inflammation on the 
brain would be beneficial.  
Common sense suggests that patients with inflammatory rheumatic diseases should be 
encouraged to adopt healthy lifestyles and actively monitored for vascular risk factors 
and carefully managed within current guidelines.  This may help prevent stroke but 
also mitigate long term accumulated brain damage thus helping to preserve cognition 
and wellbeing.  The efficacy of such common sense approaches would require testing 
in randomized controlled trials.     
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